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Aim and outline of the thesis
It has been well established that SUMOylation regulates a wide variety of cellular processes, 
either on its own or in coordination with other post translational modifications such as 
ubiquitination. Currently, little is known about the cooperative actions of different PTMs and 
quite often we lack knowledge on how global SUMOylation contributes to cellular processes. 
Therefore, the main aims of this thesis are to study the crosstalk between SUMOylation and 
ubiquitin, identify SUMO target proteins and their acceptor sites and to obtain more insight 
in the role that SUMOylation plays in maintaining genome stability. 
The current concepts in SUMOylation are summarized and reviewed in Chapter 1. 
An overview of the SUMOylation machinery is given and several examples of crosstalk 
between SUMOylation and other PTMs are presented. Furthermore, the role of SUMOylation 
in cell cycle progression and DNA repair is discussed as well as the current state of SUMO 
based proteomic studies. 
In Chapter 2 we have investigated the crosstalk between SUMOylation and ubiquitination. 
Using proteasome inhibition we identified a subset of SUMO2 target proteins that are 
subsequently ubiquitinated and degraded. Furthermore we have found that the ubiquitin-
proteasome system is essential for the recycling of unconjugated SUMO2 proteins and that 
SUMO2 is a direct target for ubiquitination.
Chapter 3 describes the identification of a protein that can reverse the ubiquitination of 
SUMOylated proteins. The ubiquitin specific protease protein USP11 was identified to 
interact with the SUMO targeted ubiquitin ligase RNF4. In vitro assays revealed that USP11 
can counteract RNF4 activity by removing ubiquitin proteins from SUMO-ubiquitin hybrid 
chains; this activity depends on four SUMO interacting motifs in USP11. Functionally, USP11 
stabilizes PML nuclear bodies by preventing RNF4 mediated ubiquitination and degradation. 
Studying SUMOylation is often challenging due to a lack of information on the modified 
lysines in proteins. Therefore we have developed a strategy to map SUMO acceptor sites 
in cells; this is described in Chapter 4. Site specific identification of SUMO2 target 
proteins enabled the discovery of an inverted SUMO consensus site and the identification 
of a hydrophobic cluster SUMOylation motif. Furthermore, we found direct evidence for 
crosstalk between phosphorylation and SUMOylation on several proteins.
In Chapter 5 we have analyzed global SUMOylation dynamics during cell cycle progression. 
Cell cycle synchronization experiments enabled us to identify and quantify SUMOylation 
of proteins at different phases of the cell cycle. Bioinformatics revealed that transcription 
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factors belong to the largest SUMO regulated group of proteins, including transcription factor 
Forkhead box protein M1 (FoxM1). Follow-up studies showed that FoxM1 SUMOylation 
mainly takes place during G2 and M phase. During these phases, SUMOylation enhances 
transcriptional activity of FoxM1 by counteracting autorepression. Functionally, FoxM1 
SUMOylation contributes to the maintenance of genome stability by reducing the risk of 
developing polyploidy. 
Chapter 6 focuses on the SUMOylation of the Cockayne Syndrome B protein (CSB). Mass 
spectrometry based experiments showed that CSB is specifically and rapidly SUMOylated 
upon UV induced DNA damage. Although this process is dispensable for cells to survive after 
DNA damage, global SUMOylation events seem to contribute to efficient DNA repair. We 
show that the recruitment of the Cockayne Syndrome A (CSA) E3 ubiquitin ligase complex 
to sites of DNA damage induces the destabilization of SUMOylated CSB, potentially via the 
ubiquitination and degradation of RNA polymerase II. 
The work presented in this thesis is summarized and discussed in Chapter 7. 





Schimmel, Joost; and Vertegaal, Alfred CO 
(December 2009) SUMOylation. In: Encyclopedia of Life 







Cells are the main building block of living organisms. All cells contain the genetic 
blueprint, known as DNA that harbors the information needed to execute all cellular 
processes that eventually results in proper cell division. The ‘central dogma of 
molecular biology’, first stated by Francis Crick (1), describes the transfer of this 
information in cells. It starts with the cell making an exact copy of its own DNA, a 
process known as replication. Subsequently, this DNA is transcribed into messenger 
RNA (mRNA) by enzymes and the unique code on this mRNA is translated by 
ribosomes into a specific order of amino acids that finally forms a protein. The 
unique code on a particular segment of DNA, also known as a ‘gene’, determines 
which protein is made. On estimate, the human genome spans between 20.000 and 
25.000 genes (2); theoretically resulting in the same amount of proteins. However, 
mechanisms like genomic recombination, alternative splicing and alternative start 
and stop sites for transcription generate different mRNA transcripts from one unique 
gene (3). The total set of proteins expressed by the genome (the proteome) is thus 
significantly higher than the amount of genes. 
 The functional diversity of the proteome is further expanded by post-translational 
modifications (PTMs) of proteins. PTMs are chemical alterations to amino acids 
in proteins ranging from small chemical modifications to modifications by small 
proteins. Conjugation of these modifications is most often regulated by enzymatic 
activities and they can be reversible by the action of deconjugating enzymes. Due to 
its dynamic nature, PTMs are used by the cell to quickly alter the function of protein 
groups to regulate cellular processes (4). Deregulation of PTMs can cause genome 
instability and as a consequence lead to cancer due to uncontrolled cellular processes 
(5-7). Consequently, PTMs are believed to be interesting potential biomarkers or 
therapeutic targets in cancer; global identification of protein modifications and the 
biological repercussion of PTMs in all cellular processes therefore is an interesting 
and expanding field in scientific research.
1.1 SUMOylation
The activity of many proteins is controlled by post-translational modifications such 
as phosphorylation, acetylation and methylation. Small proteins like ubiquitin can 
also be used as post-translational modifiers of target proteins. Covalent binding of 
ubiquitin polymers to substrate proteins is well known for its role in regulating protein 
stability. These poly-ubiquitinated proteins are recognized by the proteasome and 
degraded. In addition, ubiquitin regulates target proteins in stability-independent 
ways. Several ubiquitin-like proteins exist including Neural precursor cell Expressed 
Developmentally Down-regulated protein 8 (NEDD8), Interferon-Stimulated Gene 




(HUB1) and Small ubiquitin-like Modifiers (SUMOs) (8). SUMOs are also covalently 
attached to extensive sets of target proteins to regulate their function mainly in a 
degradation-independent way. The process of SUMO conjugation to a target protein 
is termed SUMOylation and requires three enzymatic activities known as E1, E2 and 
E3, analogous to the ubiquitin system. SUMOylation is reversible; SUMO-specific 
proteases (SENPs) can remove SUMOs from target proteins (9). 
SUMOs were first discovered in the mid-1990s, where researchers observed a 
larger, modified form of the Ran GTPase-Activating Protein 1 (RanGAP1) (10, 11). 
These studies revealed that RanGAP1 was covalently modified by a so far unknown 
ubiquitin-like modifier, SUMO. Functionally, SUMOylation of RanGAP1 targets the 
protein to the nuclear pore complex (NPC) to facilitate nuclear import of proteins. 
RanGAP1 turned out to be a unique SUMO target since the modified form of the 
protein is often observed as the predominant form. For most other SUMO target 
proteins the stoichiometry of SUMOylation is low and often not detectable without 
pre-enrichment of SUMOylated proteins (12, 13). 
Despite limited sequence identity (18%) between SUMOs and ubiquitin, the 
structures of SUMOs and ubiquitin are very similar. Three functional SUMO family 
members have been identified in vertebrates, SUMO-1, SUMO-2 and SUMO-
3. SUMO-2 and SUMO-3 share 95% sequence identity and are therefore often 
referred to as SUMO-2/3, since it is difficult to discriminate between the two proteins. 
SUMO-2/3 are significantly different from SUMO-1 (+/- 50% sequence identity)(14). 
SUMOylation can affect the activity and subcellular localization of target proteins. 
More recently, it has been shown that SUMOylation can also affect the stability of 
a subset of target proteins. Furthermore, SUMOs are regulators of non-covalent 
protein-protein interactions via SUMO Interaction Motifs (SIMs).
SUMOs are mainly found throughout the nucleus and regulate virtually all 
nuclear processes such as transcription, DNA repair, replication, mitosis, transport 
and ribosome biogenesis (15,16). However, SUMOs are not restricted to the nucleus 
and also affect cytoplasmic processes including signaling and translation. Hundreds 
of target proteins and interacting proteins have been uncovered via proteomic 
approaches and the functional analysis of these SUMO targets will help us to 
understand in detail how SUMOs contribute to eukaryotic life. A second challenge 
for the future is to learn more about cooperation between SUMOylation and other 
post-translational modifications.                                                                                  
1.2 The SUMOylation Machinery
SUMOs are covalently attached to lysines in target proteins via an enzymatic 
cascade (Figure 1A). The cycle of SUMO conjugation begins with the expression 
of a precursor protein. This SUMO precursor protein is cleaved by SUMO specific 




protein is subsequently activated by the dimeric E1 enzyme in an ATP-dependent 
reaction. Activated SUMO is transferred to the SUMOylation specific E2 enzyme 
Ubc9 and subsequently attached to lysines in target proteins. Several E3 enzymes 
have been identified that can catalyze this conjugation and provide target protein 
specificity. SUMOylation is a reversible process; SUMO specific proteases are also 


































Figure 1. The SUMOylation machinery. (A) SUMO precursor proteins are cleaved by SUMO 
specific proteases (SENPs). The mature SUMO protein can be conjugated to target substrates via 
an ATP-dependent E1, E2 and E3 enzymatic cascade. SUMOylation is a reversible process; SENPs 
can deconjugate SUMO modified substrates. (B) Targets can be modified by a single SUMO protein 
(monoSUMOylation), by multiple SUMOs on different lysines (multiSUMOylation) and by SUMO chains 
(polySUMOyaltion) 
E1 enzyme
The SUMO E1 protein was first identified as a heterodimeric enzyme consisting of 
Ubiquitin Activating enzyme E1-like (Uba2) and Activation of Smt3 (Aos1), activating 
the SUMO homologue in yeast, Smt3 (17). The human E1 protein comprises the 
38 kDa SUMO Activating Enzyme subunit 1 (SAE1) subunit and the 72 kDa SAE2 
subunit (18). The small subunits of these heterodimers are similar to the N-terminus 
of classical ubiquitin E1s, whereas the large subunits resemble the C-terminus of 
ubiquitin E1s. The SUMO E1 forms a high-energy thioester bond between a catalytic 
cysteine residue in its large subunit and the C-terminal part of a mature SUMO 





An E1-activated SUMO protein is subsequently transferred to the SUMO specific 
E2, Ubiquitin carrier protein 9 (Ubc9). In contrast to the multiple E2 proteins that 
regulate ubiquitination, Ubc9 has been identified as the single SUMO E2 and Ubc9 
is incapable of conjugating ubiquitin to target proteins (20, 21). Interaction between 
SAE1/SAE2 and Ubc9 initiates the transfer of an activated SUMO protein to the 
active cysteine in Ubc9, forming a SUMO-E2 thioester complex. In the final step of 
SUMOylation, Ubc9 covalently couples SUMO to a target substrate via an isopeptide 
bond formed by the C-terminal glycine of SUMO and the ε-amino group of a lysine 
residue in the target protein.
Consensus SUMOylation site
The acceptor lysine for SUMO conjugation is commonly located in a consensus 
SUMOylation site, ψKxE/D, where ψ represents a large hydrophobic amino acid 
and x can be any amino acid (22). Although a significant number of published 
SUMO target proteins are modified on a lysine located in the consensus site, many 
exceptions have been found. Furthermore, many proteins that contain a SUMOylation 
consensus motif are not detectably SUMOylated possibly due to limited accessibility 
of these lysines in folded proteins (23). Thus, the presence of a SUMO consensus 
site is not sufficient for SUMO conjugation and other target protein features are also 
important for target selection. Ubc9 can directly bind to the SUMO consensus site 
which is sufficient for SUMOylation in vitro (24). However, there are several SUMO 
E3 proteins that can catalyze this conjugation and provide target specificity. 
E3 enzymes
The Protein Inhibitor of Activated STAT (PIAS) protein family and the closely related 
yeast proteins SAP and Miz-finger domain-containing proteins (Siz) 1 and 2 are 
SUMO E3 ligases (25, 26). These proteins contain the catalytically important Siz/
PIAS-RING (SP-RING) domain that resembles the Really Interesting New Gene 
(RING) motif found in ubiquitin E3 ligases. PIAS proteins can interact with the SUMO-
Ubc9 complex and thereby act as an adapter protein between this complex and a 
target substrate for SUMOylation. PIAS-regulated or -enhanced SUMOylation has 
been shown for several transcription factors. SUMOylation of transcription factors 
can influence their activity; therefore, PIAS can act as a regulator of transcription 
(27-29). However, this regulating function is not only due to its SUMO E3 ligase 
activity; PIAS proteins can also regulate the activity of substrates independent of 
SUMOylation (30).
A second type of SUMO E3 ligase is the nuclear pore complex protein Ran 
Binding Protein 2 (RanBP2). RanBP2 forms a stable complex with SUMOylated 




structure; its SUMO ligase activity could be explained by stable binding to Ubc9 and 
by providing an optimal orientation of the SUMO-Ubc9 complex (31). Indeed, it was 
recently found that the complex formation between RanBP2/RanGAP1 and SUMO-
1/Ubc9 induces activation of a catalytic site in RanBP2 which results in its E3 ligase 
activity (32). In vitro, RanBP2 can enhance the SUMOylation of several proteins 
(33). In cells, RanBP2 mediates SUMOylation of topoisomerase IIα (Topo IIα) (34) 
and Borealin (32, 35). 
Another SUMO E3 ligase, the Polycomb group (PcG) Chromobox Protein 
Homolog 4 (CBX4, also known as Pc2), is localized at polycomb bodies in the 
nucleus. Potentially this restricts the SUMO ligase activity of CBX4 to substrates that 
are also localized at these nuclear bodies. CBX4 also lacks a RING-like structure 
and is not related to RanBP2 (36), it acts as a SUMO E3 ligase by recruiting Ubc9 
to polycomb bodies (37). CBX4 mediated SUMOylation has been linked to the DNA 
damage response (38, 39). 
The Methyl methanesulfonate sensitive 2/ Non-structural maintenance of 
chromosomes element 2 homolog (MMS21/NSE2) SUMO E3 ligase that is part of 
the Structural maintenance of chromosomes protein 5 and 6 (SMC5/6) complex is 
important for genome stability (40-42). Interestingly, one protein was identified that 
can act as a dual SUMO and ubiquitin E3 ligase. The C3HC4-type RING finger 
protein topoisomerase I-binding, arginine/serine-rich (TOPORS) can enhance both 
the ubiquitination and the SUMOylation of p53 (43).
SUMO proteases
Several proteins are involved in processing of the SUMO precursor proteins and in 
deconjugating SUMOylated substrates. The best studied SUMO proteases belong 
to the Ulp/SENP family and comprises six SUMO specific protease- 1, 2, 3, 5, 6 and 
7 (SENPs) in humans and Ubiquitin-like-specific protease (Ulp) 1 and 2 in yeast 
(44). SENPS recognize precursor SUMO proteins and remove C-terminal residues 
to expose the di-glycine motif. Deconjugation of a SUMOylated target protein is 
initiated by cleavage of the isopeptide bond between the ε-amino group of the target 
lysine and the C-terminus of SUMO (45). The SENP family members have different 
preferences for processing and deconjugating SUMO-1, -2 and -3 proteins. SENP1 
preferentially processes and deconjugates SUMO-1 and shows less activity towards 
SUMO-2/3. SUMO-2/3 conjugated lysines are preferentially deconjugated by SENP 
-2, -3 and -5. In addition, SENP2 efficiently processes SUMO-2/3 precursor proteins. 
SENP6 and SENP7 appear to be SUMO-2/3 chain specific SUMO proteases. 
SENPs are localized at specific sites in cells that presumably restricts their 
activity to local subsets of target proteins. SENP1 is located in the nucleoplasm, 
SENP2 is located at the nuclear pore and in nuclear speckles, SENP3 and SENP5 




SENP7 are nucleoplasmic components. Yeast expresses only two SUMO proteases, 
the nuclear envelope component Ulp1 and the nucleoplasmic component Ulp2.
DeSumoylating Isopeptidase 1 (DeSI-1) was identified as a second class of 
SUMO proteases. DeSI-1 shows almost no activity towards SUMO-1 and SUMO-2 
precursor proteins, but can deSUMOylate the transcriptional repressor Zinc finger 
and BTB-containing protein 46 (BZEL) (46, 47). Finally, the catalytic domain of 
Ubiquitin-specific protease-like 1 (USPL1) proteins can cleave SUMOs from targets 
in vitro and deconjugate SUMO conjugates when overexpressed in cells; however, 
no endogenous target proteins for USPL1 activity were identified so far (48). 
1.3 SUMOylation is essential for eukaryotic life
Several studies have shown that reversible SUMOylation is essential for eukaryotic 
life. Mice deficient for the SUMO E2 enzyme Ubc9 die after embryonic day 3.5 and 
prior to embryonic day 7.5. Cells derived from these Ubc9-deficient embryos show 
major defects in chromosome condensation and segregation and defects in nuclear 
organization (49). Ubc9-deficiency leads to either embryonic lethality or severe cell-
cycle defects in other eukaryotic organisms. Both SUMO E1 subunits are essential 
for proper cell-cycle progression in budding yeast (17) and E1-deficiency leads to 
embryonic lethality in C.elegans (50). Heterozygous Uba2 (part of the SUMO E1 
dimer) mutant mice showed decreased body length and a decreased number of 
lumbar and sacral vertebrae. Homozygous mutant embryos were not identified 
during gestation, suggesting that they are not viable (51)(the International Mouse 
Phenotyping Consortium (IMPC)). Furthermore, the SUMO E3 enzyme RanBP2 is 
essential for embryonic development (34). Similar to Ubc9-deficiency, mice with low 
amounts of RanBP2 develop severe aneuploidy due to anaphase-bridge formation. 
Mechanistically, this is linked to reduced Topoisomerase IIα SUMOylation during 
mitosis.
Contradictory results have been published about SUMO-1 deficient mice; 
Alkuraya and coworkers proposed that SUMO-1 plays a role in palatogenesis 
whereas Zhang and coworkers and Evdokimov and coworkers found that SUMO-1 
is not essential for normal mouse development due to compensation by SUMO-
2 and SUMO-3 (52-54). It is currently unclear whether SUMO-2 and SUMO-3 are 
required for viability. Interestingly, loss of SENP1 also results in embryonic lethality in 
mice due to reduced Hypoxia-inducible factor 1-alpha (HIF1α) stability (55, 56), and 
loss of SENP2 resulted in embryonic lethality in mice due to a deficiency in cell cycle 
progression (57), indicating that a finely balanced SUMOylation / deSUMOylation 






In addition to covalent attachment of SUMO proteins to lysines in target substrates 
via peptide-bonds, several proteins are able to interact with SUMO non-covalently 
via SUMO-interaction motifs (SIMs). It is known that a hydrophobic core in a target 
protein mediates SUMO binding, and the Val/Ile-X-Val/Ile-Val/Ile sequence has 
been proposed as a consensus SIM domain. This hydrophobic core is preferentially 
flanked by acidic residues. Hydrophobic and aromatic amino acids located in a 
SIM-binding groove of a SUMO protein can interact with the hydrophobic core of a 
SIM in binding proteins. Acidic amino acids surrounding the hydrophobic core can 
promote electrostatic interaction between SUMO and a binding protein. Furthermore, 
phosphorylation of residues surrounding a SIM can introduce a negative charge 
resulting in an interaction between these residues and lysines located in SUMO. 
SIMs have been identified in many proteins, including SUMO enzymes to increase 
their SUMOylation activity (58, 59). 
PML nuclear bodies
SIM-mediated protein interactions are important for the formation of PML nuclear 
bodies (PML-NBs) (60). PML-NBs act as repositories for many proteins and these 
nuclear domains are important in processes such as DNA repair, transcription and 
tumor suppression. PML proteins form SIM-containing SUMOylated homodimers. 
SUMO proteins that are conjugated to lysines of PML homodimers interact non-
covalently with SIMs on other PML homodimers, forming a complex network of PML 
proteins. Mutant PML proteins in which the SUMO accepting lysines or the SIM have 
been mutated fail to form PML-NBs. Thus, covalent and non-covalent interactions 
between PML and SUMO are required for the formation of nuclear bodies. 
Interestingly, several proteins that are recruited to PML-NBs also contain SIMs and 
can be SUMOylated. Recruitment of these proteins could also depend on covalent 
and non-covalent interaction with SUMO. A good example for SUMO-dependent 
recruitment of proteins to PML-NBs is Death Domain-Associated Protein 6 (Daxx). 
The Daxx protein can interact non-covalently with SUMOylated transcription factors 
and thereby repress transcriptional activity. Daxx can also interact with SUMOylated 
PML, resulting in the recruitment of Daxx to PML-NBs and relief of its transcriptional 
repression (61).
Noncovalent interactions and Ubc9
Non-covalent interaction with SUMO also influences target protein preferences of 
Ubc9. Ubc9 can be auto-SUMOylated on a non-consensus lysine in its N-terminus. 




Speckled 100 kDa protien (Sp100) and IE2 in vitro in a SIM-dependent manner, 
whereas the SUMOylation of several other targets is not affected or impaired (62, 
63). SIMs have other important functions in several cellular processes such as DNA 
repair, protein stability and SUMO chain formation; these functions will be discussed 
hereafter.
1.5 SUMOs in chains
Ubiquitin chains attached to target proteins play important roles in many cellular 
processes in a chain architecture-dependent manner. Initially it was believed that 
SUMO target proteins are usually conjugated to one or more SUMO monomers. 
However, research on SUMOylation over the years showed that SUMOs are also 
able to form chains on target proteins. Mammalian SUMO-2 and SUMO-3 contain 
an internal consensus SUMOylation site located in their unstructured N-terminal 
protrusion. Interestingly, this site is missing in SUMO-1 (64). The yeast SUMO 
homologue Smt3 contains two SUMOylation consensus sites (65).
SUMO polymer formation in cells
Polymeric SUMO chains were initially identified in vitro. Using a recombinant 
SUMOylation system, it was first found that SUMO-2 and -3 multimerize very 
efficiently in vitro (64). Efficient chain formation occurs on lysine 11 (K11) located 
in a consensus site on SUMO-2 and SUMO-3, however chain formation has also 
been observed on non-consensus lysines in SUMO-1, -2 and -3 in vitro. Furthermore 
it has been shown that SUMO chains can be anchored to recombinant targets 
(e.g. PML, HIF-1α) in vitro. Previously we showed that SUMO chain formation 
also occurs in cells. Using a mass spectrometry approach, we found evidence for 
SUMO polymerization in vivo by detecting the SUMO-2/3 branched peptide that is 
SUMOylated on K11. This study also showed that SUMO-1 can be conjugated to 
K11 in SUMO-2/3 and thereby limit SUMO-2 chain formation in vitro (66). 
Ubc9 regulates SUMO chain formation
The observation that Ubc9 can interact with SUMO in a non-covalent manner has 
provided mechanistic insight into SUMO chain formation. Ubc9 binds SUMO non-
covalently on a site that is located distal to the active cysteine that is used for the 
formation of a SUMO-Ubc9 thioester complex. This non-covalent interaction is 
important for SUMO multimerization since mutating the binding site in Ubc9 strongly 
reduced SUMO chain formation in vitro. Mechanistically, it is not completely clear 
how this non-covalent interaction induces chain formation. One possibility is that 
Ubc9 can dimerize and that a non-covalently bound SUMO on one Ubc9 moiety 
is SUMOylated on K11 by another SUMO-Ubc9 thioester complex (67). SUMO E3 




SUMO that are not situated in SUMOylation consensus sites. The SUMO specific 
proteases Ulp2 in yeast and SENP6 and SENP7 in mammals are very efficient 
in disassembling SUMO chains both in vitro and in vivo (68, 69). Research has 
provided insight into some biological functions of SUMO chain formation in cells, 
some examples can be found in the following sections. 
1.6 Crosstalk between SUMOylation and other PTMs
In addition to SUMOylation, proteins are regulated by a diverse set of other post-
translational modifications. Orchestration of these different modifications is important 
for full control of protein activity. Antagonistic and cooperative forms of crosstalk 
have been reported between SUMOylation and other types of post-translational 
modifications including phosphorylation, acetylation and ubiquitination (Figure 2).
Crosstalk between SUMOylation and phosphorylation
Phosphorylation events that occur in the vicinity of SUMOylation consensus sites 
can positively enhance SUMOylation. A specific Phosphorylation-dependent 
SUMOylation Motif (PDSM) was discovered, ψKxExxSP, that mediates 
phosphorylation-dependent SUMOylation of target proteins such as heat-shock 
factors, GATA-1 and myocyte enhancer factor 2 (70). The local negative charge is 
important for enhancing SUMOylation since clusters of negatively charged amino 
acids can also enhance SUMOylation via increased binding of Ubc9 (71). The 
precise spacing between phosphorylation sites and SUMOylation sites might be 
critical for phosphorylation-mediated SUMOylation. Phosphorylation of residues that 
are not situated in PDSMs can also negatively influence SUMOylation. Interestingly, 
SUMO itself is a phosphoprotein, although the functional relevance of SUMO 
phosphorylation is currently unclear (72, 73).
Crosstalk between SUMOylation and acetylation
Other forms of crosstalk have been identified between SUMOylation and acetylation. 
A key function of SUMOs is repressing transcription factors (74). Interplay between 
SUMOylation and acetylation can explain the repressive activity of SUMO on the 
transcription factor Elk-1 (75). SUMOylation of Elk-1 promotes association with 
Histone Deacetylase 2 (HDAC2) to remove acetyl groups from histones in a local 
manner, thereby repressing transcription. Alternatively, HDACs can also promote 
SUMOylation of target proteins by deacetylation of lysines used for SUMO 
modification. SUMOylation and acetylation can also compete for the same lysine. 
SUMOylation of p53 blocks the acetylation of the same acceptor lysine and inhibits 
p53 binding to DNA (76). Furthermore it has been established that acetylation of 
SUMO proteins interferes with its binding to SIMs, thereby blocking the interaction 













































Crosstalk between SUMOylation and ubiquitination
Although they were first seen as mutually exclusive events, extensive crosstalk 
between SUMOylation and ubiquitination has been uncovered by many studies. 
First of all, SUMOs and ubiquitin can compete for acceptor lysines in target proteins. 
For example, SUMOylation of the Nuclear Factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) inhibitor alpha (IκBα) on a lysine that is also used for 
ubiquitination protects IκBα from proteasomal degradation (78). Phosphorylation 
of IκBα induces its ubiquitination and degradation, resulting in translocation of NF-
κB to the nucleus and activation of its target genes. Interestingly, phosphorylation 
inhibits the SUMOylation of IκBα, indicating an antagonistic relation between 
SUMOylation and phosphorylation-dependent ubiquitination of IκBα. 
 Another target for crosstalk between SUMO and ubiquitin in the NF-κB pathway 
is the IκBα kinase component Inhibitor of NF-κB kinase subunit gamma/ NF-kappa-B 
essential modulator (IKKγ/NEMO) (79). Activation of this structural IκBα kinase 
component depends on sequential modification of NEMO by SUMO and ubiquitin. 
Upon genotoxic stress, NEMO translocates to the nucleus and accumulates in 
a SUMOylated form. Upon deSUMOylation, NEMO gets phosphorylated and 
subsequently ubiquitinated on the same two lysines used for SUMOylation. 
Ubiquitin-modified NEMO translocates to the cytoplasm where it forms an active 
IKK kinase complex (80).   
 
Figure 2. Crosstalk between SUMO and other PTMs. (A) Phosphorylation (P) downstream of a SUMO 
consensus site can induce SUMOylation by increased Ubc9 binding. (B) SUMOylation and acetylation 
(Ac) can compete for the same lysine. Acetylation of SUMOylated proteins blocks the interaction between 
SUMO and SIM-containing proteins. (C) SUMOylation can have both positive and negative effects on 
protein stability, by either blocking ubiquitination (Ub) of lysines or by targeting proteins for proteasomal 




Originally it was understood that SUMOylation did not affect target protein stability. 
However, more recent studies have shown that SUMOylation of some proteins can 
act as an ubiquitination signal. This was uncovered via functional studies on the 
yeast Synthetic lethal of unknown function protein 5 and 8 (SLX5/8) complex and 
the mammalian RING finger protein 4 (RNF4) protein (81, 82). These ubiquitin E3 
ligases can interact with SUMOylated proteins via internal SIMs and subsequently 
ubiquitinate these SUMOylated proteins and are therefore called SUMO-targeted 
ubiquitin ligases (STUBLs) (83). Yeast strains lacking SLX5/8 accumulate 
SUMOylated proteins and show genomic instability. PML was the first identified 
mammalian target protein for SUMO-dependent ubiquitination. It was shown that 
proteasomal degradation of PML and PML-retinoic acid receptor alpha (PML-RARα) 
upon arsenic treatment depends on poly-SUMOylation of these proteins. Four internal 
SIMs in RNF4 are essential for targeting PML, most likely via binding to a SUMO 
chain on lysine 160 (84, 85). In another study, ubiquitin was found to co-purify with 
SUMO-2 target proteins. Quantitative proteomics was subsequently employed to 
identify a large set of proteins that are regulated by crosstalk between the ubiquitin-
proteasome pathway and SUMOylation. It was shown that the SUMOylated fraction 
of several proteins strongly increased upon proteasome inhibition. This indicates that 
a subset of SUMO-2 modified proteins are subsequently degraded by the ubiquitin-
proteasome system, possibly in an RNF4-dependent manner. Interestingly, this 
study identified a second set of SUMOylated proteins that were negatively affected 
by proteasome inhibition. The decrease in SUMOylation of these target proteins by 
proteasome inhibitors could potentially be explained by a lack of recycled SUMOs 
(86). 
 Two additional STUBLs were identified more recently; Ubiquitin ligase for SUMO 
conjugates protein 1 (Uls1) and RNF111. Uls1 is responsible for the ubiquitination 
and clearance of poly-SUMOylated Rap1 proteins to facilitate non-homologous 
end joining at telomeres (87). RNF111 is recruited to sites of DNA damage by 
SUMOylated Xeroderma Pigmentosum group C-complementing protein (XPC) to 
induce nonproteolytic ubiquitination (88). Like RNF4, RNF111 also seems to have 
an effect on PML stability (89). Crosstalk between SUMOylation and ubiquitination 
regulate several processes during the DNA damage response, this is further 
discussed in the section ‘SUMOylation in DNA repair’.  
1.7 SUMOylation and cell cycle progression
Cell cycle defects upon alterations in the SUMO landscape
Since its discovery, SUMO has been linked to cell cycle progression in many reports. 
A lot of these studies were based on interfering with expression levels of SUMO, 




1995, when Seufert and coworkers found that knocking out Ubc9 expression in 
yeast caused an accumulation of large budded cells with a 4n DNA content due to 
an arrest at the G2 or M phase of the cell cycle (90). Similar defects on cell cycle 
progression in yeast were found upon interference with expression of the two SUMO 
E1 enzyme subunits, Uba2 and Aos1 (17, 91). Absence of Ubc9 or Smt3 (SUMO 
in yeast) expression in S.cerevisiae had an effect on the activity of the anaphase-
promoting complex/cyclosome (APC/C), resulting in a metaphase block and defects 
in chromosome segregation (92). Furthermore, it has been shown that the formation 
of SUMO chains by Ubc9 plays an essential role in meiosis in S.cerevisiae (93). 
 Deletion of Ulp1 and Ulp2, the two SUMO specific proteases in yeast, also 
resulted in cell cycle defects. Deletion of Ulp1 expression caused a G2/M block, 
this was however partly unrelated to the effect on SUMO conjugation (44). Ulp2 
expression is essential for the restart of cell division after checkpoint arrest by 
regulating mitotic spindle dynamics (94). These yeast studies revealed an emerging 
role for SUMOylation in cell cycle progression; this was further emphasized by studies 
in mammalian systems. Mouse embryonic fibroblast (MEFs) derived from Ubc9-
deficient embryos displayed severe chromosome condensation and segregation 
defects, resulting in an increase in amount of cells that contain more than two paired 
sets of chromosomes (polyploidy) (49). Interestingly, although the total number of 
Ubc9 knockout MEFs was reduced compared to wild-type MEFs, the mitotic index 
was almost unchanged. Human fibroblasts with a decreased Ubc9 expression 
showed reduced proliferation without an arrest in a particular phase of the cell cycle, 
suggesting that Ubc9 knockdown induces a general growth arrest (95). Interestingly, 
knocking down the SUMO specific protease SENP5 in human HeLa cells, led to 
similar phenotypes. A strong reduction in proliferation rate was observed in cells with 
reduced SENP5 expression. In alignment with the results from the Ubc9 study, this 
could not be explained by an arrest during a specific phase of the cell cycle (96). 
Disruption of SENP2 expression in mice revealed an essential role for this SUMO 
specific protease in cell cycle progression rate and the transition from G1 to S phase 
(57). Together these studies showed that a dynamic SUMOylation/deSUMOylation 
system is essential for proper cell cycle progression.
SUMO targets at chromosomes
SUMO signals in fluorescence microscopy are often observed at centromeres and 
kinetochores of condensed chromosomes during the first stages of mitosis. Several 
centromere and kinetochore proteins that play essential roles during mitosis were 
identified as SUMO targets (97, 98). The SUMO E3 ligase RanBP2 SUMOylates Topo 
IIα during mitosis. This is essential for the targeting of Topo IIα to inner centromeres 
where it subsequently allows proper separation of sister chromosomes in anaphase 




accumulation of the SUMOylated form of Topo IIα in yeast after Ulp2 deletion results 
in prolonged metaphase and defects in centromeric cohesion (99). 
 Two other identified SUMO target proteins with a role in mitosis are members of 
the chromosomal passenger complex (CPC); this complex regulates the attachment 
of kinetochores to microtubules and cytokinesis. SUMOylation of the CPC member 
Aurora B during mitosis is needed for proper chromosome segregation, most likely by 
regulating the removal of CPC complexes from chromosomes during prometaphase 
(100, 101). Another member of the CPC, Borealin, was identified as a mitotic specific 
SUMO-2/3 target protein. The role of Borealin SUMOylation is currently unknown but 
does not affect CPC assembly and localization (35). 
 Centromere (CENP) protein family members form another group of SUMO 
regulated targets. SENP6 dependent deSUMOylation of CENP-I and CENP-H 
protects these proteins for proteasomal degradation during S phase, this is essential 
for the proper localization of kinetochore proteins (102, 103). The microtubule motor 
protein CENP-E specifically recognizes and binds to SUMO-2/3 chains which is 
essential for kinetochore localization of CENP-E. This is potentially regulated via non-
covalent interactions between CENP-E and SUMO-2/3 chains on the centromere/
kinetochore associated proteins Budding uninhibited by benzimidazoles 1 beta 
(BubR1) and Kinetochore protein Nuf2 (104); see also figure 3A.
SUMOylation and transcription
Besides regulating proteins directly involved in mitosis, SUMO also regulates cell 
cycle progression indirectly by affecting the expression of many genes. SUMOylation 
and its role in transcription is probably one of the most studied and best documented 
downstream consequence of SUMO modification and is extensively reviewed (105-
107). Initially SUMOylation was mainly linked to transcription repression but now 
a growing number of studies report on examples where SUMOylation can also 
activate transcription. Genome-wide studies have uncovered a general link between 
SUMOylation and gene repression. It has been shown that targeting Ubc9 to a 
promoter decreases transcriptional activity (108) and that active SUMOylation at 
promoter regions represses expression of several classes of genes (95). 
 Several mechanisms can explain the regulation of transcription by SUMO. 
SUMOylation can induce or inhibit enzymatic activity of proteins and SUMOylation can 
directly affect the DNA binding capacity of transcription factors. Furthermore, SUMO 
can organize both the formation of repressive complexes as well as the formation 
of activation complexes on chromatin. A lot of studies report on how SUMOylation 
can either repress or activate the transcription of genes, one example for each case 
is given below (additional examples can be found in the section ‘crosstalk between 
SUMOylation and acetylation’). SUMOylation of the maintenance methylase DNA 





Figure 3. SUMOylation plays several roles during cell cycle progression. (A) SUMO (S) regulates 
the translocation of proteins to chromosomes and SUMOylation of chromosome interacting proteins 
induces the recruitment of SIM containing proteins. (B) SUMOylation has repressive effects on 
gene expression by recruiting inhibitory complexes or chromatin remodelers to transcription factors 
(TF). (C) SUMOylation has activating effects on gene expression by recruiting activation complexes 
to transcription factors and by blocking the interaction between transcription factors and inhibitory 






































protein on chromatin. Methylation of DNA physically blocks the binding of sequence 
specific transcriptional proteins and methylated DNA recruits chromatin remodeling 
proteins resulting in the formation of inactive chromatin. SUMO induced DNMT1 
activity therefore results in repression of gene expression (109). One example 
where SUMOylation activates gene expression was reported for the transcriptional 
repressor Ikaros. SUMOylation of Ikaros hinders the interaction of Ikaros with the 
co-repressor complexes transcriptional regulatory protein Sin3 and Nucleosome 
Remodeling Deacetylase (NuRD), resulting in the release of repression (110). The 
effect of SUMOylation on transcription is thus substrate-dependent and can therefore 
not simply be described as ‘repressive’ or ‘activating’; see also figure 3B and 3C.
1.8 SUMOylation and DNA repair
The genomic stability of cells is maintained by a variety of DNA repair pathways 
collectively called the DNA Damage Response (DDR). These DDRs consist of 
proteins that are responsible for the recognition, removal and repair of DNA lesions. 
These proteins are extensively regulated by dynamic post-translational modifications 
during the DDR. SUMOylation has been shown to play crucial roles during several 
DNA repair mechanisms, sometimes in coordination with ubiquitination (111, 112). 
Some of these roles are summarized in this section and in figure 4.
A role for SUMO in Base Excision Repair
The first link between SUMOylation and DNA repair was revealed in studies on Base 
Excision Repair (BER). During BER, base lesions are recognized by the Thymine-DNA 
glycosylase (TDG) protein, an enzyme that removes the damaged base. Removal of 
this base results in an abasic site, which in turn induces a strong interaction between 
TDG and the abasic site. This strong interaction has to be reduced to facilitate the 
subsequent steps in BER and to guarantee proper repair of the lesion. SUMO-1 
modification on the C-terminus of TDG upon DNA binding induces a conformational 
change in the DNA bound N-terminus of this protein, leading to reduced binding of 
TDG to the abasic site. This initiates the next step in BER and is also needed for the 
enzymatic turnover of TDG (113, 114).
A SUMO – ubiquitin switch on PCNA
A good example of the cooperative regulation of DNA repair by SUMO and ubiquitin 
is the Proliferating Cell Nuclear Antigen (PCNA) protein, an essential cofactor for 
DNA polymerases (115, 116). PCNA encircles the DNA as a sliding clamp thereby 
acting as a docking platform for many proteins involved in DNA metabolism. Crosstalk 
between SUMO and ubiquitin on PCNA acts as a switch for different pathways of 
processing DNA lesions during replication. Monoubiquitination of PCNA on lysine 




damage tolerant polymerase Polη. In yeast, K63 ubiquitin chain formation on K164 
of PCNA is somehow involved in error-free replication of the damaged DNA. Also in 
yeast, PCNA is SUMOylated in S phase on K164 as well as K127. SUMOylated PCNA 
recruits the antirecombinogenic helicase Srs2, thereby limiting recombination during 
replication (117, 118). Upon DNA damage, Srs2 bound to SUMOylated PCNA blocks 
the recombination machinery resulting in a stalled replication fork when it encounters 
a lesion. This Srs2 mediated block in replication results in damage avoidance. 
Crosstalk between SUMO and ubiquitin on PCNA has mainly been studied in yeast; 
PCNA SUMOylation is difficult to detect in human cells. More recently, PCNA-
interacting partner (PARI) was identified as PCNA-interacting protein in human cells 
with a preferential binding to SUMOylated PCNA in vitro (119). This Srs2-like protein 
inhibits unwanted recombination at mammalian replication forks. 
Coordinated SUMOylation and ubiquitination signals in DDR
The DDRs that regulate the repair of double strand breaks (DSBs) are broadly regulated 
by both SUMOylation and ubiquitination. Several members of the SUMOylation 
machinery were found to accumulate at sites of DSBs (120, 121). Accumulation of 
the SUMO E3 ligases PIAS1 and/or PIAS4 at DSBs induces a wave of SUMOylation 
which is needed for the recruitment of crucial repair factors such as RNF168, Tumor 
suppressor p53-binding protein 1 (53BP1), Receptor-associated protein 80 (RAP80) 
and Breast Cancer Type 1 Susceptibility Protein (BRCA1). This is regulated by the 
SUMOylation of several DSBs repair factors. SUMOylation of the ubiquitin E3 ligase 
BRCA1 at DSBs induces its ubiquitination activity in vitro, potentially by enhancing 
the interaction between SUMO-BRCA1 and target proteins that harbor SIMs. Other 
targets for PIAS1 / PIAS4 mediated, DSBs specific SUMOylation are the repair 
factors 53BP1 and RNF168. DNA damage- and PIAS4-dependent SUMOylation of 
Human epidermal growth factor receptor 2c (HERC2) is required for its binding to 
RNF8 at DSBs (122). 
 Another form of crosstalk between SUMO and ubiquitin at sites of DSBs is the 
recruitment of the STUBL RNF4 by SUMOylated DSB-response proteins. Interfering 
with RNF4 expression in human and chicken cells caused defects in the DSBs repair 
pathways homologous recombination (HR) and non-homologous end joining (NHEJ). 
RNF4 accumulates at sites of DNA damage through interactions between its SIMs 
and SUMOylated 53BP1, Mediator of DNA damage checkpoint protein 1 (MDC1) 
and Replication protein A (RPA). At DSBs, RNF4 mediates the ubiquitination and 
proteasomal degradation of DSB-repair proteins including MDC1, RPA and BRCA1. 
This is required for the rapid turnover of these proteins and for the efficient loading 
of Radiation sensitive 51 (RAD51) (123-126). 
  Another STUBL, RNF111, plays a critical role in nucleotide excision repair (NER). 




damage and subsequently recognized by RNF111. Together with the E2 enzyme 
Ubc13-Mms2, RNF11 promotes the nonproteolytic, K63-linked ubiquitination of 
SUMOylated XPC. This process is also regulating the recruitment of XPC to UV-














































































Figure 4. SUMOylation plays several roles in the DNA damage response. (A) SUMOylation (S) 
facilitates Base Excision Repair by inducing a conformational change in the Thymine-DNA glycosylase 
(TDG) protein. (B) The Proliferating Cell Nuclear Antigen (PCNA) protein is regulated by a SUMO – 
ubiquitin switchboard to process DNA lesions. (C) Recruitment of the SUMO machinery regulates 
different processes in double strand break repair. SUMOylation induces complex formation of repair 
proteins, enhances the ubiquitination activity of BRCA1 and initiates the recruitment of RNF4. Figures 




Thus, DNA damage triggers SUMOylation of many proteins involved in DSBs repair. 
Interestingly, it was recently reported that only abolishing SUMOylation of several 
repair proteins significantly impairs HR pathway in yeast (127). The authors suggest 
that SUMOylation acts as a ‘molecular glue’ to enhance interactions between DNA 
repair proteins and that SUMO acts synergistically on protein groups to facilitate 
DNA repair. Protein group modification by SUMO was also found to be important for 
proper nucleotide excision repair in yeast (128). 
1.9 SUMO proteomics
A revolution in understanding protein SUMOylation came with the introduction of 
mass-spectrometry (MS) based proteomics to study SUMO targets, SUMOylation 
dynamics and SUMO acceptor sites. MS based approaches are widely used for the 
systematic, quantitative and qualitative identification of post-translational modifications 
on proteins (129, 130). For ubiquitin-like modifications, these approaches are based 
on the purification of conjugated proteins using cells expressing tagged ubiquitin-
like (UBL) proteins. These purified proteins are subjected to tryptic-digestion, the 
resulting peptide mixture is analyzed by MS and specific software is used to identify 
and quantify peptides. In addition, stable isotope labeling by amino acids in cell 
culture (SILAC), has enabled the metabolic labeling of endogenous proteins and 
subsequent quantification (131). SILAC can be used to study PTMs dynamics in 
response to different stimuli by labeling two or three sets of cells with distinct isotope 
variants, metabolic incorporation of the distinct amino acids results in a mass shift of 
labeled peptides. Cells that do not express tagged-UBL proteins are often included in 
SILAC experiments to discriminate between UBL target proteins and contaminants. 
 Studying SUMOylation by MS is challenging for different reasons. First of all, the 
low modification stoichiometry for many SUMOylated proteins requires the efficient 
and large scale purification of SUMO conjugates from cells. The activity of SUMO 
specific proteases in lysates during these purifications form another pitfall in SUMO 
based proteomics. Finally, site-specific identification of SUMO targets is very difficult 
due to the large SUMO peptide branch remaining after tryptic digestion (132). 
Nevertheless, SUMO proteomics has significantly increased our knowledge on 
SUMO target proteins and on SUMO dynamics during different cellular processes. 
By using denaturing buffers to inactivate SUMO proteases it has been revealed that 
SUMO-1 and SUMO-2/3 have both distinct and overlapping target proteins (133, 
134). 
 So far hundreds of SUMO target proteins have been identified by MS-based 
studies in different organisms, revealing roles for SUMOylation in many cellular 
processes including transcription, DNA repair, growth control and RNA metabolism 
(135-140). 




in SUMOylation patterns upon different cellular stress conditions such as heat 
shock (141, 142) and oxygen/glucose-deprivation (143). In these studies, it was not 
possible to discriminate between mono-SUMOylated and poly-SUMOylated target 
proteins. Interestingly, a method was developed that allowed the identification of 
polySUMO conjugates in cells (144). Although these studies shed light on which 
proteins are regulated by SUMOylation, they did not provide information on the 
exact acceptor lysines used for SUMO modification. This information is needed to 
be able to make SUMO-deficient mutants to study the effect of SUMOylation on 
individual target proteins. Mutating SUMO consensus sites only is often not sufficient 
to generate a SUMO-deficient mutant and quite often these consensus sites are not 
used since they are inaccessible for the SUMO machinery in folded proteins (145). 
Compared to other PTMs, mapping of SUMOylation sites by mass spectrometry is 
technically challenging since the long SUMO tryptic peptide conjugated to target 
lysines produces complex MS/MS spectra. 
 Despite its difficulties, several approaches were proven to be successful in 
mapping acceptor lysines for SUMO. Peptides modified by SUMO in vitro were 
successfully detected by a pattern recognition tool (SUMmOn) and low-resolution 
MS (146). In a previous study, we have used linearization of branched peptides in 
combination with targeted MS to identify SUMO polymerization sites (66). In other 
approaches, the tryptic SUMO remnant was shortened by mutating an amino acid 
close to the C-terminus of SUMO into a trypsin cleavable arginine. These mutations 
do not alter the conjugation efficiency of SUMOs to target proteins (147, 148). 
Utilizing these constructs, researchers identified 14 SUMO-1 sites in HeLa cells 
(149), 17 SUMO-3 sites in A. thaliana (150) and 17 SUMO-1 sites in HEK293 cells 
(151). Furthermore, the development of the database search tool “ChopNSpice” has 
enabled the identification of SUMO sites on endogenous proteins (152). 
 Despite the fact that SUMO proteomics has significantly contributed to our 
knowledge of SUMO’s function, still a lot of targets and modified lysines remain to 
be identified. Improvement of proteomic based techniques will give us more detailed 
insight into SUMOylation dynamics in different cellular processes. 
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Chapter 2. The ubiquitin-proteasome system is a key 
component of the SUMO-2/3 cycle
Abstract
Many proteins are regulated by a variety of post-translational modifications and 
orchestration of these modifications is frequently required for full control of activity. 
Currently, little is known about the combinatorial activity of different post-translational 
modifications. Here we show that extensive crosstalk exists between sumoylation 
and ubiquitination. We found that a subset of SUMO-2 conjugated proteins is 
subsequently ubiquitinated and degraded by the proteasome. In a screen for 
preferential SUMO-1 or SUMO-2 target proteins, we found that ubiquitin accumulated 
in purified SUMO-2 conjugates, but not in SUMO-1 conjugates. Upon inhibition of 
the proteasome, the amount of ubiquitin in purified SUMO-2 conjugates increased. 
In addition, we found that endogenous SUMO-2/3 conjugates, but not endogenous 
SUMO-1 conjugates, accumulated in response to proteasome inhibitors. Quantitative 
proteomics experiments enabled the identification of 73 SUMO-2 conjugated proteins 
that accumulated in cells treated with proteasome inhibitors. Crosstalk between 
SUMO-2/3 and the ubiquitin-proteasome system controls many target proteins that 
regulate all aspects of nucleic acid metabolism. Surprisingly, the relative abundance 
of 40 SUMO-2 conjugated proteins was reduced by proteasome inhibitors, possibly 
due to a lack of recycled SUMO-2. We conclude that SUMO-2/3 conjugation and the 
ubiquitin-proteasome system are tightly integrated and act in a cooperative manner.
Introduction
The ubiquitin-proteasome system plays a key role in virtually all cellular processes 
by tightly regulating the degradation of a large set of proteins (1). Proteins are 
targeted for degradation by lysine-48 linked polyubiquitin chains that are covalently 
conjugated to lysines in target proteins. Ubiquitination furthermore regulates target 
proteins in a degradation-independent manner, e.g. mono-ubiquitination is important 
for endocytosis (2). A significant part of the human genome encodes components 
of the ubiquitin-proteasome system, including E1, E2 and hundreds of E3 enzymes 
that mediate the conjugation of target proteins to ubiquitin, and ubiquitin proteases 
that remove ubiquitins from target proteins. 
 The ubiquitin family comprises ubiquitin-like proteins NEDD8, ISG15, SUMO-
1, -2, -3, FAT10, FUB1, UBL5, URM1, ATG8 and ATG12 (3, 4). These proteins 
share the 3D structure of ubiquitin and are also conjugated to target proteins. Like 
ubiquitination, sumoylation is essential for eukaryotic life (5). The largest functional 
group of SUMO targets are transcription factors (6) and in general, sumoylation 




processes including DNA-repair, RNA metabolism, protein transport, translation 
and replication (8-10). Whereas mature SUMO-2 and SUMO-3 are nearly identical 
(~95% identity), they differ significantly from SUMO-1 (~50% identity). Previously, we 
have shown that SUMO-1 and SUMO-2 are conjugated to preferential sets of target 
proteins (6). Furthermore, SUMO-2 and SUMO-3 contain an internal sumoylation 
site that is used for SUMO chain formation in vivo (11-13).
 Sumoylation is not linked to the degradation of target proteins, although some 
exceptions have been reported. The SUMO-accepting lysine 160 in PML and in the 
oncogenic PML-RARα protein is required for the degradation of this fusion protein 
upon arsenic-trioxide treatment (14). Furthermore, it has been published that 
sumoylation might be important for the degradation of DNA Topoisomerase IIα in 
response to a catalytic inhibitor (15).
 Different kinds of crosstalk between ubiquitination and sumoylation have currently 
been reported (16). SUMO and ubiquitin were shown to counteract each other by 
competing for the same acceptor lysine in IκBα (17). NF-κB signaling is furthermore 
affected by the ubiquitination and sumoylation of NEMO/IKKγ, a structural component 
of the IKK complex (18). In this case, SUMO-1 and ubiquitin do not directly compete 
for the same acceptor lysine, but are conjugated in a sequential manner in response 
to genotoxic stress. PCNA is also modified by SUMO and ubiquitin on the same 
acceptor lysine (K164) (16, 19). Sumoylation enables the interaction between PCNA 
and the helicase Srs2, whereas monoubiquitination enables translesion synthesis by 
Polη, a DNA damage-tolerant polymerase and polyubiquitination is needed for DNA 
repair.
 In a screen for preferential SUMO-1 and preferential SUMO-2 conjugates, we 
found that ubiquitin specifically co-enriched with SUMO-2. The amount of ubiquitin in 
SUMO-2 purified fractions significantly increased upon inhibition of the proteasome. 
Quantitative proteomics enabled us to study the crosstalk between sumoylation and 
the ubiquitin-proteasome system at the target protein level. We show here that the 
conjugation of a large set of target proteins to SUMO-2 is tightly connected to the 
ubiquitin-proteasome system and conclude that the ubiquitin-proteasome system is 
a key component of the SUMO-2/3 cycle in cells.
Results
Ubiquitin co-purifies preferentially with SUMO-2 conjugates
The quantitative proteomics experiment that we previously described to show that 
SUMO-1 and SUMO-2 are conjugated to preferential sets of target proteins (6) 
was repeated using lysine encoding instead of arginine encoding (Fig. 1A). Control 
HeLa cells were labeled with Lys0, HeLa cells stably expressing His6-SUMO-1 were 
labeled with Lys4 and HeLa cells stably expressing His6-SUMO-2 were labeled with 




Fig. 1. SUMO-2 conjugates are enriched for ubiquitin. A, a quantitative proteomics strategy to identify 




were mixed in a 1:1:1 ratio. His6-SUMO conjugates were subsequently purified 
and separated on a one-dimensional gel (Fig. 1B). The gel lane was cut in slices 
and proteins were in-gel digested by Lys-C and analyzed by mass spectrometry. 
Interestingly, we identified two different ubiquitin peptides from the top slices of the 
gel lane that were preferentially enriched in the Lys8 encoded form, indicating that 
endogenous ubiquitin co-purified with large His6-SUMO-2 conjugates but not with 
large His6-SUMO-1 conjugates (Fig. 1C and Supplementary Fig. S1). The amount 
of ubiquitin that co-purified with His6-SUMO-2 conjugates significantly increased 
upon inhibition of the proteasome (Fig. 1D-F). The reverse experiment showed that 
endogenous SUMO-2/3 co-purified with His6-ubiquitin conjugates (Fig. 1G-I).
Endogenous SUMO-2/3 conjugates accumulate in cells treated with proteasome 
inhibitors
To study the effect of proteasome inhibition on endogenous SUMO-1 and 
endogenous SUMO-2/3, HeLa cells were treated with MG132 or epoxomicin for 
up to eight hours (Fig. 2). These inhibitors caused rapid accumulation of ubiquitin 
in cells (Fig. 2A and E) and in addition caused the accumulation of SUMO-2/3 
conjugates, albeit with slower kinetics (Fig. 2C and G). Simultaneously, the amount 
of non-conjugated SUMO-2/3 was significantly reduced by these inhibitors (Fig. 
2M). The total amount of SUMO-1 conjugates in cells was not affected by MG132 
or epoxomicin treatments, although the pattern of SUMO-1 conjugates slightly 
changed (Fig. 2B and F). Control DMSO treatments did not affect ubiquitination or 
sumoylation (Fig. 2I-K). 
with Lys4 and HeLaHis6-SUMO-2 cells were labeled with Lys8. Equal amounts of nuclear lysates from the 
three different populations were mixed and proteins conjugated to His6-SUMO were purified. The SUMO 
enriched fraction was separated by SDS-PAGE, proteins were visualized by Coomassie staining, the 
gel lane was cut in slices and the proteins present in these slices were digested by Lys-C and identified 
by mass spectrometry. Peptide mass spectra were quantified to identify proteins potentially conjugated 
to SUMO-1 and/or SUMO-2. C, the His6-SUMO-2 purified fraction is specifically enriched for ubiquitin. 
Two different ubiquitin peptides (aa MQIFVK and TITLEVEPSDTIENVK) were found to be enriched in 
His6-SUMO-2 conjugates but not in His6-SUMO-1 conjugates in the top part of the gel lane. The peptide 
mass spectra of the ubiquitin peptide TITLEVEPSDTIENVK is shown. D-F, the proteasome inhibitor 
MG132 increases the amount of ubiquitin in His6-SUMO-2 conjugates. HeLa cells, HeLaHis6-SUMO-1 cells 
and HeLaHis6-SUMO-2 cells were treated for 1 or 3 hours with MG132 or were treated with DMSO for 3 hours. 
Whole cell lysates were prepared, size-separated by SDS-PAGE and transferred to a membrane. Total 
protein was visualized by Ponceau S staining (D) and the membrane was probed using antibody SC-8017 
to detect ubiquitin (E). His6-SUMO conjugates from whole cell lysates were purified, size-separated by 
SDS-PAGE, transferred to a membrane and probed to detect ubiquitin (F). G-I, the proteasome inhibitor 
MG132 increases the amount of SUMO-2/3 in His6-ubiquitin conjugates. HeLa cells were transfected 
with a plasmid that encodes His6-ubiquitin, or with an empty control plasmid and cells were subsequently 
treated with MG132 or DMSO for 3 hours. Whole cell lysates were prepared, size-separated by SDS-
PAGE and transferred to a membrane. Total protein was visualized by Ponceau S staining (G) and the 
membrane was probed using antibody AV-SM23-0100 to detect SUMO-2/3 (H). His6-ubiquitin conjugates 
were purified from whole cell lysates, size-separated by SDS-PAGE, transferred to a membrane and 




Fig. 2. Endogenous SUMO-2/3 conjugates accumulate in cells 
treated with proteasome inhibitors. A-M, HeLa cells were treated for 
the indicated periods of time with the proteasome inhibitors MG132 (A-D 
and M) or epoxomicin (E-H and M) or with DMSO (I-L and M). Whole 
cell extracts of HeLa cells were separated by SDS-PAGE, transferred 
to membranes, stained with Ponceau S to visualize total protein (D, H 
and L) and probed using antibody SC-8017 to detect ubiquitin (A, E 
and I), antibody 21C7 to detect SUMO-1 (B, F and J) or antibody AV-




Identification of SUMO-2 target proteins that are affected by the proteasome 
inhibitor MG132
To identify individual SUMO-2 target proteins that are sensitive to proteasome 
inhibition, quantitative proteomics was employed (Fig. 3A). Two pools of HeLaHis6-
SUMO-2 cells were used for this experiment, the first pool of cells was labeled with Arg0 
and Lys0 and treated with DMSO and the second pool of cells was labeled with 
Arg10 and Lys8 and treated with MG132. It is important to note that this strategy 
was optimal for identifying SUMO-2 conjugates that were sensitive to proteasome 
inhibition, but it is likely that contaminating non-sumoylated proteins were co-purified. 
Especially the group of purified proteins with an unaltered ratio might contain a 
significant percentage of contaminants. Cells were harvested and whole cell lysates 
were mixed in a 1:1 ratio. His6-SUMO-2 conjugates were subsequently purified, 
digested in solution with trypsin, and analyzed by mass spectrometry. A summary 
of the results is depicted in Fig. 3B. 847 proteins were identified by at least two 
unique peptides (Supplementary Table 1 Proteins Sheet) and in total 7643 peptides 
were identified by mass spectrometry (Supplementary Table 1 Peptides Sheet). 
Interestingly, two different subsets of MG132-sensitive SUMO-2 target proteins were 
identified, 73 target proteins showed a significant increase in sumoylation upon 
inhibition of the proteasome (Supplementary Table 3) and 40 target proteins showed 
a significant decrease in sumoylation in response to MG132 (Supplementary Table 
4). The MG132 mediated increase in SUMO-2 conjugation was consistent with the 
immunoblot experiments (Fig. 2) whereas the MG132 mediated decrease in SUMO-
2 conjugation of other target proteins was unexpected. The decrease in sumoylation 
of these target proteins might potentially be explained by a reduction in free SUMO-2 
(Fig. 2M). 
The largest functional group of MG132-regulated SUMO-2 conjugated proteins 
control nucleic acid metabolism (Supplementary Fig. S2). This group constitutes 
47% of all MG132-upregulated targets and 40% of all MG132-downregulated targets 
and includes DNA repair factors, replication factors, helicases, basal transcription 
machinery components, transcription factors, chromatin modifiers and RNA binding 
and processing factors (Supplementary Fig. S2). In addition, both MG132 sensitive 
subsets contain a variety of other proteins, implicating that crosstalk between SUMO-
2 and ubiquitin has a broad impact on cellular processes.
 To confirm our findings independently, His6-SUMO-2 conjugates were purified 
from DMSO or MG132 treated cells and immunoblotting experiments were carried 
out (Fig. 4). These experiments confirmed the accumulation of SUMO-2 conjugated 
forms of hnRNP M, MCM-7 and PIAS1 upon proteasome inhibition (Fig. 4A-C) and 
a decrease of SUMO-2 conjugated forms of SAFB and SART1 (Fig. 4E and F). We 
noticed a slight decrease in SUMO-2 conjugation of RanGAP1 in this experiment 




Fig. 3. Dynamic alterations in the SUMO-2 conjugated proteome in response to the proteasome 
inhibitor MG132. A, a quantitative proteomics strategy to study the effect of MG132 on the SUMO-2 
conjugated proteome. HeLaHis6-SUMO-2 cells were labeled with Arg0 and Lys0 and treated with DMSO for 
three hours and a second pool of HeLaHis6-SUMO-2 cells were labeled with Arg10 and Lys8 and treated 
with MG132 for 3 hours. Equal amounts of whole cell lysates from the two different populations were 
mixed and proteins conjugated to His6-SUMO-2 were purified, digested by trypsin and identified by mass 
spectrometry. Peptide mass spectra were quantified to identify MG132-induced changes in the SUMO-2 
conjugated proteome. B, In total 847 proteins were identified by at least two unique peptides, including 73 
proteins that were preferentially enriched upon MG132 treatment and 40 proteins that were significantly 
reduced in response to MG132. The natural logarithm of the SILAC ratio for each protein is depicted in 
order to visualize upregulated- and downregulated proteins.
indicating that the ubiquitin-proteasome system specifically regulates SUMO-2 
conjugated forms of these proteins (Fig. 4A-F, inputs).
 The most obvious explanation for our results would be that a subset of SUMO-
2/3 target proteins is subsequently ubiquitinated and degraded by the proteasome. 
Inhibition of the proteasome system could then lead to proteins accumulating in 
the sumoylated and ubiquitinated form. To study the ubiquitination status of hnRNP 
M, MCM-7, PIAS1, SAFB and SART1, similar experiments were carried out using 
His6-ubiquitin instead of His6-SUMO-2 (Fig. 5). As expected, hnRNP M, MCM-7 and 
PIAS1 were indeed ubiquitinated in an MG132-sensitive manner. PIAS1 (30) was 
also previously reported to be ubiquitinated. In contrast, ubiquitinated forms of SAFB 
or SART1 could not be detected in these experiments.
SUMO-2/3 chains accumulate in cells treated with MG132
Previously, we have shown that SUMO-2 and SUMO-3 are able to multimerize 
in cells in an ubiquitin-like manner (11). To investigate whether SUMO-2/3 chains 
accumulated in cells treated with proteasome inhibitors, we searched for tryptic 
SUMO-SUMO peptides in purified His6-SUMO-2 conjugates from our quantitative 
proteomics experiments. Interestingly, both SUMO2-SUMO2 and SUMO2-SUMO3 
peptides were shown to accumulate upon MG132 treatment (Fig. 6A and B). 
In order to determine whether these SUMO polymers are functionally important for 




Fig. 4. Dynamic alte-
rations in the SUMO-2 
conjugated proteome in 
response to the protea-
some inhibitor MG132 
detected by immuno-
blotting. A-F, HeLa cells 
and HeLaHis6-SUMO-2 cells 
were treated with MG132 
or DMSO for 3 hours and 
His6-SUMO-2 conjugates 
were purified from equal 
amounts of whole cell ly-
sates. His6-SUMO-2 con-
jugates or equal amounts 
of whole cell extracts 
were size-separated by 
SDS-PAGE, transfer-
red to membranes and 
probed using antibodies 
to detect hnRNP M (A), 
MCM-7 (B), PIAS1 (C), 
RanGAP1 (D), SAFB (E), 
or SART1 (F). Note that 
the PIAS levels are slight-
ly higher in the HeLaHis6-
SUMO-2 cells compared to 
the HeLa cells.
Fig. 5. hnRNP M, MCM7 
and PIAS1 are conju-
gated to ubiquitin. A-E, 
HeLa cells were trans-
fected with a plasmid that 
encodes His6-ubiquitin, 
or with an empty control 
plasmid and cells were 
treated with MG132 or 
DMSO for 3 hours. His6-
ubiquitin conjugates were 
subsequently purified 
from equal amounts of 
whole cell lysates. His6-
ubiquitin conjugates or 
equal amounts of whole 
cell extracts were size-
separated by SDS-PAGE, 
transferred to membranes 
and probed using antibo-
dies to detect hnRNP M 
(A), MCM-7 (B), PIAS1 





encode SUMO-2 mutants reduced for chain formation. HeLa cells were transiently 
transfected, treated with DMSO or MG132 and proteins conjugated to wild-type 
or mutant SUMOs were purified and analyzed by immunoblotting. The SUMO-2 
mutants accumulated in MG132-treated cells similarly to wild-type SUMO-2 (Fig. 
6C) and ubiquitin still co-purified with the SUMO-2 mutants (Fig. 6D). Furthermore, 
both wild-type- and mutant SUMO-2-conjugated forms of hnRNP M, MCM-7 and 
PIAS1 accumulated upon inhibition of the proteasome (Fig. 6E-G). We conclude that 
SUMO chain formation is not required for the processing of SUMO-2 targets by the 
proteasome.
Fig. 6. SUMO chains accumulate in cells treated with MG132. A and B, a quantitative proteomics 
experiment was performed to identify changes in SUMO chains induced by MG132. HeLaHis6-SUMO-2 cells 
were labeled with Arg0 and Lys0 and treated with DMSO for 3 hours and a second set of HeLaHis6-SUMO-2 
cells were labeled with Arg10 and Lys8 and treated with MG132 for 3 hours. Equal amounts of whole 
cell lysates from the two different populations were mixed and proteins conjugated to His6-SUMO-2 
were purified, digested by trypsin in solution and identified by mass spectrometry. A, MS spectrum of 
a tryptic peptide consisting of aa 59-92 of SUMO-2 and aa 8-20 of another molecule of SUMO-2 (m/z 
1338.1246 (4+); mass deviation - 1.21 ppm). B, MS spectrum of a tryptic peptide consisting of aa 59-92 
of SUMO-2 and aa 8-21 of SUMO-3 (m/z 1366.6353 (4+); mass deviation - 1.65 ppm). C-G, HeLa cells 
were transfected with plasmids that encode His6-tagged forms of wild-type (w.t.), K11R- or E13A SUMO-2 
mutants that are reduced for SUMO chain formation. Cells were treated with MG132 or DMSO for 5 hours 
and His6-SUMO-2 conjugates were purified from equal amounts of whole cell lysates. Purified fractions 
were size-separated by SDS-PAGE, transferred to membranes and probed using antibodies to detect 





The accumulation of ubiquitin in SUMO-2 conjugates could potentially be explained 
by the formation of mixed SUMO-2 / ubiquitin chains and also by the conjugation of 
SUMO-2 and ubiquitin to independent lysines in target proteins. To test the formation 
of mixed chains, His6-ubiquitin was purified from cells, digested and analyzed by 
mass spectrometry to investigate the ubiquitination of endogenous SUMO-2/3. A high 
quality MS/MS spectrum was obtained showing the ubiquitination of endogenous 
SUMO-2 on lysine 32 or the ubiquitination of endogenous SUMO-3 on lysine 33 
(Fig. 7A). 
Fig. 7. SUMO-2 is ubiquitinated in cells. A, HeLa cells were transfected with a plasmid that encodes 
a His6-tagged lysine-deficient ubiquitin mutant. Cells were lysed and His6-ubiquitin conjugates were 
purified and digested by trypsin. The digest was analyzed by mass spectrometry and a peptide was 
identified that corresponds to ubiquitinated SUMO-2/3. The MS/MS fragmentation spectrum of this tryptic 
peptide consisting of aa 21-34 of SUMO-2 and the diglycine fragment of ubiquitin attached to lysine 32 
of SUMO-2 is shown. This tryptic peptide is identical to a tryptic peptide consisting of aa 22-35 of SUMO-
3 and the diglycine fragment of ubiquitin attached to lysine 33 of SUMO-3. Precursor ion mass was 
measured in the orbitrap mass spectrometer (m/z 530.6264 (3+); mass deviation - 1.12 ppm) and the 
peptide was fragmented and acquired in the LTQ mass spectrometer (Mascot Score 49.73; Mascot Delta 
3.28; false positive rate: 1.765E-20). B-F, His6-SUMO-2 plasmids were generated that encode K32R- or 
K32, 34, 41 and 44R (4KR) mutants. HeLa cells were transfected with plasmids that encode His6-tagged 
forms of wild-type (w.t.), K32R- or 4KR SUMO-2 mutants. Cells were treated with MG132 or DMSO for 
5 hours and His6-SUMO-2 conjugates were purified from equal amounts of whole cell lysates. Purified 
fractions were size-separated by SDS-PAGE, transferred to membranes and probed using antibodies to 




 In order to determine whether mixed chains are functionally important for the 
processing of SUMO-2 targets by the proteasome, a plasmid was generated that 
encoded a SUMO-2 K32R mutant and a second mutant was generated that lacked 
other adjacent lysines 34, 41 and 44 (4KR). HeLa cells were transiently transfected, 
treated with DMSO or MG132 and proteins conjugated to wild-type or mutant SUMOs 
were purified and analyzed by immunoblotting. The SUMO-2 mutants accumulated 
in MG132-treated cells similarly to wild-type SUMO-2 (Fig. 7B) and ubiquitin co-
purified efficiently with the SUMO-2 mutants (Fig. 7C). Both wild-type- and mutant 
SUMO-2-conjugated forms of hnRNP M, MCM-7 and PIAS1 all accumulated upon 
inhibition of the proteasome (Fig. 7D-F). Moreover, a lysine-deficient SUMO-2 
mutant accumulated in MG132-treated cells similarly to wild-type SUMO-2 and both 
wild-type- and mutant SUMO-2-conjugated forms of hnRNP M, MCM-7 and PIAS1 
all accumulated upon inhibition of the proteasome (Fig. 8A-E) 
Fig. 8. A lysine-deficient SUMO-2 
mutant is sensitive to proteasome 
inhibition. A-E, a His6-SUMO-2 
plasmid was generated that encodes 
a lysine-deficient mutant (allKR). 
HeLa cells were transfected with 
plasmids that encode His6-tagged 
forms of wild-type (w.t.) or the allKR 
SUMO-2 mutant. Cells were treated 
with MG132 or DMSO for 5 hours 
and His6-SUMO-2 conjugates were 
purified from equal amounts of 
whole cell lysates. Purified fractions 
were size-separated by SDS-PAGE, 
transferred to membranes and 
probed using antibodies to detect 
SUMO-2/3 (A), ubiquitin (B) hnRNP 
M (C), MCM-7 (D) or PIAS1 (E).
We conclude that SUMO-2 / ubiquitin mixed chain formation and SUMO-SUMO 
chain formation are not required for the processing of SUMO-2 targets by the 
proteasome. In principle, it is still possible that these SUMO-2 mutants form residual 
polymers with endogenous SUMO-2/3. However, dimers consisting of the lysine-
deficient SUMO-2 mutant and endogenous SUMO-2/3 could not be detected by 




sumoylation and ubiquitination of a significant subset of SUMO-2 target proteins via 
independent lysines in these target proteins (Fig. 9). Upon ubiquitination, SUMO-2/3 
conjugated proteins are degraded by the proteasome, which enables the recycling 
of SUMO-2/3.
Fig. 9. The ubiquitin-proteasome system is a component of the SUMO-2/3 cycle. Our data indicate 
that the turn-over of a subset of SUMO-2/3 conjugates is regulated by the ubiquitin-proteasome system. 
Target proteins that are conjugated to a single monomer of SUMO-2 or SUMO-3 or to multiple monomers 
can subsequently be ubiquitinated and degraded by the proteasome. This process enables the recycling 
of SUMOs to provide sufficient amounts of free SUMOs for new rounds of conjugation. In addition, mixed 
SUMO / ubiquitin chains are formed and SUMO-SUMO chains.
Discussion
Ubiquitination and sumoylation are generally considered to be independent protein 
modifications. We have shown here that extensive crosstalk exists between ubiquitin 
and SUMO-2/3 conjugation of target proteins (Fig. 9). This crosstalk regulates 
selected SUMO-2/3 targets either directly or indirectly. A substantial percentage 
of SUMO-2/3 conjugates is directly regulated by subsequent ubiquitination and 
processing by the proteasome. A second subset of target proteins is indirectly 
dependent on the ubiquitin-proteasome system to provide a sufficiently large pool of 
free recycled SUMO-2/3 for subsequent rounds of conjugation.
 The recent identification of the SLX5/8 complex in yeast and RNF4 in mammals 




sumoylated proteins (31-36). These proteins contain both a RING domain and 
SUMO Interaction Motifs (SIMs) and act as ubiquitin E3 ligases that are targeted to 
sumoylated proteins via these SIMs (32-34, 36-38). SLX5 and SLX8 are required for 
maintenance of the genome (32-35, 39-43). The identification of a large subset of 
nucleic acid binding proteins that are sumoylated in a proteasome inhibitor sensitive 
manner provides an important framework for further detailed analysis of the regulation 
of nucleic acid metabolism by SUMO-2/3 and the ubiquitin-proteasome system. 
 The precise roles of SUMO-SUMO chains as shown in Fig. 6A and B and of 
mixed SUMO-2/3 ubiquitin chains as shown in Fig. 7A is currently unclear. Since 
mutants that lack acceptor lysines still accumulate in cells treated with proteasome 
inhibitors and ubiquitin still co-purified similarly to wild-type SUMO forms, these chains 
are not required for targeting the majority of SUMO-2/3 targets to the proteasome. 
Nevertheless, it is possible that certain proteins are targeted to the proteasome 
via these chains (37, 38). Alternatively, these chains could regulate degradation-
independent processes.
 The conjugation of another subset of SUMO-2 target proteins was unaffected 
by the inhibition of the proteasome, including RanGAP1. Interestingly, a very large 
fraction of RanGAP1 exists in a sumoylated form, mainly conjugated to SUMO-1 
(6). It seems likely that sumoylated forms of RanGAP1 are very stable and have a 
very slow turnover compared to most other known target proteins. The half-life of 
the sumoylated forms of a subset of target proteins is regulated by ubiquitination 
and degradation by the proteasome as shown here, but also via SUMO proteases 
(SENPs) (44). Sumoylated RanGAP1 is localized at the cytoplasmic surface of the 
nuclear pore complex (45, 46), which might positively contribute to its stability since 
the majority of SUMO proteases are nuclear proteins (44). 
Although the sumoylated forms of hnRNP M, MCM7 and PIAS1 and the 
ubiquitinated forms of these proteins are strongly stabilized by MG132, the total 
pools of these proteins were unaffected by this inhibitor. It is therefore likely that only 
a small fraction of these proteins are modified within the three hour time frame of the 
experiment.
 Transiently sumoylated proteins with short half-lives of the sumoylated forms 
due to the activity of SUMO proteases are likely to show the strongest decrease in 
sumoylation upon inhibition of the proteasome due to insufficient amounts of free 
SUMO-2/3. Therefore, the relative reduction in sumoylation of SUMO-2/3 target 
proteins upon inhibition of the proteasome is likely to reflect the relative instability of 
the sumoylated forms of these proteins. 
 Currently, it is unclear why some SUMO-2/3 targets are subsequently 
ubiquitinated and degraded whereas sumoylated forms of other SUMO-2/3 targets 
such as SART1 and SAFB are not subjected to detectable amounts of ubiquitination. 




2/3 target proteins. Alternatively, the localization of RNF4 in the cell might limit its 
activity to a subset of SUMO-2/3 target proteins in a manner similar to the SUMO 
proteases (44). It is interesting to note that RNF4 specifically localizes to PML-
bodies (47), sites that are significantly enriched in SUMOs (23, 48). These nuclear 
bodies have also been shown to contain ubiquitin and proteasomal proteins (49), 
suggesting that the ubiquitination and degradation of sumoylated proteins can occur 
in PML-bodies (37, 38). 
 The total levels of SUMO-1 were not affected by inhibition of the proteasome 
(Fig. 2), in contrast to a previous publication (50), nevertheless SUMO-1 accumulated 
in purified SUMO-2 in a manner similar to ubiquitin. Currently, the role of SUMO-1 
attached to SUMO-2 conjugates is unclear. Previously, we have shown that SUMO-
1 can directly be attached to lysine 11 of SUMO-2 (11). These mixed SUMO chains 
are unlikely to play a role in targeting proteins to the proteasome, since SUMO-2 
K11R or E13A mutants still accumulated upon proteasome inhibition and ubiquitin 
efficiently co-purified with these mutants (Fig. 6).
 In summary, we have shown here that the ubiquitin-proteasome system is 
an important component of the cellular SUMO-2/3 cycle that is required for the 
processing of a subset of SUMO-2/3 targets and the recycling of SUMO-2/3. The 
identification of other components of this pathway and the detailed dissection of the 
regulated target proteins will be an important step towards uncovering the connection 
between SUMO-2/3 and the ubiquitin-proteasome system in detail. 
Materials and methods
Cell culture and transfections 
HeLa cells stably expressing His6-SUMO-1 or His6-SUMO-2 were previously described (6). HeLa cells 
were grown in Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 10% FCS and 100 U/ml 
penicillin and streptomycin (Invitrogen). Stable isotope labeling was carried out essentially as described 
(6, 20), using 12C6
14N4-Arginine (referred to as Arg0), 
13C6
14N4-Arginine (referred to as Arg6), 
13C6
15N4-
Arginine (referred to as Arg10), 12C6
14N2-Lysine (referred to as Lys0), 
2H4
12C6
14N2-Lysine (referred to as 
Lys4) or 13C6
15N2-Lysine (referred to as Lys8) as indicated. Transfections were carried out using 25kDa 
linear polyethyleneimine (Brunschwig-Chemie) essentially as described (21).
Plasmids, Mutagenesis, Antibodies, Protein Electrophoresis and 
Immunoblotting
The plasmids encoding His6-ubiquitin wild-type or 7KR and the plasmid encoding wild-type His6-SUMO-2 
were previously described (22, 23). The His6-SUMO-2 K11R, E13A, K32R, K32,34,41,44R and allKR 
plasmids were generated by site-directed mutagenesis using the QuikChange II kit according to the in-
structions of the manufacturer (Stratagene). Mutants were confirmed by DNA sequencing.





DVFQQQTGG (12). Peptide antibody AV-SM23-0100 against SUMO-2/3 was generated in rabbit using 
the peptide MEDEDTIDVFQQQTG (Eurogentec) (6, 23). Peptide antibody 1607 against SART1 was 
also generated in rabbit by Eurogentec using peptides CSLSIEETNKLRAKLGLKPLEV and CNLD-
EEKQQQDFSASSTT as described previously (6). Monoclonal antibodies 21C7 against SUMO-1 and 
19C7 against RanGAP1 were obtained from Zymed, monoclonal antibodies HIS-1 against polyHisti-
dine, R-3902 against hnRNP M and M-7931 against MCM-7 were obtained from Sigma, monoclonal 
antibody SC-8017 against ubiquitin and polyclonal antibody SC-8152 against PIAS1 were obtained from 
Santa-Cruz Biotechnology, monoclonal antibody ab8060 against SAFB was obtained from Abcam. This 
antibody also recognizes SAFB2. Secondary antibodies used were anti-rabbit HRP and anti-mouse 
HRP (1:5000, Pierce Chemical Co.) and anti-goat HRP (1:5000, Sigma).
 Protein samples were size fractionated on Novex 4-12% Bis-TRIS gradient gels using 4-morpholine-
propanesulfonic acid buffer (Invitrogen). For immunoblotting experiments, size fractionated proteins were 
subsequently transferred onto Hybond-C extra membranes (Amersham Biosciences) using a submarine 
system (Invitrogen). The membranes were incubated with specific antibodies as indicated. Bound antibo-
dies were detected via chemiluminescence with ECL Plus (Amersham Biosciences).
Purification of His6-SUMO and His6-ubiquitin conjugated proteins 
His6-SUMO conjugates and His6-ubiquitin conjugates were purified essentially as previously described 
(24). Cells were scraped in ice-cold PBS. Two small aliquots of each sample were lysed in LDS protein 
sample buffer (Invitrogen) as input control, or in 8 M Urea, 100 mM Na2HPO4/NaH2PO4, 10 mM Tris/
HCl, pH 7.0 to determine the protein concentration. The remaining cells were solubilized in lysis buffer 
(6 M Guanidinium-HCl, 100 mM Na2HPO4/NaH2PO4, 10 mM Tris/HCl, pH 8.0, 20 mM Imidazole, 10 mM 
β mercapto-ethanol) and sonicated to reduce the viscosity. His6-SUMO conjugates or His6-ubiquitin 
conjugates were enriched on Ni-NTA Agarose beads (Qiagen) and washed using wash buffers A-D. (Buffer 
A: 6 M Guanidinium-HCl, 100 mM NaH2PO4 /Na2HPO4, 10 mM Tris/HCl pH 8.0 and 0.2% Triton-X-100. 
Buffer B: 8 M Urea, 100 mM NaH2PO4 /Na2HPO4, 10 mM Tris/HCl pH 8.0 and 0.2% Triton-X-100. Buffer 
C: 8 M Urea, 100 mM NaH2PO4 /Na2HPO4, 10 mM Tris/HCl pH 6.3 and 0.2% Triton-X-100. Buffer D: 8 M 
Urea, 100 mM NaH2PO4 /Na2HPO4, 10 mM Tris/HCl pH 6.3 and 0.1% Triton-X-100. These wash buffers 
also contained 10 mM β mercapto-ethanol. Samples were eluted in 6.4 M Urea, 80 mM NaH2PO4 /
Na2HPO4, 8 mM Tris/HCl pH 7.0, 200 mM imidazole. 
 For the experiment described in Fig. 1A-C, a previously described method was used (6). For the 
experiments described in Fig. 3A and B and 6A and B His6-SUMO conjugates were immunoprecipated 
using monoclonal antibody HIS-1 (Sigma) as described previously (24). For the experiment described in 
Fig. 7A HeLa cells were transfected with the His6-ubiquitin 7KR encoding plasmid. Cells were lysed in 
6 M Guanidinium-HCl, 100 mM NaH2PO4 /Na2HPO4, 10 mM Tris/HCl pH 8.0 and proteins were digested 
with endopeptidase Lys-C. His6-ubiquitin conjugates were subsequently purified on Talon beads (BD 
Biosciences), washed 2x with lysis buffer and 4x with 8 M Urea, 100 mM NaH2PO4 /Na2HPO4, 10 mM 
Tris/HCl pH 8.0 and eluted in 6.4 M Urea, 80 mM NaH2PO4 /Na2HPO4, 8 mM Tris/HCl pH 7.0, 200 mM 





Mass spectrometry and data analysis 
Mass spectrometric analysis was performed by nanoscale liquid chromatography-tandem mass 
spectrometry (LC MS/MS) using a linear ion trap Fourier-transform ion-cyclotron resonance mass 
spectrometer (LTQ-FT-ICR, Thermo-Finnigan, Bremen). Eluates were analyzed by 1-dimensional gel 
electrophoresis. Gel lanes were cut in slices and subjected to in-gel digestion with Lys-C. The resulting 
peptides were extracted, concentrated, and then loaded onto a fused silica capillary with a 75 μm ID and 
an 8 μm tip opening (New Objective, Woburn, MA) filled with Reprosil 3 μm reverse phase material (Dr. 
Maisch, Ammerbuch, Germany). Peptides were eluted with a 140 min linear gradient of 95% buffer A 
(0.5% acetic acid in H2O) to 50% buffer B (80% acetonitrile, 0.5% acetic acid in H2O). The LTQ-FT-ICR 
instrument was operated in the data dependent mode to acquire high-resolution precursor ion spectra 
(from m/z 300-1500, R=50,000, and ion accumulation to a target value of 5,000,000) in the ICR cell. The 
three most intense ions were sequentially isolated for accurate mass measurements by SIM scans (10 
Da mass window, R=50,000, and a target accumulation value of 90,000). The ions were simultaneously 
fragmented in the linear ion trap with a normalized collision energy setting of 27 % and a target value of 
10,000. 
 Peak list-generating software was DTA supercharge (release date April 20, 2006). Combined peak 
list were searched in the International Protein Index (IPI) database (http://www.ebi.ac.uk/IPI/IPIhelp.
html; release date April 21, 2006; total of 66279 sequences) using the Mascot program (Matrix Science, 
London). The enzyme specificity was set to Lys-C, allowing for cleavage N-terminal of proline and 
between aspartic acid and proline. Cysteine carbamidomethylation was selected as fixed modification, 
and methionine oxidation, protein N-acetylation, Lysine D4 and Lysine-13C6
15N2 were searched as variable 
modifications. LTQ-FT-ICR data were searched with a peptide mass tolerance of 10 ppm and a fragment 
mass tolerance of 0.6 Da. Iterative calibration algorithms on the basis of identified peptides resulted in 
an average absolute peptide mass accuracy of better than 1 ppm. A maximum of 1 missed cleavage was 
allowed. Stringent criteria were required for protein identification based on the LTQ-FT-ICR data: at least 
two matching peptides per protein, a mass accuracy within 3 ppm, a Mascot score for individual ions of 
better than 20, and a delta score of better than 5. 
 Protein ratios were calculated for each peptide and peptide ratios were averaged for all quantified 
peptides sequenced for each protein. MSQuant, an in-house developed software program was used to 
extract information from the Mascot HTML database search files and to manually validate the certainty in 
peptide identification and in peptide abundance ratio. The quantitation was based on relative intensities 
from combined scans. The program is available as open source at http://msquant.sourceforge.net/. 
 For the experiments described in Fig. 3A and B and 6A and B mass spectrometric analysis was 
performed by nanoscale liquid chromatography-tandem mass spectrometry (LC-MS/MS) using a LTQ-
Orbitrap mass spectrometer (LTQ-FT-ICR, Thermo Fisher Scientific, Bremen, Germany) equipped with 
a nanoelectrospray ion source (Proxeon Biosystems, Odense, Denmark) and coupled to an Agilent 
1200 nano-HPLC system (Agilent Technologies), fitted with an in-house made 75 μm reverse phase C18 
column, as described previously (25). In-solution digestion was performed essentially as in (26). The 
resulting peptides were desalted on RP-C18 STAGE tips (27). Peptides were eluted with a 140 min linear 





 Data were acquired in the data dependent mode: full scan spectra (m/z 300-2000, R=60000 and 
ion accumulation to a target value of 1,000,000), were acquired in the orbitrap. The ten most intense 
ions were fragmented and recorded in the ion trap, as described in (25). Raw files were processed 
with our in-house quantitative proteomics software MaxQuant (version 1.0.7.5) which performs peak list 
generation, SILAC-based quantitation, false discovery rate determination, peptide to protein assembly 
and data filtration, essentially as described in (28, 29). The quantitation was based on relative intensities 
from combined scans. The data were searched against a target/decoy human IPI database (version 
3.24) supplemented with frequently observed contaminants (total of 66948 forward) using Mascot (Matrix 
Science, version 2.1.04). The enzyme specificity was set to trypsin, allowing for cleavage N-terminal of 
proline and between aspartic acid and proline. Cysteine carbamidomethylation was selected as fixed 
modification, and methionine oxidation and protein N-acetylation and deamidation of asparagine and 
glutamine were searched as variable modifications. Spectra determined to be heavy-labeled in the pre-
search MaxQuant detection of SILAC pairs were searched with the fixed modifications Arg10 and Lys8; 
for MS/MS spectra with a SILAC state not determinable before the database search Arg10 and Lys8 were 
taken as variable modifications. Initial maximum allowed mass deviation was set to 7 ppm for peptide 
masses and 0.5 for MS/MS peaks. The minimum peptide length was set to 6 amino acids and a maximum 
of 3 missed cleavages and 3 labeled amino acids were allowed. Two proteins were grouped together if 
the peptide sequence set of one protein was equal to or a subset of the second protein’s set. 
 A false discovery rate of 1% at both the protein and peptide level was used. Peptide false positive 
rates were calculated by deriving with the Bayes theorem the probability of a false identification for a top-
scoring peptide from Mascot score and peptide sequence length dependent histograms. Protein group 
false positive rates were calculated by multiplying the contained peptide sequences’ false positive rates. 
Each distinct peptide sequence contributed only one factor, the false positive rate of the MS/MS spectrum 
for a given peptide sequence with the best false positive rate value. All MS/MS spectra associated with 
a peptide sequence, which might consist of re-sequencing events on the same peak, sequencing on 
different isotopic peaks in the same isotope pattern, sequencing of different charge states, different SILAC 
or modification states, were entering the protein false discovery rate only with one single peptide false 
positive rate. Protein groups were then sorted by the false positive rate and a given false discovery 
rate was ensured by terminating a list of proteins so that a given percentage of reverse proteins were 
contained. The used FDR of 1% ensured that at most one percent of the proteins were wrongly identified. 
Peptides that lost all containing proteins after this procedure were also removed from the peptide list. In 
addition to the protein false discovery rate threshold, proteins were considered identified by at least two 
unique-sequence peptides; quantified with at least one quantifiable SILAC pair. No outliers were removed 
due to the use of median instead of average values. 
 Significance of protein ratios was calculated in two different ways. Significance A was calculated 
by first estimating the variance of the distribution of all protein ratios in a non-parametric way and then 
reporting the error function for the z-score corresponding to the given ratio. A robust and asymmetrical 
estimate of the standard deviation was obtained by calculating the 15.87, 50 and 84.13 percentiles r-1, r0 




and r0-r-1 as left-sided robust standard deviations. In case of normally distributed data, r1-r0 and r0-r-1 would 
be equal to each other (conventional definition of standard deviation). The distance of a ratio r>r0 from the 
main distribution is measured in terms of the right standard deviation as follows.
    Z = 
 An analogous calculation is defined for r<r0. Significance A is the value of the complementary error 
function for the z above, which for a normal distribution corresponds to the probability of obtaining a value 
this large or larger by chance. Significance B was calculated using the same strategy, but in addition it 
is based on the dependence of the distribution on the summed protein intensity. We consider a protein 
as upregulated if its significance B was below 0.001 and the ratio higher than 1; downregulated with the 
significance B below 0.001 and the ratio lower than 1; not regulated if the significance B was higher than 
0.001. 
Raw mass spectrometric files are stored at Tranche (http://tranche.proteomecommons.org/), a 
public repository for sharing scientific data. From this link (http://www.proteomecommons.org/dev/dfs/
GetFileTool.jnlp) files can be downloaded with the following hash: 51ebd8yrJijxprwSrYIms0w9M4ZhR-
6rwulAmeLgyGs4WgqWQ4e8vcMgaqspsuaRcEwBJ4l1pFV6ZlLZBVLdEMWQJO5oAAAAAAAAFjA== 
 To address the reproducibility of the data, independent control immunoblotting experiments were 
performed (Fig 4). We have used antibodies directed against six different proteins identified by mass 
spectrometry and confirmed increases and decreases in sumoylation of these proteins upon inhibition of 
the proteasome, showing the reproducibility of the data.
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Chapter 3. USP11 counteracts RNF4 and stabilizes PML 
Nuclear Bodies
Abstract
RNF4 is a SUMO-targeted ubiquitin E3 ligase, with a pivotal function in the DNA 
damage response (DDR). We identified the deubiquitylating enzyme USP11, a 
known DDR-component, as an interactor of RNF4. USP11 can deubiquitylate hybrid 
SUMO-ubiquitin chains to counteract RNF4. Four closely spaced SUMO Interacting 
Motifs (SIMs) in USP11 are required for its activity, revealing USP11 as a SUMO-
targeted ubiquitin protease. SUMO-enriched nuclear bodies are stabilized by 
USP11, which functions downstream of RNF4 as a counterbalancing mechanism. In 
response to DNA damage induced by methyl methanesulfonate, USP11 counteracts 
RNF4 to block the dissolution of nuclear bodies. Thus, we provide novel insight into 
crosstalk between ubiquitin in SUMO, and uncover USP11 and RNF4 as a balanced 
SUMO-targeted ubiquitin ligase/protease pair with a role in the DDR.
Introduction
Small Ubiquitin-like Modifiers (SUMOs) are predominantly located in the nucleus 
and play key roles in all nuclear processes including transcription, chromatin 
modification and maintenance of genome stability (1). Analogous to the ubiquitin 
system, a set of E1, E2 and E3 enzymes mediate the conjugation of SUMO to target 
proteins, and a set of SUMO-specific proteases is responsible for the reversible 
nature of this post-translational modification (2, 3). Mouse models have shown that 
the SUMOylation system is essential for embryonic development. Mice deficient for 
the single SUMO E2 enzyme Ubc9 die at the early post-implantation stage as a 
result of hypocondensation and other chromosomal aberrancies (4).
 Large sets of target proteins have been identified for the different SUMO family 
members, involved in all different nuclear processes (5-7). About half of the SUMO 
acceptor lysines in these target proteins are located in short stretches that fit the 
SUMOylation consensus motif ΨKxE (7, 8), a motif that is directly recognized by 
Ubc9 (9, 10). SUMO signal transduction furthermore includes proteins that bind 
non-covalently to SUMOylated proteins via SUMO-Interaction Motifs (SIMs) (11), 
including the novel SUMO-binding Zinc finger identified in HERC2 (12).
 Interestingly, extensive crosstalk exists between the SUMOylation system and 
the ubiquitylation system (13, 14). This crosstalk includes competition between 
SUMO and ubiquitin for the same acceptor lysines (15), or sequential modification by 
SUMO and ubiquitin of a target protein (16). Moreover, the SUMO system is tightly 
connected to the ubiquitin-proteasome pathway since a significant subset of SUMO-




(17, 18). Inhibition of the proteasome led to accumulation of SUMO-2/3 conjugates 
and the depletion of the pool of non-conjugated SUMO-2/3, indicating that this 
biochemical pathway is required for SUMO-2/3 recycling. SUMO and ubiquitin can 
form hybrid chains, including via lysine 32 of SUMO-2 or lysine 33 of SUMO-3 (17).
 The SUMO system and the ubiquitin system are linked together via the SUMO-
targeted ubiquitin ligases (STUbLs), responsible for ubiquitylating SUMOylated 
proteins. They were first identified in Schizosacharomyces pombe as Rfp1 and 
Rfp2 and in Saccharomyces cerevisiae as the Slx5-Slx8 complex (19, 20). Rfp1 and 
-2 each have an N-terminal SIM and a C-terminal RING-finger domain to enable 
interaction with SUMOylated proteins. Ubiquitin E3 ligase activity is obtained by 
RING-RING-mediated recruitment of the active RING-finger protein Slx8. RNF4 is 
a major mammalian STUbL containing four N-terminal SIMs and a C-terminal RING 
domain that enables homodimerization (21). More recently, RNF111/Arkadia was 
identified as a second mammalian STUbL (22, 23).
 STUbLs play key roles in the DNA damage response (24). Schizosacharomyces 
pombe strains deficient for STUbLs display genomic instability and are hypersensitive 
to different DNA damaging agents including hydroxyurea (HU), methylmethane 
sulfonate (MMS), camptothecin (CPT) and ultraviolet (UV) light (19, 20). RNF4 
knockdown in human cells also results in increased sensitivity to DNA-damaging 
agents (25). Moreover, RNF4 accumulates at DNA damage sites induced by laser 
micro-irradiation (25-27). SUMOylated target proteins for RNF4 include MDC1 and 
BRCA1 (27, 28) and furthermore HIF-2α (29). Mice deficient for RNF4 die during 
embryogenesis (27, 30). Mice expressing strongly reduced levels of RNF4 are born 
alive, albeit at a reduced Mendelian ratio, and showed an age-dependent impairment 
in spermatogenesis (27). MEFs derived from these mice exhibit increased sensitivity 
to genotoxic stress.
 A key feature of ubiquitin-like modification systems is their reversible nature to 
carefully balance cellular systems (2, 31). Deubiquitylating enzymes (DUBs) play a 
pivotal role in the regulation of cellular ubiquitylation levels, essentially controlling all 
cellular processes. There are around 100 DUBs, with different substrate specificity, 
subcellular localization, and protein-protein interactions (31, 32). Currently, it is not 
clear how the activity of the STUbLs is balanced. Here, we report the identification of 
a ubiquitin-specific protease with the ability to counteract RNF4.
Results
Purification of FLAG-tagged Ring Finger Protein 4 (RNF4) from MCF7 cells
SUMO-targeted ubiquitin ligase RNF4 specifically recognizes targets that are modified 
by multiple SUMOs, through recognition of the SUMO-fold with its SUMOylation 




ubiquitylated by RNF4, which can lead to the degradation of these proteins by the 
proteasome (21, 34, 35). Poly-SUMOylated targets of RNF4 have been identified 
employing a trap consisting of the RNF4 SIM-domain (36).
We were interested in identifying SIM-independent RNF4 interactors. In order to 
facilitate this study, an MCF7 cell line stably expressing C-terminally FLAG-tagged 
RNF4 was generated, and a biological triplicate experiment comparing the parental 
MCF7 cell line versus the RNF4-FLAG cell line was performed. The levels of RNF4-
FLAG in all experiments were investigated following lysis of the cells (Figures 1A 
and 1B). Relative to the endogenous RNF4, there is a moderate overexpression 
of RNF4-FLAG. Considering the highly specific nature of the FLAG antibody, and 
the exploratory nature of our experiment, such expression levels are acceptable. 
The subcellular localization of RNF4-FLAG was inspected by confocal fluorescent 
microscopy, demonstrating the fusion protein to be located correctly and exclusively 
in the nucleus (Figure 1C). Some of the RNF4-FLAG localized into nuclear bodies, 
which likely correspond to PML nuclear bodies. The non-fused and co-expressing 
Green Fluorescent Protein (GFP) was included as a control.
We performed FLAG-immunoprecipitation (IP), and found that RNF4-FLAG is 
very efficiently purified, with no other signal other than RNF4-FLAG being detectable 
by immunoblot (Figure 1D). Lysis of the cells and IP of FLAG was performed 
under relatively stringent conditions, but mild enough for the robust SUMO-specific 
proteases (SENPs) to still be able to cleave SUMO off all target proteins. Finally, 
prior to in-gel digestion and LC-MS/MS analysis, Coomassie analysis of the purified 
RNF4-FLAG and its potential interactors revealed a singular and very clear band 
corresponding to RNF4-FLAG, indicative of a clean and highly stringent purification 
of RNF4-FLAG (Figure 1E).
Identification of Ubiquitin-Specific Protease 11 (USP11) as an Interactor of 
RNF4
The RNF4-FLAG IP was performed in biological triplicate, and the gel lanes were 
cut in five separate slices and analyzed by mass spectrometry experiments. Over 
800 proteins were identified in the FLAG-IP samples, with nearly all of these proteins 
being background proteins equally identified in the RNF4-FLAG line and the parental 
control. Only a few proteins were specifically and significantly enriched in the RNF4-
FLAG line, indicatory of the stringent purification conditions. Strikingly, we did not 
detect free or conjugated forms of SUMO in the IP, proving that our lysis and IP 
conditions were sufficiently harsh to yield a clean IP, yet mild enough to allow the 
highly robust SENPs to cleave SUMO off virtually all proteins. Unsurprisingly, RNF4 
itself was detected as the highest enriching protein after RNF4-FLAG IP. Furthermore, 
we identified the ubiquitin carboxyl-terminal hydrolase 11 (USP11) as an important 























































Figure 1. Generation of a cell line stably expressing RNF4-FLAG. A) MCF7 cells were infected with 
a bicistronic lentivirus encoding RNF4-FLAG and GFP separated by an Internal Ribosome Entry Site 
(IRES). Cells stably expressing low levels of the transgene were selected by flow cytometry. Total lysates 
were analyzed by immunoblotting to confirm expression of RNF4-FLAG relative to endogenous RNF4. 
The experiment was performed in biological triplicate for mass spectrometric analysis. B) Ponceau-S 
loading control for section A. C) Stable cell lines were investigated by confocal fluorescent microscopy 
to confirm the nuclear localization of RNF4-FLAG. GFP was visualized as an expression control, and 
differential interference contrast (DIC) was used to localize the cellular nuclei. Scale bars represent 10 
µm. D) RNF4 complexes were purified by immunoprecipitation (IP), and three biological replicates were 
analyzed by immunoblotting (IB) for the presence of RNF4. Parental cells were included as a negative 
control. E) Coomassie analysis of one replicate of the FLAG-IP, loaded over two lanes, prior to in-gel 




is directly opposing of RNF4’s function as a ubiquitin ligase. USP11 was found to 
be enriched over the control with a Log2 ratio of 5.1, and eleven MS/MS spectral 
identifications matching USP11 were made in the RNF4-FLAG IP as opposed to 
zero in the control IP.
After finding USP11 as an interactor of RNF4 through mass spectrometry 
analysis, the experiment was repeated, and samples were analyzed by 
immunoblotting (Figure 2B). Additionally, a potential effect of the DNA damaging 
agent methyl methanesulfonate (MMS) on the interaction between RNF4 and USP11 
was investigated, as MMS is known to cause disassembly of the PML nuclear bodies 
harboring RNF4 (37). After RNF4-FLAG IP, immunoblot analysis with an antibody 
against endogenous USP11 shows a very clear and specific interaction with RNF4, 
with no signal detectable in the parental control (Figure 2B). There was no indication 
that the interaction between RNF4 and USP11 is disrupted upon treating the cells 
with MMS. A small decrease in both RNF4 and USP11 levels was observed after 
DNA damage, indicative of their function in the DNA damage response, which may 
eventually lead to their degradation. Even though input levels of both RNF4-FLAG 
and USP11 dropped slightly after MMS treatment, the detectable level of USP11 co-
immunoprecipitating with RNF4 remains identical. Finally, equal protein loading was 
validated through Ponceau-S staining, and immunoblot analysis with an antibody 
against SUMO-2 was performed to investigate the SUMOylation state of proteins 
in the total lysate and the IP fractions (Figure 2C). In agreement with the mass 
spectrometry findings, free SUMO was detected only in the total lysates, a direct 
result of the SENPs removing all SUMO from target proteins following lysis, indicating 
that the interaction between USP11 and RNF4 is SUMOylation-independent.
USP11 deubiquitylates SUMO-2-ubiquitin hybrid chains in vitro in a SIM-
dependent manner
To test whether USP11 can counteract RNF4 in vitro, a hybrid SUMO-2-ubiquitin 
polymer was generated as a potential USP11 substrate, using a recombinant linear 
SUMO-2 polymer, composed of four SUMO proteins which was ubiquitylated in 
vitro by RNF4 (21). Subsequently, recombinant USP11 was added to the reaction 
to analyze the deubiquitylation activity of USP11. Adding wild type USP11 resulted 
in the deubiquitylation of SUMO-2-ubiquitin hybrid chains while adding a catalytic 
inactive USP11 mutant (C318A) had no effect on these chains (Figure 3A). Since 
USP11 and RNF4 were simultaneously present in the reaction mixture, a limited 
amount of ubiquitylated SUMO-2 polymer was still detected, probably representing 
multiple mono-ubiquitylated forms. We conclude that USP11 could indeed counteract 
the activity of RNF4 on a SUMO-2 polymer in vitro.
Analysis of the USP11 sequence revealed four potential SIMs located in 
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Figure 2. Identification of USP11 as an RNF4-interacting ubiquitin protease. A) Overview of the mass 
spectrometry results pertaining to USP11 and RNF4. USP11 was found to be significantly enriched after 
FLAG-IP from the RNF4-FLAG stable cell line, with 0/0/0 USP11 MS/MS counts in the parental line versus 
8/14/11 USP11 MS/MS counts in the RNF4-FLAG line, respectively. USP11 was found to be enriched 
after RNF4-FLAG IP with a Label-Free Quantification (LFQ) Log2 ratio of over 5. B) MCF7 cell lines 
expressing RNF4-FLAG and parental controls were treated with methyl methanesulfonate (MMS), lysed, 
and FLAG-IP was performed. Total lysates and IP fractions were analyzed by immunoblotting against 
USP11 to confirm the co-immunoprecipitation of endogenous USP11 with RNF4-FLAG. Immunoblotting 
for RNF4 was performed as an immunoprecipitation control. C) Ponceau-S loading control for section B. 
Additionally, total lysates and IP fractions were analyzed by immunoblotting against SUMO-2 to investigate 
































































































































































































































































Figure 3. USP11 deubiquitylates hybrid SUMO-
2-ubiquitin chains in vitro in a SIM-dependent 
manner. A) His6-tetra-SUMO-2 proteins were in vitro 
ubiquitylated by GST-RNF4. The resulting SUMO-
ubiquitin hybrid chains were incubated with increasing 
concentrations of His6-MBP-USP11 wild-type (WT) 
or a catalytic inactive mutant (C318A). Hybrid chains 
were analyzed by immunoblotting against SUMO-
2/3 and His6-MBP-USP11 levels were analyzed by 
immunoblotting against the poly-Histidine tag (anti-His). 
B) Cartoon depicting USP11. USP11 harbors a Domain 
present in Ubiquitin-Specific Proteases (DUSP) and an 
Ubiquitin Carboxyl-terminal Hydrolase domain (UCH). USP11 contains four potential SUMO interacting 
motifs (SIMs), located in between the DUSP and UCH domains. Hydrophobic residues depicted in red 
were incubated replace by alanines to generate a USP11 ΔSIM mutant. C) Ubiquitin chains only (-) or 
SUMO-2-Ubiquitin mixed chains (+) were incubated with His6-MBP(HM)-RNF4, His6-MBP(HM)-USP11-
C318A, or His6-MBP(HM)-USP11-C318A proteins where the four potential SIMs were mutated (ΔSIMs-
C318A). His6-MBP proteins were subsequently purified with amylose beads to enrich for the MBP tag. 
Amylose beads-only samples were used as a negative control. Inputs and bound proteins were analyzed 
by immunoblotting with the indicated antibodies. D) The experiment described in section A was repeated 
and the His-MBP-USP11-ΔSIMs protein was included to study the contribution of the SIMs.
3B). To further establish confidence in these SIMs, PHYRE2 (38) was used to 
generate a structural model of USP11 (Figure S1A). Using homology modeling 




structure was generated with 65% of residues modeled at 90% or greater confidence. 
283 out of 931 residues could not be aligned to existing structures, and were modeled 
ab initio. These residues were mainly located within the center of the UCH. The 
four potential SIMs in USP11 (Figure 3B and S1B) were observed to be located on 
a “bridge” connecting the DUSP with the UCH domains in a clustered manner to 
enable synergistic binding to SUMO polymers (Figure S1C). All of the SIMs were 
solvent-exposed, and located in a region of USP11 accessible for small proteins 
such as SUMO or ubiquitin.
A USP11 mutant lacking SIMs (ΔSIMs) was generated by mutating the large 
hydrophobic residues in the SIMs to alanines. Note that this mutant was made in the 
background of the C318A mutant to prevent deubiquitylation activity on the chains 
during the interaction experiments. To analyze the interaction between USP11 and 
SUMO-2 and/or ubiquitin, the SUMO-Ubiquitin mixed chains described above or 
unanchored ubiquitin chains made by RNF4 were used. SUMO-2/3 immunoblot 
analysis confirmed the strong interaction between RNF4 and SUMO-2-Ubiquitin 
mixed chains. Compared to RNF4, USP11 displayed a weak but visible interaction 
with these mixed chains and this interaction was reduced by mutating the SIMs of 
USP11 (Figure 3C). In contrast, USP11 had more affinity for binding unanchored 
ubiquitin chains as compared to RNF4 (Figure 3C).
Interestingly, mutating these four SIMs in USP11 prevented the processing of 
these hybrid chains, indicating that USP11 deubiquitylates SUMO-ubiquitin hybrids 
in a SIM-dependent manner (Figure 3D).
USP11 counterbalances RNF4 and controls stability of nuclear bodies
Since RNF4 is known to ubiquitylate SUMOylated PML, which in turn leads to 
degradation of PML and the destabilization of nuclear bodies (21), we set out to 
study the role of endogenous USP11 in nuclear body integrity. Lentiviral shRNA-
mediated depletion of endogenous USP11 or RNF4, or depletion of both proteins 
was performed in U2OS cells, prior to analysis of the cells by confocal Z-stacked 
fluorescent microscopy (Figure 4A). The effect on PML bodies and additionally the 
effect on other SUMO nuclear bodies was investigated. Although SUMO and PML 
can co-localize in nuclear bodies, the overlap is limited.
Strikingly, after depletion of endogenous USP11, a significant reduction in PML 
and SUMO nuclear bodies was observed (Figure 4A). Accordingly, depletion of 
endogenous RNF4 led to significant increases in PML bodies and SUMO bodies. 
Multiple fields of cells were recorded, and at least 400 cells per experimental condition 
were quantified, by counting several thousands of nuclear bodies. Ultimately, a 25% 
reduction in PML bodies and a 50% reduction in SUMO bodies was found upon 
USP11 depletion, and a 35% increase in PML bodies and a 50% increase in SUMO 




Figure 4. USP11 stabilizes PML and SUMO nuclear bodies, counteracting the destabilizing effect 
of RNF4. A) U2OS cells were depleted for endogenous USP11, RNF4, or both, by infection with lentiviral 
knockdown constructs. As a control, an untargeted lentiviral knockdown construct was used. Following 
depletion of proteins, cells were fixed, immunostained and subsequently analyzed by confocal fluorescence 
microscopy for the presence of PML and SUMO-2/3 positive nuclear bodies. Images represent maximum 
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SUMO-2/3 nuclear bodies, whereas depletion of RNF4 stabilizes PML and SUMO-2 nuclear bodies. 
Scale bars represent 25 μm. B) Multiple maximum projected fields of cells were recorded as in section 
A. Cells were counted, and PML and SUMO-2/3 nuclear bodies were quantified per cell. At least 400 
cells were counted for each experimental condition, with the exact number of cells shown below each 
experiment. Error bars represent 2x SEM. Student’s t-test p-values are indicated over their respective 
experiments. C) Total cell lysates were analyzed by immunoblotting to confirm the depletion of USP11 
and RNF4.
RNF4 was confirmed through immunoblot analysis (Figure 4C). Similar results were 
obtained in MCF7 cells (data not shown).
Interestingly, when combining depletion of both USP11 and RNF4, a somewhat 
intermediate phenotype was observed (Figures 4A and 4B). Whereas the increase in 
PML bodies resulting from depletion of RNF4 was modestly countered by additional 
knockdown of USP11, there was no clear effect on SUMO positive nuclear bodies. 
Thus, it is likely that USP11 acts downstream of RNF4, providing an important 
counterbalancing mechanism to the ubiquitin ligase activity of RNF4 to establish an 
important equilibrium characteristic of ubiquitin signaling and generally characteristic 
for post-translational modifications.
USP11 modulates the level of SUMOylated PML
In addition to cellular analysis by microcopy, the SUMOylation state of the PML 
protein after depletion of endogenous USP11 in HeLa cells was investigated. In order 
to facilitate the experiment, HeLa cell lines stably expressing His-tagged SUMO-2 
were used to allow for efficient purification of SUMOylated proteins. Additionally, 
a similar cell line stably expressing lysine-deficient His-tagged SUMO-2 was used 
in order to investigate a potential effect of inhibited SUMO-2 chain formation on 
the SUMOylation of PML, and any cumulative result in combination with USP11 
depletion. Parental HeLa cells, and the two cell lines expressing the His-tagged 
SUMO-2 wild-type or lysine-deficient mutant, were all treated with either a lentiviral 
shRNA targeted against USP11 or a non-targeted shRNA. After depletion of USP11 
and enrichment of SUMOylated proteins, total lysates and SUMO-enriched fractions 
were analyzed by immunoblotting using an antibody against PML (Figure 5A).
Similar to observations made with counting PML bodies, a significant decrease 
in SUMOylated PML was found after depletion of USP11, in both total lysate and 
SUMO-enriched fractions. Interestingly, in the cell line expressing lysine-deficient 
SUMO-2, PML was found to be SUMOylated at a somewhat lower base level as 
compared to the cell line expressing wild-type SUMO-2 (Figure 5A). However, a 
further decrease in SUMOylated PML upon additional USP11 depletion was still 
observed. Thus, while SUMO-2 deficient in chain-formation reduced the overall 
levels of SUMOylation on PML, RNF4 was still able to ubiquitylate SUMOylated 
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Figure 5. USP11 stabilizes SUMOylated PML. A) HeLa cells expressing His-tagged SUMO-2, HeLa cells 
expressing His-tagged lysine-deficient SUMO-2, and parental HeLa cells were either depleted of USP11 
by infection with lentiviral knockdown constructs, or treated with an untargeted knockdown construct. After 
depletion of USP11 cells were lysed, and His-pulldown was performed to enrich SUMOylated proteins. 
Total lysates and SUMO-enriched fractions were analyzed by immunoblotting using an antibody against 
PML. Note that PML modified with lysine-deficient SUMO has slightly different migration behavior due 
to lysine-to-arginine substitutions. B) Quantification of the PML-SUMO signal in the total lysate and 
SUMO-enriched lanes corresponding to the His-SUMO cell lines, comparing the PML-SUMO signal in 
the control versus USP11-depleted cells. Error bars represent standard deviation. Student’s t-test p-value 
is indicated. C) Total lysates from section A were analyzed by immunoblotting with an antibody versus 
USP11 as a knockdown control, and Ponceau-S staining was used as a loading control. SUMO-enriched 
fractions from section A were analyzed by immunoblotting with an antibody versus SART1 as a SUMO-
level control, and Ponceau-S staining was used as a pulldown control. Note that SART1 modified with 
lysine-deficient SUMO has slightly different migration behavior due to lysine-to-arginine substitutions. 
D) HeLa cells were depleted of USP11 by infection with five different lentiviral knockdown constructs, or 
treated with an untargeted knockdown construct. Subsequently, cells were lysed, and total lysates were 
analyzed by immunoblotting using an antibody against USP11. All five viruses were found to be efficient, 
and a low-concentration mixture of all viruses was used for all other USP11 depletion experiments to 




The decrease in SUMOylated PML signal was found to be 30% (Figure 5B); 
highly similar to the 25% decrease in PML nuclear bodies observed through confocal 
microscopy (Figure 4B). Efficient depletion of endogenous USP11 was validated by 
immunoblotting (Figures 5C and 5D), and additionally the well-known SUMOylation 
target protein SART1 (39) was investigated as a control for equal SUMO-enrichment 
(Figure 5C). The SUMOylation state of SART1 was virtually identical regardless 
of USP11 depletion, indicating that the effect on PML SUMOylation was specific. 
Note that the slight shift in migration behavior visible between the wild-type SUMO-2 
and the lysine-deficient SUMO-2 is a direct effect of lysine-to-arginine substitutions. 
Equal total lysate loading and equal pulldown efficiency and loading were confirmed 
by Ponceau-S staining (Figures 5C and 5D).
 
USP11 prevents the disintegration of nuclear bodies in response to DNA 
damage
In order to investigate the extent of protection USP11 offers to SUMOylated PML 
and their associated nuclear bodies, an overexpression experiment was performed 
where U2-OS cells were transfected with V5-tagged USP11. Subsequently, the 
cells were treated with MMS, which is known to cause degradation of SUMOylated 
PML and instigate a disassembly of nuclear bodies (37). The treatment dose and 
time chosen for the experiment was sufficient to completely abolish all PML nuclear 
bodies. Confocal fluorescence microscopy was used to investigate mock treated 
cells, as well as cells treated with MMS for an extended period of time. Antibodies 
directed against the V5 tag and against PML were used to detect exogenous V5-
USP11 and PML nuclear bodies, respectively. Differential interference contrast (DIC) 
was used to visualize the nuclei (Figure 6).
In untreated cells, nuclear bodies were observed to be distributed fairly equally 
between cells expressing V5-USP11 and untransfected cells. However, upon MMS 
treatment, all untransfected cells completely lost their nuclear bodies, whereas many 
cells overexpressing V5-USP11 were able to retain some PML nuclear bodies, and in 
some cases these cells even retained all PML bodies (Figure 6). Thus, an increased 
presence of USP11 within the cell was able to counteract the ubiquitylation and 
degradation of SUMOylated PML, and could counteract the disassembly of the PML 
nuclear bodies in response to DNA damage.
DISCUSSION
Using a proteomic screen, we have identified USP11 as a ubiquitin protease that 
co-purified with RNF4, possessing the ability to process hybrid SUMO-ubiquitin 
polymers. This USP family member contains a DUSP domain with the ability to 
bind ubiquitin, as well as a catalytic UCH domain. Furthermore, four putative SIMs 
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Figure 6. USP11 counteracts RNF4-mediated degradation of nuclear bodies in response to 
treatment the DNA damaging agent methyl methanesulfonate. U2OS cells were transfected with 
a construct encoding V5-USP11, and subsequently mock treated or treated with 0.02% MMS for 135 
minutes. Following treatment, cells were fixed, and immunostained. Confocal fluorescence microscopy 
was used to visualize V5 (USP11 - green) and PML (red). DIC was used to visualize nuclei. Three separate 
fields of cells are shown for each experimental condition. Upon treatment with MMS, cells overexpressing 





enabled the processing of hybrid SUMO-ubiquitin chains that were synthesized by 
RNF4. USP11 was able to deubiquitylate these hybrid chains via its catalytically 
active C-terminal hydrolase domain. A USP11 mutant lacking the four SIMs between 
the DUSP domain and the UCH domain was found to be deficient in deubiquitylating 
hybrid SUMO-ubiquitin chains.
 USP11 possesses the ability to counteract RNF4 during regular growth 
conditions. Depletion of USP11 led to a decrease in the amount of nuclear bodies, 
whereas depletion of RNF4 led to the exact opposite. Furthermore, we observed 
cells containing a far-above-average amount of PML and SUMO bodies even with 
the double knockdown, analogous to RNF4-only knockdown (Figure 4A and 4B). 
This could be indicative of USP11 primarily functioning downstream of RNF4. 
If SUMOylated proteins were not ubiquitylated in the first place, USP11 would 
logically not have SUMOylated proteins to deubiquitylate. We also noted that USP11 
knockdown led to a decrease in the SUMOylated form of PML, indicative of a more 
rapid degradation through the mechanistic action of RNF4. We did not note a large 
effect of USP11 on total PML levels overall, as compared to the SUMOylated form 
(Figure 5A).
 Moreover, we found that USP11 could counteract RNF4’s role in the DNA 
damage response by blocking the dissociation of PML bodies in response to MMS. 
We also observed a slight decrease in USP11 levels after MMS treatment in MCF7 
cells (Figure 2B), suggesting that USP11 may be degraded or otherwise inactivated. 
The dissociation of PML bodies enables proper progression of the DNA damage 
response (40) or induction of apoptosis (41, 42).
 USP11 was previously found to be involved in repair of double-stranded breaks 
by homologous recombination, where knockdown of USP11 resulted in spontaneous 
activation of DNA damage response pathways, rendering cells hypersensitive to 
PARP inhibition, ionizing radiation and other genotoxic stresses (43). This finding 
coincides with our findings, as a loss of PML bodies could prohibit cells from properly 
responding to DNA damage, and could ambiguously initiate the DNA damage 
response or cause induction of apoptosis. Similarly, the ability to rescue PML bodies 
by overexpression of USP11 would thus serve to block the DNA damage response 
from proceeding efficiently. Furthermore, USP11 has been shown to interact with 
BRCA2, a key component of the homologous recombination pathway, where BRCA2 
was shown to be a target for deubiquitylation by USP11 (44). Treatment of cells by 
Mitomycin C led to a degradation of BRCA2, which could be countered by USP11 
overexpression, and inhibition of USP11’s function increased cellular sensitivity to 
Mitomycin C (44). BRCA2 is not known to be SUMOylated. Similar to USP11, RNF4 
is also required for homologous recombination (25-27), indicating that balanced 
ubiquitylation and deubiquitylation of SUMOylated proteins is required for efficient 




 The function of USP11 in the DNA damage response makes it a potential clinical 
target, as inhibition of USP11 would render cancer cells susceptible to apoptosis, 
especially combined with other treatments such as PARP inhibition. Accordingly, 
some progress has been made on compounds targeting and counteracting USP11, 
displaying the ability to inhibit pancreatic cancer cells (45).
 More recently, USP11 has been found to interact directly with PML (46). 
Contrarily, we found USP11 to interact with the SUMO-targeted ubiquitin ligase RNF4, 
and a set of SIMs in USP11 potentiated its activity towards hybrid SUMO-ubiquitin 
chains. Wu et al. further reported that USP11 depletion leads to a decrease in PML 
bodies, which is consistent with our findings. USP11 overexpression was shown by 
Wu et al. to be able to counteract arsenic-induced degradation of PML, but a role 
in the DNA damage response was not investigated by Wu et al. USP11 was found 
to be transcriptionally repressed in human glioma, with upregulation of the Hey1/
Notch pathway resulting in downregulation of USP11 and correspondingly PML (46). 
Interestingly, this was found to increase cellular malignancy as well as potentiate 
survival and resistance to therapeutic treatment, which is directly opposing findings 
where antagonizing USP11 leads to inhibition of pancreatic cancer (45), and general 
findings where USP11 depletion leads to cellular hypersensitivity to DNA damage 
(43, 44).
 We propose that USP11 keeps RNF4 in check, and is able to reverse RNF4’s 
ubiquitylation of SUMOylated proteins (Figure 4B). Under certain stress conditions, 
such as DNA damage, USP11 loses its ability to effectively counteract RNF4, allowing 
the cellular stress response to proceed efficiently. Thus, our results provide novel 
insight in crosstalk between SUMOylation and ubiquitylation, and further elucidate 
the function of USP11 in the DNA damage response.
Materials and methods
Plasmids
The cDNA encoding the USP11 protein was a kind gift from Dr. Long Zhang. The cDNA 
encoding the RNF4 protein was obtained from the Mammalian Gene Collection (Image ID 
4824114; supplied by Source Bioscience). Both cDNAs were amplified by a two-step PCR 
reaction using the following primers: 5’-AAAAAGCAGGCTATATGGCAGTAGCCCCGCGA 
CTG-3’ and 5’- AGAAAGCTGGGTGTCAATTAACATCCATGAACTC-3’ (USP11), 5’-AAAAA 
GCAGGCTCAATGAGTACAAGAAAGC-3’ and 5’- AGAAAGCTGGGTTTCATATATAAATGG GGTG-
3’ (RNF4) for the first reaction and 5’- GGGGACAAGTTTGTACAAAA AAGCAGGCT-3’ and 
5’-GGGGACCACTTTGTACAAGAAAGCTGGGT-3’ for the second reaction. RNF4 was cloned in between 
the SpeI and XhoI sites of the plasmid pLV-CMV-X-FLAG-IRES-GFP (kind gift from Dr. R.C. Hoeben). 
Additionally, RNF4 and USP11 cDNAs were inserted into pDON207 employing standard Gateway 
technology (Invitrogen). The C318A mutation in USP11 was introduced by QuickChange site-directed 




and 5’-CCGAGTTCATGAAGGCCGTGTTGCCCAGATTG-3’. pDON207-USP11-C318A-ΔSIMs was 
generated by a gene synthesis service (GenScript) by replacing residues V183, I184, L186, V197, L199, 
L200, L201, L202, V203, I259, V261, L262, L271, I272, I273 and M274 with alanines. These different 
cDNAs were subsequently transferred to the destination vector pDEST-T7-His6-MBP (a kind gift from Dr. L. 
Fradkin). RNF4 was cloned into pGEX-2T to obtain a construct encoding GST-tagged RNF4 by amplifying 
RNF4 cDNA using the following primers: 5’-ACAAACGGATCCATGAGTACAAGAAAGCGTCGTG-3’ and 
5’-GCCGCGGAAT TCTCATATATAAATGGGGTGGTAC-3’. Both the PCR product and the pGEX-2T 
vector were subsequently digested with BamHI and EcoRI and the PCR product was ligated into the 
vector with T4 ligase (New England Biolabs). The His6-ΔN11-SUMO-2-Tetramer expression vector was a 
kind gift of Prof. Dr. R.T. Hay (Dundee, U.K.) (21).
Cell culture & cell line generation
MCF7, U2-OS and HeLa cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% FBS and 100 U/mL penicillin and streptomycin (Invitrogen). MCF7 cells stably 
expressing RNF4-FLAG were generated through lentiviral infection with a construct carrying RNF4-FLAG-
IRES-GFP. The Internal Ribosome Entry Site (IRES) allowed the same mRNA to code for a non-fused 
GFP, in order to quantify RNF4-FLAG expression without adding a bulky fusion tag to RNF4. Similarly, 
MCF7 and HeLa cell lines stably expressing His-SUMO-2 were generated through lentiviral infection with 
a construct encoding His-SUMO-2-IRES-GFP. Two weeks after infection, cells were sorted for a low level 
of GFP by flow cytometry, using a FACSAria II (BD Biosciences). All cells were cultured in CELLSTAR 
flasks (175cm2) and petri dishes (145 x 20 mm) (both from Greiner Bio-One).
Treatments, transfection and lentiviral infection
Cells were treated with 0.02% MMS and 1 µM As2O3 (Sigma) for the indicated amounts of time. For 
transfection, cells were cultured in DMEM lacking penicillin and streptomycin. Transfections were 
performed using 2.5 µg of polyethylenimine (PEI) per 1 µg of plasmid DNA, using 1 µg of DNA per 1 
million cells. Transfection reagents were mixed in 150 mL NaCl and allowed to rest for 15 minutes before 
adding it directly to the cells. Cells were split after 24 hours (if applicable) and investigated after 48 hours. 
Lentiviruses were generated essentially as described previously (47). Infections were performed with 
a multiplicity of infection of 2 and using a concentration of 8 µg/mL polybrene in the medium. 24 hours 
after infection the medium was replaced. Cells were split 72 hours after infection (if applicable) and 
investigated 96 hours after infection.
RNF4-FLAG purification
Parental MCF7 cells and MCF7 cells stably expressing RNF4-FLAG were grown in regular DMEM, until 
fully confluent in 10x 15-cm dishes (approximately 0.2 billion cells). Cells were washed 3 times in ice-cold 
PBS prior to addition of 3 mL of ice-cold Lysis Buffer to each plate (150 mM NaCl, 50 mM TRIS, 0.5% 
sodium deoxycholate, 1.0% N-P40, buffered at pH 7.5, with every 10 mL of Lysis Buffer supplemented 
by one tablet of protease inhibitors + EDTA (Roche)). Subsequently, cells were scraped in the Lysis 




microtip sonicator at 30 Watts. Next, lysates were centrifuged at 4 °C and 10,000 RCF to clear debris 
from the soluble fraction. Lysates were equalized using the bicinchoninic acid assay (BCA, Pierce). 1 µL 
(dry volume) of FLAG-M2 agarose beads (Sigma) were prepared per 1 mL of lysate, and equilibrated by 
washing 5 times in ice-cold Lysis Buffer. FLAG-M2 beads were added to the lysates and incubated while 
tumbling for 2 hours at 4 °C. Next, beads were pelleted by centrifugation at 250 RCF and washed 5 times 
with ice-cold Lysis Buffer. After every single wash step, the tubes were exchanged. RNF4-FLAG and 
interacting proteins were eluted off the beads by incubating them for 10 minutes with three bead volumes 
of Lysis Buffer supplemented with 1 mM FLAG-M2 peptide. Elution of the beads was repeated twice, and 
a fourth elution was performed with 2x LDS Sample Buffer (Novex). The primary three peptide elutions 
were pooled and concentrated. Culturing of cells, immunoprecipitation of RNF4-FLAG and subsequent 
steps leading to the LC-MS/MS analysis were performed in biological triplicate.
Purification of His-SUMO-2
Purification of His-SUMO-2-modified proteins was essentially performed as described previously (8).
Recombinant proteins
His6-MBP and His6-ΔN11-SUMO-2-Tetramer recombinant proteins were purified essentially as described 
previously (39). Briefly, BL21 cells were transformed with expression constructs. Cells were grown to an 
OD600 of 0.6. Subsequently, cells were grown overnight at 24°C in the presence of 0.1 mM isopropyl-β-
D-thiogalactopyranoside (IPTG), 20 mM HEPES pH 7.5, 1 mM MgCl2 and 0.05% Glucose. Lysates were 
prepared and proteins were affinity-purified on TALON beads (BD Biosciences). GST-tagged RNF4 was 
produced in E. coli and purified as described previously (48).
In vitro ubiquitylation and deubiquitylation assay
15 ng of His6-ΔN11-SUMO-2-Tetramer was in vitro ubiquitylated using 8 µM ubiquitin, 40 nM UBE1, 
0.7 µM UbcH5a (all from Boston Biochem), 0.5 µM GST-RNF4 in 50 mM TRIS pH 7.5, 5 mM MgCl2, 
1 mM DTT, and 4 mM ATP. 5 µL reactions were incubated at 37°C for three hours after which different 
concentrations (1 to 7.5 µg) of His6-MBP-USP11 proteins were added to a final volume of 15 µL. Reaction 
were incubated at 37°C for an additional three hours. Finally, reactions were stopped by adding 5 µL 4X 
LDS Sample Buffer (Novex).
In vitro interaction assay
In vitro ubiquitylation reactions were performed as described above in the presence or absence of 250 
ng His6-ΔN11-SUMO-2-Tetramer. Ubiquitin or SUMO-2-Ubiquitin chains were incubated with 5 µg His6-
MBP-RNF4, His6-MBP-USP11-C318A, His6-MBP-USP11-ΔSIMs-C318A or His6-MBP elution buffer in 
EBC buffer (50 mM TRIS pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 0.5 % NP-40) (23). Reactions 
were incubated at 4°C for 2 hours, and subsequently bound to 25 µL of Amylose resin (New England 
Biolabs) for another 2 hours at 4°C. Beads were washed extensively with EBC buffer and finally eluted in 





Protein samples were size-fractioned on Novex 4-12% Bis-Tris gradient gels using MOPS as a running 
buffer (Invitrogen), or on regular SDS-PAGE gels with a Tris-Glycine running buffer. Size-separated 
proteins were transferred to Hybond-C membranes (Amersham Biosciences) using a submarine system 
(Invitrogen). Membranes were stained for total protein loading using Ponceau-S (Sigma). Membranes were 
blocked using PBS containing 0.1% Tween-20 (PBST) and 5% milk powder for one hour. Subsequently, 
membranes were incubated with primary antibodies as indicated, in blocking solution. Incubation with 
primary antibody was performed overnight at 4 °C. Subsequently, membranes were washed three times 
with PBST and briefly blocked again with blocking solution. Next, membranes were incubated with 
secondary antibodies (donkey-anti-mouse-HRP or rabbit-anti-goat-HRP) for one hour, before washing 
three times with PBST and two times with PBS. Membranes were then treated with ECL2 (Pierce) as 
per manufacturer’s instructions, and chemiluminescence was captured using Biomax XAR film (Kodak).
Antibodies
The following antibodies were used in this study: mouse α FLAG (M2, Sigma), mouse α PML (5E10, kind 
gift from Prof. R. van Driel, University of Amsterdam (49)), rabbit α USP11 (A301-613A, Bethyl), mouse α 
SUMO-2/3 (8A2, Abcam), rabbit α SUMO-2/3 (raised against the C-terminus of SUMO-2), rabbit α RNF4 
(raised against GST-RNF4), rabbit α SART1 (raised against GST-SART1), rabbit α V5 (V8137, Sigma), 
mouse α His (HIS-1, Sigma) and rabbit α Ubiquitin (9133, Santa Cruz).
Electrophoresis, Coomassie Staining and In-gel digestion
RNF4-FLAG IP samples were size-separated by SDS-PAGE using Novex 4-12% gradient gels and MES 
SDS running buffer (Invitrogen), followed by staining with Colloidal Blue Kit (Invitrogen). Gel lanes were 
excised as ten slices per eluted fraction, cut into 2-mm3 cubes and in-gel digested with sequencing-grade 
modified trypsin (Promega) as described before (Shevchenko et al., 2006). The peptides extracted from 
the gel after digestion were cleaned, desalted and concentrated on C18 reverse phase StageTips (50).
LC-MS/MS analysis and data processing
Experiments were performed in triplicate. The analysis of in-gel digested samples was performed as 
described previously (Schimmel et al. 2014, in press). Raw data were processed using MaxQuant (51, 
52). RNF4-FLAG interactors were investigated through inspection of Label-Free Quantification (LFQ) 
intensities as well as MS/MS spectral counting.
Microscopy
Cells were seeded on glass coverslips, and fixed 24 hours later for 10 minutes in 3.7% paraformaldehyde 
in PHEM buffer (60 mM PIPES, 25 mM HEPES, 10 mM EGTA, 2 mM MgCl2 pH 6.9) at 37 °C. After 
washing with PBS, cells were permeated with 0.1% Triton-X100 for 10 minutes, washed with PBST, 
and blocked using TNB (100 mM TRIS pH 7.5, 150 mM NaCl, 0.5% Blocking Reagent (Roche)) for 30 
minutes. Cells were incubated with primary antibody as indicated, in TNB for one hour. Subsequently 




488 and Goat α Rb Alexa 594 (Invitrogen)) in TNB for one hour. Next, cells were washed five times with 
PBST and dehydrated using alcohol, prior to fixing them in DAPI solution (Citifluor) and sealing the slides 
with nail varnish. Images were recorded on a Leica SP5 confocal microscope system using 488 nm 
and 561 nm lasers for excitation, a 63X lens for magnification, and were analyzed with Leica confocal 
software. For quantification of PML bodies, groups of cells were recorded in similar-sized fields using 
Z-stacking with steps of 0.5 µm to acquire 10 images ranging from the bottom to the top of the cells. 
Images were maximum projected, individual cells were localized and PML bodies were counted using 
in-house customized Stacks software (53).
Structural modeling of USP11
The structure of USP11 was modeled using the Protein Homology/analogY Recognition Engine V 2.0 
(PHYRE2)(38). Homo sapiens USP11 (Uniprot ID P51784) was submitted to the PHYRE2 Protein Fold 
Recognition Server, and subjected to Intensive Modelling. 3D Molecule Viewer (Vector NTI Advance 
11.5.1, Invitrogen), was used to highlight putative SIMs within the structure. 
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Figure S1. Structural modeling of USP11 reveals four putative SIMs to be located within the DUSP 
and UCH domains. A) A rainbow-ribbon model of USP11, using a gradual transition in color to indicate 
progression from N-terminus to C-terminus. Alpha helices and beta sheets are indicated. B) Cartoon de-
picting USP11. USP11 harbors a Domain present in Ubiquitin-Specific Proteases (DUSP) and an Ubiqui-
tin Carboxyl-terminal Hydrolase domain (UCH). USP11 contains four potential SUMO interacting motifs 
(SIMs), located in between the DUSP and UCH domains. C) A structural skeleton model of USP11, with 
the SIMs indicated in yellow and using space-fill modelling for the respective molecules. The general 
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Chapter 4. Site-specific identification of SUMO-2 targets 
in cells reveals an Inverted SUMOylation Motif and a 
Hydrophobic Cluster SUMOylation Motif
Abstract
Reversible protein modification by Small Ubiquitin-like Modifiers (SUMOs) is critical 
for eukaryotic life. Mass spectrometry-based proteomics has proven effective at 
identifying hundreds of potential SUMO target proteins. However, direct identification 
of SUMO acceptor lysines in complex samples by mass spectrometry is still very 
challenging. We have developed a generic method for the identification of SUMO 
acceptor lysines in target proteins. We have identified 103 SUMO-2 acceptor lysines 
in endogenous target proteins. 76 of these acceptor lysines are situated in the 
SUMOylation consensus site [VILMFPC]KxE. Interestingly, eight sites fit the inverted 
SUMOylation consensus motif [ED]xK[VILFP]. In addition, we found direct mass 
spectrometric evidence for crosstalk between SUMOylation and phosphorylation with 
a preferred spacer between the SUMOylated lysine and the phosphorylated serine of 
four residues. In 16 proteins we identified a Hydrophobic Cluster SUMOylation Motif 




Ubiquitin (Ub) and ubiquitin-like proteins (Ubls) are covalently attached to other 
proteins via an isopeptide bond, which links the C-terminal glycine in these protein 
modifiers to the ε-amino group of lysines in substrate proteins. The Ubl family 
includes Nedd8, SUMO-1, -2, -3, ISG15, FAT10, FUBI, UBL5, URM1, ATG8 and 
ATG12. Reversible attachment of ubiquitin and Ubls to target proteins involves a set 
of enzymes (1-3). Components of the SUMO system play critical roles in regulation 
of fundamental cellular processes such as gene expression, cell cycle progression, 
DNA replication and DNA repair (1, 4). 
 A significant number of previously identified SUMOylated lysines in target 
proteins reside within the consensus motif ΨKXE/D, where Ψ is a large hydrophobic 
amino acid and X is any amino acid. However, this motif also frequently occurs in 
non-SUMOylated proteins and many functionally important SUMO sites are known to 
be in non-consensus sequences. Therefore, bioinformatic analysis is not sufficient. 
Instead, SUMO sites need to be determined directly. 
 Mass spectrometry (MS)-based proteomics has established itself as the leading 
high-throughput proteomics technology and has become sufficiently mature to allow 




main applications of MS is the direct mapping and quantitation of post-translational 
modifications (PTMs) of proteins. These modifications result in mass changes that 
can be detected by MS analysis (7). Although all PTMs can potentially be studied by 
MS, site-directed large scale proteomics analysis of a specific PTM requires efficient 
enrichment of modified peptides. For example, for phosphorylation it is possible to 
identify thousands of modification sites (8, 9).
 MS is also well suited for the characterization of Ub/Ubls substrate proteomes. 
However, in contrast to phosphorylation, the application of MS to the Ub/Ubl field 
currently relies on purification at the protein level. In a typical Ub/Ubl proteomics 
experiment for the study of these PTMs, targets covalently attached to the Ub/Ubl 
of interest are purified from cells expressing a tagged form of the modifier, such as 
His6-Ub or TAP-SUMO-2. Although this approach has been successfully employed 
to identify and quantify proteins modified by Ub/Ubls (10-16), purification of intact 
modified species produces a peptide mixture that is too complex for efficient detection 
of Ub/Ubls modification sites. This is particularly problematic for SUMOylation since 
most SUMO substrates are low-abundant proteins and are modified at a small 
percentage. 
 In addition, the analysis of crosslinked peptides containing the large C-terminal 
SUMO sequence makes MS analysis challenging. Trypsin-digested SUMOs release 
large signature tags, such as 19 and 32 amino acids respectively for mammalian 
SUMO-1 and SUMO-2/3, which produce many fragment ions during MS/MS 
fragmentation. Although this makes the SUMO-crosslinked peptide identification 
unambiguous as compared to ubiquitin, it also makes identification challenging 
because the long modifying tryptic SUMO peptide leads to complex MS/MS 
fragmentation patterns. Several different approaches have been proposed for the 
identification of SUMOylated peptides. SUMmOn (17), a pattern recognition tool, in 
combination with low resolution mass spectrometry, has been successful in detecting 
peptides modified by SUMO in vitro. In a previous study we have applied a targeted 
mass spectrometric approach combined with the linearization of the branched 
peptides to detect SUMO polymerization sites in vivo (18). In another approach, a 
database containing “linearized branched” peptides is employed to detect SUMO 
modified lysines (19). Despite the validity and sophistication of these strategies, their 
application to in vivo samples has been limited by the much higher complexity of 
the peptide mixture and very low abundance of SUMO conjugates (20). Here we 
report a method for selective enrichment of SUMOylated peptides from complex 
cellular proteomes. We have used this method to map SUMO modification sites in 






A strategy to enrich SUMO modified peptides
In contrast to phosphorylation, direct identification of SUMO acceptor lysines in target 
proteins purified from cell lysates has remained very challenging. To selectively 
enrich SUMO modified peptides from cells, we employed a previously published 
His6-tagged SUMO-2 mutant in which internal lysines were replaced by arginines 
(13). In addition, arginines were introduced at positions 90 (mutant T90R) or 87 
(mutant Q87R; Figure 1A) to shorten the SUMO branched peptide generated after 
tryptic digestion (21). The positions of these arginines correspond to the arginines 
that are present in ubiquitin or Smt3, respectively. Smt3 is the single SUMO family 
member found in S. cerevisiae. These mutants behave very similar to the wild-
type counterpart (Figures 2 and S2) and related mutants have already been used 
successfully (22-24). These lysine-deficient SUMO mutants are sensitive to digestion 
by trypsin, but not by Lys-C, an enzyme that specifically cleaves after lysine residues. 
After Lys-C digestion, peptides from target proteins that are covalently attached to 
lysine-deficient SUMOs via their SUMOylated lysines were purified under denaturing 
conditions via the His6-Tag. Next, in solution or in gel tryptic digestion removed a 
large part of SUMO from the substrate peptides while leaving short SUMO remnants 
– namely GG for the T90R mutant and QQTGG in case of the Q87R mutant (Figure 
1B). This is an efficient way to limit the complexity of the purified sample (Figure 1C).
Mass spectrometric mapping of SUMOylation sites
SUMOylated peptides were analyzed by nanoscale liquid chromatography coupled 
to high resolution hybrid mass spectrometers (LTQ-Orbitrap XL and LTQ-Orbitrap 
Velos) (see Materials and Methods). The LTQ Orbitrap Velos was operated in the 
higher-energy C-trap dissociation (HCD) mode, in which fragment ions are acquired 
with high resolution (25, 26). Samples were analyzed multiple times using different 
acquisition strategies. SUMOylated peptides identified by standard database 
search were manually validated to maximize the confidence of identification (see 
Supplementary Material and Methods for a description of the measurements and for 
manual validation criteria). This was beneficial especially for the Q87R experiments 
because fragmentation of the QQTGG tag produced peaks that are not assigned by 
the search engine. During manual inspection of high resolution MS/MS spectra, we 
noticed the presence of QQTGG signature fragment ions in the low mass region, 
namely m/z 257.125 (QQ), m/z 240.097 (QQ with loss of ammonia) and m/z 239.114 
(QQ with loss of water) (Figure 3A and Figure S1). These ions were subsequently 
used as reporter ions for SUMOylated peptides.
 Our strategy enabled the identification of 103 SUMOylated lysines from 82 
endogenous target proteins (Table S1). This is significantly better than previous 




Figure 1. A method to identify SUMO acceptor lysines in endogenous target proteins purified from 
cell lysates. (A) The carboxyl-termini of mature ubiquitin, SMT3 and human SUMO-2 are depicted. Two 
SUMO-2 mutants were created, Q87R and T90R that contained arginines on positions corresponding 
to arginines in SMT3 or ubiquitin, respectively. (B) Purification Strategy. Lysine deficient His6-SUMO-2 
mutants were expressed in HeLa cells and proteins in cell lysates were digested with endoprotease 
Lys-C that cleaves after lysine residues. His6-SUMO-2 and conjugated target protein fragments were 
purified by Immobilized Metal Affinity Chromatograpy (IMAC), digested with trypsin and analyzed by 
nano LC-MS/MS. Mascot and MaxQuant software were employed to identify SUMO-2 acceptor lysines 
in target proteins. (C) The SUMO-2 mutant proteins were efficiently conjugated to target proteins and 
conjugates were efficiently digested by Lys-C. Protein samples were analyzed by immunoblotting using 
an antibody directed against SUMO-2/3. (D) Out of the 103 SUMO-2 conjugated lysines that were 
detected in our screen 63 were situated in the SUMOylation consensus motif [VIL]KxE. Seven sites were 
situated in the consensus site [MF]KxE and nine were situated in [PCSQD]KxE sites. Ten SUMOylated 
lysines were situtated in the inverted consensus site [ED]xKx[≠ED] and two contained aspartic acids 
at position +2. Twelve SUMOylated lysines were missing acidic residues at position +2 or -2. (E-G) 
Graphical representations of the local target protein contexts of SUMO-2 conjugated lysines situated in 
the consensus motif KxE/D (E), in the inverted consensus motif E/DxKx[≠ED] (F) and in the Hydrophobic 
Cluster SUMOylation Motif (G). See also Figure S1. 
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Ubiquitin       LHLVLRLRGG
SMT3            IEAHREQIGG
SUMO2 wild-type IDVFQQQTGG
SUMO2-Q87R      IDVFRQQTGG


















detected in both T90R and Q87R experiments, additionally validating the accuracy 
of our approach. 
Analysis of SUMOylation Sites
Among the identified SUMO sites, 69% conformed to the previously established 
consensus site for SUMOylation, ψKxE/D, were ψ represents a large hydrophobic 
amino acid (Figure 1D and E). Remarkably, with the exception of the ψKxD type 
site that we identified in H/ACA ribonucleoprotein complex subunit 2, all sites that 
fit the SUMOylation consensus contain a glutamic acid. SUMOylation of H/ACA 
ribonucleoprotein complex subunit 2 on lysine 5 was confirmed in the accompanying 
paper by Westman et al. The SUMOylated lysines were most frequently preceded by 
isoleucine, valine or leucine. Alternative amino acids that preceded the SUMOylated 
lysines were phenylalinine (4x), proline (4x), methionine (3x), cysteine (2x), aspartic 
acid (1x), glutamine (1x) and serine (1x) (Table S1). The validity of our approach was 
confirmed by the identification of previously published SUMO attachment sites in 
e.g. RanGAP1, PML, DNA topoisomerase I, PARP1, Sp1, Sp3 and SUMO-2 (Table 
S1).
 The identification of SUMO attachment sites that are not situated in the 
SUMOylation consensus motif remains a challenge. Interestingly, we identified ten 
SUMO attachment sites that contained acidic residues two positions upstream of 
the SUMOylated lysine (Figure 1F and Figure S1B). The SUMOylated lysines were 
directly followed by phenylalanine (3x), proline (2x), isoleucine, leucine, valine, and 
also aspartic acid and tyrosine, so there is some preference for a hydrophobic residue. 
In contrast to the identified SUMO sites that matched the regular SUMOylation 
consensus motif, five of the inverted SUMOylation consensus sites contained an 
aspartic acid and the other five contained a glutamic acid at position -2. We have 
named this type of SUMOylation motif the inverted SUMOylation consensus motif E/
DxKψ. Surprisingly, SUMO-1 contains an inverted SUMOylation consensus site that 
was empirically identified in the present study, indicating unexpected atypical chain 
formation between SUMO-2 and SUMO-1 (18, 28). 
 We were intrigued by the identification of SUMO attachment sites in ACIN1, 
ADAR, AHNAK, APC4, BRD4, FOSL2, GRL, hnRNP-M, NUMA1, RanGAP1, RSF1, 
SAFB2, SNIP-1, YLPM1, ZBTB1 and ZNF280C on lysines that were preceded by 
hydrophobic clusters of at least three hydrophobic residues instead of the single 
hydrophobic residue that is usually present (Figure 1G and Table S1). We have 
named this type of SUMOylation site the Hydrophobic Cluster SUMOylation Motif 
(HCSM). These results will help to predict SUMO attachment sites in proteins. To 
facilitate the prediction of SUMOylation sites in proteins based on our results, we 





Interestingly, SUMO-acceptor lysines in BRD4 (K1111), RanGAP1 (K526), SAFB2 
(K293) and Treacle protein TCOF1 (K755) (Table S1) were previously identified 
as acetylated lysines (18, 30). Since SUMOylation and acetylation are mutually 


























































Figure 2. Verification of 
SUMO-2 mutants that 
were used for proteomics 
experiments. HeLa cells were 
transfected with plasmids 
expressing wild-type His6-
SUMO-2 or the indicated 
lysine-deficient His6-SUMO-2 
mutants. Cells were lysed 
and SUMOs were purified 
by IMAC. Input and SUMO-2 
enriched fractions were size-
separated by SDS-PAGE, 
blotted onto membranes and 
probed with antibodies directed 
against SART1, PML, DNA 
Topoisomerase IIα, RanGAP1, 
hnRNP M or Ubc9. SUMO-
2/3 probed immunoblots are 
depicted in Figure S2.
Crosstalk between SUMOylation and phosphorylation
Our mass spectrometry results revealed that the SUMOylated tryptic peptides of 
NOP5/58, RBM25, APC4, SNIP-1 and TOP2 contained downstream phosphorylated 
serines (Figure 3 and Figures S3). The spacing between the SUMOylated lysines 
and the downstream phosphorylated serines is remarkably consistent in NOP5/58, 
RBM25, SNIP-1 and APC4 with a preferred spacer of four amino acids between the 
SUMOylated lysine and the phosphorylated serine (Table S1, Figure S3). To establish 
the relevance of the phosphorylation of serine 502 in NOP5/58, we mutated this 
serine to alanine and studied the SUMOylation of this mutant (Figure 3C). Our results 







































































































































































































































SUMOylation + + + +
D
Figure 3. Phosphorylation-directed SUMOylation of NOP5/58. (A and B) Lysine 497 of NOP5/58 was 
identified as a SUMO-2 acceptor site in our screen using the SUMO-2 mutant Q87R (A) or the SUMO-2 
mutant T90R (B). In both cases, the identified tryptic fragments contained phosphorylated serines on 
position 502. The doubly modified peptide was identified by high resolution tandem mass spectrometry 
using HCD fragmentation. Insets, magnifications of the low mass regions showing QQTGG signature 
fragment ions (A) and the a2/b2 pair (B). (C) Serine 502 of NOP5/58 was mutated to alanine to prevent 
phosphorylation or to aspartic acid to mimick phosphorylation using a plasmid encoding NOP5/58-GFP. 
In addition, lysine 467 of NOP5/58 was mutated to arginine to avoid SUMOylation on this lysine residue. A 
double mutant (2KR) in which lysines 467 and 497 were replaced for arginines was included as a negative 
control. HeLa cells expressing His6-SUMO-2 were transfected with these plasmids or with the wild-type 




were analyzed by immunoblotting using antibodies against GFP and against SART1 as a control. (D) 
A biotin-tagged NOP5/58 PDSM peptide (residues 495-505 Biotin-HIKEEPLSEEE) and control peptide 
(Biotin-HIREEPLSEEE) were synthesized, phosphorylated in vitro by Casein Kinase 2 and SUMOylated. 
After termination of the reaction with LDS sample buffer, samples were size-separated by SDS-PAGE and 
immunoblots were analyzed using an antibody against the Biotin-tag. See also Figure S3.
SUMO conjugation of lysine 497. Remarkably, the three glutamic acids on positions 
503-505 were not able to compensate for the absence of the serine in the S502A 
mutant. Serine 502 is situated in the Casein Kinase II consensus phosphorylation site 
[ST]xx[ED]. Consistently, Casein Kinase II-mediated phosphorylation of a peptide 
matching the SUMO-phospho motif in NOP5/58 enhanced its SUMOylation (Figure 
3D). Functionally, the SUMOylation of NOP5/58 is relevant for snoRNA binding 
(Westman et al. accompanying manuscript).
SUMOylation of ZBTB1 via an extended SUMOylation motif
The Hydrophobic Cluster SUMOylation Motif in ZBTB1 was studied in detail by 
mutagenesis (Figure 4). The ZBTB1 protein contains an amino-terminal BTB 
domain, eight Zinc fingers, two nuclear localization signals and two lysines situated 
in the SUMOylation consensus motif ψKxE, lysines 265 and lysine 328 (Figure 4A). 
Lysine 328 was identified in our screen for SUMOylated lysines and is preceded 
by three consecutive isoleucines (Figure S4A). ZBTB1 was efficiently conjugated 
to SUMO-2 in vitro mainly via lysine 328 and to a lesser extent via lysine 265 
(Figure 4B and C). Similar results were obtained for SUMOylation of ZBTB1 in cells, 
uncovering a remarkably efficient SUMOylation of this protein (Figure 4D and E and 
S4B). The hydrophobic cluster preceding lysine 328 enhanced the SUMOylation 
efficiency, since mutating the isoleucines to corresponding amino acids serine and 
asparagine that precede the less efficiently SUMOylated lysine 265 significantly 
reduced the SUMO conjugation of lysine 328 (Figure 4F). This strikingly efficient 
SUMOylation site does not consist of an integrated SUMO Interaction Motif (SIM) 
and a SUMOylation site, since mutating the isoleucines on position 325 and 326 to 
alanines did not affect the SUMOylation efficiency (Figure S4C) in contrast to SIM-
mediated SUMO conjugation of USP25 (31). 
The BTB domain regulates the SUMOylation level of ZBTB1
Four ZBTB family members were identified in our SUMOylation site screen, ZBTB1, 
ZBTB2, ZBTB9 and ZBTB38. Previously, the BTB domain has been shown to mediate 
protein ubiquitination via interaction with Cul-3 (32). Furthermore, the BTB-domain 
enables BTB-proteins to oligomerize. To test whether the BTB domain is involved in 
protein SUMOylation, we created a ZBTB1 mutant lacking the BTB domain (Figure 
5A and B). As expected, this mutant lacked the capacity to form oligomers (Figure 
5C). A striking decrease in SUMOylation was observed for the mutant protein 


















































































































































































Figure 4. A Hydrophobic Cluster SUMOylation Motif mediates efficient conjugation of ZBTB1 to 
SUMO-2. (A) Cartoon depicting Zinc finger and BTB domain protein 1 (ZBTB1). ZBTB1 is composed of 
713 amino acids and harbors a BTB domain, eight C2H2-type zinc fingers, two nuclear localization signals 
and two consensus SUMOylation sites (K265, K328). (B) ZBTB1 is SUMOylated in vitro. An in vitro 
SUMO-2 conjugation reaction was performed, containing SUMO-2, SAE1/2, and Ubc9 as indicated and 
in vitro transcribed and translated [35S] labeled ZBTB1. The reaction was incubated for 3 hours at 37°C. 
After termination of the reaction by adding LDS sample buffer, samples were fractionated by SDS-PAGE, 
and dried gels were subjected to autoradiography. (C) The in vitro SUMOylation experiment was repeated 
including ZBTB1 mutants lacking one or two SUMOylation sites (K265R, K328R or double mutant). (D) 
ZBTB1 is SUMOylated in vivo. HeLa cells stably expressing His6-SUMO-2 (S2) and control HeLa (H) 




transfection in 8M Urea and His6-SUMO-2 conjugates were purified by IMAC. Total lysates (inputs) and 
purified fractions (pull down) were separated by SDS-PAGE, transferred to a membrane and probed using 
an antibody to detect YFP. (E) The experiment described in D was repeated including ZBTB1 mutants 
lacking one or two SUMOylation sites (K265R, K328R or double mutant). (F) Hydrophobic residues on 
position 325 and 326 of ZBTB1 affect the efficiency of ZBTB1 SUMOylation. The experiments described 
in D and E were repeated including ZBTB1 K265R mutants that are only SUMOylated on lysine 328. 
Hydrophobic residues on positions 325 or 326 were replaced for the corresponding amino acids preceding 
lysine 265. See also Figure S4.
efficient SUMOylation of ZBTB1 (Figure 5D). Subsequently, we tested whether the 
recombinant BTB domain can enhance SUMOylation in trans. GST-BTB(aa1-141) 
was produced in E.coli, purified and added to in vitro SUMOylation reactions (Figure 
5E). Addition of recombinant BTB domain to these SUMOylation assays did not alter 
the SUMOylation efficiency of ZBTB1, indicating that the BTB domain functions in 
cis via oligomerization. Thus, the ZBTB1 oligomer is more efficiently SUMOylated 
compared to the monomer (33). 
SUMOylation inhibits the repressive activity of ZBTB1.
Some ZBTB family members act as transcriptional repressors (Deweindt et al., 1995; 
Numoto et al., 1993; Li et al., 1997; Koh et al., 2009; Jeon et al., 2009). Since the 
target genes of ZBTB1 are currently unknown, we employed the Gal4 system (34) 
to study the transcriptional activity of ZBTB1. The thyroid hormone receptor fused to 
the Gal4 DNA binding domain was used as a control repressor in this experiment. 
In the absence of hormone, this receptor repressed the Gal4 binding site containing 
luciferase reporter 6.1 fold whereas ZBTB1 repressed this reporter construct 10.6 
fold, indicating that ZBTB1 is a potent transcriptional repressor (Figure 6A). In general, 
SUMOylation inhibits transcription factors (35). Here, we show that SUMOylation of 
ZBTB1 via lysine 265 reduces its repressive activity (Figure 6B and C and S5A and 
B). The location of the SUMOylated lysine in the protein appears to be important 
since SUMOylation of lysine 328 did not affect the repressive activity of ZBTB1.
SUMOylation regulates subnuclear partitioning of ZBTB1
SUMOylation can affect the subcellular localization of proteins as demonstrated 
for RanGAP1, Sp3 and other proteins (1). Confocal microscopy was used to study 
the subcellular localization of YFP-ZBTB1 (Figure 6D). This revealed that ZBTB1 
is a nuclear protein, which was expected since the protein harbors two nuclear 
localization signals (aa574-578 and aa645-652) (Fig 4A). ZBTB1 mainly localized to 
the nucleoplasm and accumulated in nuclear bodies. These ZBTB1 nuclear bodies 
did not colocalize with PML (data not shown) in contrast to the BTB domain containing 
protein Bach2 (36) but did colocalize with the transcriptional repressor SMRT (Figure 
6E). Next, we compared the subcellular localization of wild-type and SUMOylation-
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ZBTB1  .......... ..MAKPSHSS YVLQQLNNQR EWGFLCDCCI AIDDIYFQAH
Bach1  ..MSLSENSV FAYESSVHST NVLLSLNDQR KKDVLCDVTI FVEGQRFRAH
 BCL6  ....MASPAD SCIQFTRHAS DVLLNLNRLR SRDILTDVVI VVSREQFRAH
MIZ-1  .......... ..MDFPQHSQ HVLEQLNQQR QLGLLCDCTF VVDGVHFKAH
 PLZF  ..MDLTKMGM IQLQNPSHPT GLLCKANQMR LAGTLCDVVI MVDSQEFHAH
  ZF5  MEFFISMSET IKYNDDDHKT LFLKTLNEQR LEGEFCDIAI VVEDVKFRAH
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ZBTB1  KAVLAACSSY FRMFFMNHQH STAQLNLSN. .......... ...MKISAEC
Bach1  RSVLAACSSY FHSRIVGQAD GELNITLP.. .......... ...EEVTVKG
 BCL6  KTVLMACSGL FYSIFTDQLK CNLSVINLD. .......... ...PEINPEG
MIZ-1  KAVLAACSEY FKMLFVDQKD VVHLDIS... .......... ......NAAG
 PLZF  RTVLACTSKM FEILFHRNSQ HYTLDFLS.. .......... .......PKT
  ZF5  RCVLAACSTY FKKLFKKLEV DSSSVIEID. .......... ....FLRSDI
ZFP67  RAVLAACSHY FKKLFTEGGG GAVMGAGGSG TATGGAGAGV CELDFVGPEA
  ZID  KVILAACSTF MRDQFLLTQS KHVRITILQS .......... .......AEV
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ZBTB1  FDLILQFMYL GKIMTAPSSF EQFKVAMNYL QLYNVPDCLE DIQDADCSSS
Bach1  FEPLIQFAYT AKLILSKENV DEVCKCVEFL SVHNIEESCF QFLKFKFLDS
 BCL6  FCILLDFMYT SRLNLREGNI MAVMATAMYL QMEHVVDTCR KFIKASEAEM
MIZ-1  LGQMLEFMYT AKLSLSPENV DDVLAVATFL QMQDIITACH ALKSLAEPAT
 PLZF  FQQILEYAYT ATLQAKAEDL DDLLYAAEIL EIEYLEEQCL KMLETIQASD
  ZF5  FEEVLNYMYT AKISVKKEDV NLMMSSGQIL GIRFLDKLCS QKRDVSSPDE
ZFP67  LGALLEFAYT ATLTTSSANM PAVLQAARLL EIPCVIAACM EILQGSGLEA
  ZID  GRKLLLSCYT GALEVKRKEL LKYLTAASYL QMVHIVEKCT EALSKYLEID


















































































































Figure 5. A role for the BTB domain in protein SUMOylation. (A) BTB domains of ZBTB1, Bach1, 
BCL6, MIZ-1, PLZF, ZV5, ZFP67 and ZID were aligned. (B) A ZBTB1 deletion construct was created 
that lacked the BTB domain. This ΔBTB mutant lacked the first 142 amino acids of the wild-type ZBTB1 
protein. (C) Wild-type ZBTB1 and the ΔBTB mutant were fused to YFP or Gal4. These proteins were 
transiently expressed in HeLa cells and immunoprecipated from lysates using rabbit anti GFP antibody. 
Inputs and immunoprecipitates were analyzed by immunoblotting using mouse anti GFP antibody and 
mouse anti Gal4 antibody. (D) HeLa cells stably expressing His6-SUMO-2 (S2) and control HeLa (H) 
cells were transfected with expression construct encoding YFP-ZBTB1 wild-type or ΔBTB mutant. His6-
SUMO-2 conjugates were purified from a denaturing lysate and analyzed by immunoblotting to visualize 
SUMOylated ZBTB1. (E) Recombinant GST-BTB domain (aa1-141) was generated in E. coli and added 
to in vitro SUMOylation assays using [35S] labeled ZBTB1 as a substrate. The reaction was incubated for 
3 hours at 37°C. After termination of the reaction by adding LDS sample buffer, samples were fractionated 




Figure 6. SUMOylation regulates the transcriptional activity and subcellular localization of ZBTB1. 
(A-C) HeLa cells were grown on 24-well dishes and transfected with 500 ng of Gal4(DBD)-fusion 
expression plasmids and 500 ng of the reporter construct 5xGal4-Tk-Pgl3. Cells were lysed in reporter 
lysis buffer 24 hours after transfection and luciferase activity was measured. Results are representative 
of four independent experiments; the error bars indicate one standard deviation from the average. (A) 
The transcriptional activity of Gal4-ZBTB1 was compared to the known transcriptional repressor thyroid 
hormone receptor (TR) fused to Gal4. (B) The transcriptional activities of Gal4-ZBTB1 wild type and 
SUMOylation mutants were determined. (C) Transfection mixtures were split and one set of wells was 
lysed in LDS sample buffer to verify the expression levels of the Gal4-ZBTB1 proteins by immunoblotting 
using an antibody directed against Gal4. (D-H) HeLa cells were (co)transfected with expression constructs 
encoding YFP-ZBTB1, CFP-ZBTB1, GFP-ZBTB1, YFP-ZBTB1 K265/328R or YFP-SMRT. Cells were fixed 
and analyzed by confocal microscopy. Scale bars are 4 μm. (D) YFP-ZBTB1 localizes to the nucleoplasm 
and accumulates in nuclear bodies. (E) Colocalization of CFP-ZBTB1 and YFP-SMRT. (F) Colocalization 
of CFP-ZBTB1 and YFP-ZBTB1 K265/328R. (G) Proximal Ligation Assay (PLA) to detect SUMOylated 
ZBTB1. Cells were transfected with an expression construct encoding GFP-ZBTB1, fixed and the PLA 
was performed using affinity purified peptide anti SUMO-2/3 antibodies and a monoclonal antibody 
directed against GFP. Secondary antibodies were labeled with specific oligonucleotides. Oligonucleotide 
hybridization, ligation, amplification and detection were performed. (H) The cartoon briefly depicts the 
PLA technique. See also Figure S5.
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nuclear bodies. SUMOylation-deficient ZBTB1 can still interact with wild-type 
ZBTB1 via BTB-domain mediated oligomerization, therefore, this experiment does 
not reveal the specific subcellular localization of the SUMOylated form of ZBTB1. 
To positively identify the location of SUMOylated ZBTB1, we adapted the Proximal 
Ligation Assay (PLA) (37, 38) for protein SUMOylation. The PLA principle is depicted 
in the cartoon in Figure 6H. Primary antibodies directed against GFP and SUMO-2/3 
and secondary antibodies labeled with oligonucleotides were employed to reveal 
the location of SUMOylated ZBTB1 (Figure 6G). The GFP signal represents the 
location of SUMOylated and non-SUMOylated ZBTB1. PLA signals were located in 
the nucleoplasm, but not in the nuclear bodies, indicating that SUMOylated ZBTB1 is 
located in the nucleoplasm outside the nuclear bodies. No detectable PLA signal was 
observed for the SUMOylation-deficient ZBTB1 mutant (Figure S5C). We conclude 





































































































anti HA anti HA
anti SART1
Figure 7. A Hydrophobic Cluster SUMOylation Motif mediates efficient conjugation of RanGAP1 
to SUMO. (A) HeLa cells stably expressing His6-SUMO-1 (S1) or His6-SUMO-2 (S2) and control HeLa 
(H) cells were transfected with expression constructs encoding HA-RanGAP1 wild-type or the indicated 
HCSM mutants. Cells were lysed 24 hours after transfection and His6-SUMO conjugates were purified 
by IMAC. Total lysates (inputs) and SUMO purified fractions (pull down) were separated by SDS-PAGE, 
transferred to membranes and probed using antibodies against HA and against SART1 as a control. (B) 
HeLa cells were transfected with expression constructs encoding HA-RanGAP1 wild-type or the indicated 
HCSM mutants. Cells were fixed, co-stained with antibodies against the HA-tag (green) and against the 




Efficient conjugation of RanGAP1 to SUMO is mediated by a HCSM. 
RanGAP1 was the first identified SUMO substrate and is very efficiently conjugated 
to SUMO via lysine 526 (39, 40) that is situated in the Hydrophobic Cluster 
SUMOylation Motif GLLKSE. To verify whether this HCSM is involved in RanGAP1 
SUMOylation, we deleted glycine 523 and leucine 524, or replaced these residues 
for the basic residue histidine or the polar residue asparagine. SUMOylation of these 
mutants was severely reduced compared to wild-type RanGAP1 indicating that 
glycine 523 and leucine 524 contribute to the efficient SUMOylation of RanGAP1 
(Figure 7A). Consistently, RanGAP1 HCSM mutants failed to accumulate at nuclear 
pore complexes due to reduced SUMOylation (Figure 7B) (39, 40).
Discussion
Reversible post-translational modification of proteins by small chemical groups and 
small proteins enables tight control of protein activity. Recently, global analysis of 
protein phosphorylation dynamics by mass-spectrometry has enabled system-wide 
insight into signal transduction networks (9, 30, 41). Mass-spectrometric analysis of 
protein SUMOylation is currently very challenging (16). We have developed a MS-
based method to map acceptor lysines for SUMOs in endogenous substrate proteins 
purified from cells. The majority of the identified SUMO acceptor lysines were 
situated in the SUMOylation consensus motif ψKxE. In addition, we have uncovered 
an inverted SUMOylation consensus motif E/DxKψ and an extended SUMOylation 
consensus motif, the HCSM, where the SUMOylated lysine is preceded by a cluster 
of at least three hydrophobic amino acids. Moreover, we uncovered crosstalk 
between SUMOylation and phosphorylation and competition between SUMOylation 
and acetylation.
 Most SUMO acceptor lysines are currently identified using site-directed 
mutagenesis of potential SUMO acceptor sites. This method is very laborious and 
is unable to discriminate between SUMOylation sites and sites whose mutation 
changes the substrates and results in loss of SUMOylation at distal lysines (16). 
In studies on SUMOylation in yeast by the Gygi laboratory, six SUMOylation sites 
were identified (27) and in a study by the Yates laboratory, 22 sites were identified 
using the Smt3 I96R mutant and seven sites using wild-type Smt3 (23). In the 
most comprehensive study on protein SUMOylation in mammalian cells (10), five 
SUMOylation sites were identified. Recently, 14 SUMOylation sites were identified 
by Blomster et al. (2010) and a single SUMO site was identified by “ChopNspice” in 
endogenous proteins purified directly from cells and 17 sites including 8 sites on the 
SUMO E3 ligase RanBP2 by “ChopNspice” after incubation of a cellular extract with 
ATP (19). Our methodology enabled us to identify significantly more SUMOylation 
sites in endogenous target proteins purified directly from cells and yielded important 




 The identification of SUMO attachment sites in target proteins that lack classical 
SUMOylation consensus sites is very challenging and this has hampered progress 
in the field. The discovery of the inverted SUMOylation consensus sites E/DxKψ in 
our study could be particularly useful to predict SUMOylation sites in these target 
proteins and enable direct follow up by mutagenesis of SUMO targets that contain 
these motifs. 
 The SUMO-phospho modified sites that we identified in our screen in NOP5/58, 
RBM25, APC4, SNIP-1 and TOP2 did not strictly fit the previously published 
Phosphorylation-Dependent SUMOylation Motif (PDSM) ψKxE/DxxSP since the 
phosphorylation event was only proline-directed in SNIP-1 (42). This indicates more 
extensive crosstalk between phosphorylation and SUMOylation than previously 
anticipated. Interestingly, it has recently been shown that phosphorylation of the 
PDSM motif in Myocyte Enhancement Factor 2 and Heat-shock Transcription 
Factor 1 mediates the binding of this protein to a basic patch in the SUMO E2 
ligase Ubc9, providing mechanistic insight into crosstalk between SUMOylation and 
phosphorylation (18, 43). 
 Phosphorylated residues downstream of SUMOylation sites that enhance 
protein SUMOylation can functionally be replaced by negatively charged residues 
in the Negatively charged amino acid-Dependent SUMOylation Motif (NDSM) (44). 
Consistently, we found that the most frequently occurring amino acids five positions 
downstream of the SUMOylated lysines are glutamic acid, aspartic acid and serine. 
Positively charged residues were frequently found upstream of SUMOylated lysines 
and can enhance SUMOylation efficiency (45).
 We have identified an additional type of extended SUMOylation motif in 
our screen, the Hydrophobic Cluster SUMOylation Motif (HCSM). Mutagenesis 
experiments with the HCSMs in ZBTB1 and RanGAP1 indicated that these sites are 
very efficiently used for SUMO conjugation possibly due to enhanced binding to the 
SUMO E2 enzyme Ubc9 (46). Unexpectedly, the BTB domain was required for the 
efficient SUMOylation of ZBTB1. Previously, the BTB-domain was shown to function 
in protein ubiquitination as an adapter protein for Cul-3 (32, 47). Mechanistically, the 
BTB domain mediates oligomerization, therefore, we expect that the ZBTB1 oligomer 
is more efficiently SUMOylated due to Ubc9 hopping to the different moieties of 
the oligomer. SUMOylated ZBTB1 does no longer co-localize with the co-repressor 
SMRT in nuclear bodies, thus we expect that SUMOylation regulates ZBTB1 activity 
via altering its subcellular localization.
 We present a strategy for selective enrichment of SUMO modified peptides in 
complex cellular proteomes. The identified SUMOylated lysines and the discovery 







Plasmid constructs are described in Supplemental Experimental Procedures.
Cell lines, cell culture and transfection
HeLa cells and HeLa cells stably expressing His6-SUMO-2 (HeLaHis6SUMO-2) (14) were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) (Invitrogen), supplemented with 10% FCS and 100 U/ml penicillin and 
streptomycin (Invitrogen). Transfections were carried out using 2.5 μl Polyethylenimine (PEI, 1 mg/ml, 
Alpha Aesar) per μg DNA or using Lipofectamine 2000 (Invitrogen) according to the instructions of the 
manufacturer.
Antibodies
Peptide antibody AV-SM23-0100 (Eurogentec) against SUMO-2/3 and peptide antibody 1607 against 
SART1 were described previously (14, 15). Monoclonal antibody 5E10 against PML was a kind gift from 
Dr. Van Driel (Amsterdam, the Netherlands) and goat antibody against RanBP2 was a kind gift from Dr. 
Melchior (Heidelberg, Germany). Other antibodies that we used were mouse anti-HA, mouse anti-GFP 
(Roche), rabbit anti GFP (Invitrogen) mouse anti-Gal4 (Santa-Cruz Biotechnology), mouse anti Ubc9 and 
mouse anti DNA Topoisomerase IIα (BD Biosciences), mouse anti RanGAP1 (Zymed) and mouse anti 
hnRNP M (Sigma).
Purification of SUMOylated proteins for mass spectrometry
Transfected cells were harvested in icecold PBS. Cells were lysed in 6M Guanidinium-HCl containing 
0.1M NaHPO4 and 0.01M Tris/HCl pH8.0. Samples were filtered 3 times over Qiashredders (Qiagen) to 
reduce the viscosity. After centrifugation for 5 minutes at 14K, proteins in the supernatants were reduced 
using 1 mM dithiothreitol and alkylated using 5 mM iodoacetamide at room temperature. Proteins were 
digested by endoprotease Lys-C and His6-SUMO-2 conjugates were purified using Ni
2+-NTA agarose 
beads. Beads were washed twice with lysis buffer and 5 times with 8M Urea containing 0.1M NaHPO4 
and 0.01M Tris/HCl pH 8.0. Samples were eluted in 6.4 M Urea pH 8.0 containing 200 mM imidazole. The 
eluted His6-SUMO-2 conjugates were diluted 4 times with 10 mM ammonium bicarbonate and digested in 
solution with trypsin for 12 hours at room temperature. In a separate set of experiments, the His6-SUMO-2 
conjugates were separated by SDS-PAGE and the bands in the molecular weight range 15-38 kDa were 
excised from the gel and subjected to in-gel digestion (48).
Mass spectrometric analysis
The procedure is detailed in supplementary materials and methods. Briefly, the trypsin-digested peptides 
were purified on StageTips (49) and analyzed by nanoscale LC-MS/MS on a LTQ-Orbitrap XL or LTQ-
Orbitrap Velos mass analyzer (Thermo Fisher Scientific, Germany) coupled to EASY-nLC system 
(Proxeon Biosystems, Denmark). Raw MS data were processed with MaxQuant (50, 51) and the Mascot 
search engine (Matrix Science, UK). MS/MS spectra of identified SUMO modified peptides were 




using WebLogo (Computational Genomics Research Group, University of California, Berkeley).
Microscopy and Proximity Ligation Assay
Cells were grown on glass coverslips and transfected with expression constructs encoding EGFP-, 
EYFP- ECFP- or HA-tagged proteins. Cells were fixed 24 hours after transfection for 10 minutes in 3.7% 
paraformaldehyde in PHEM buffer (60 mM PIPES, 25 mM HEPES, 10 mM EGTA, 2 mM MgCl2, pH 6.9) at 
37°C. After washing with PBS, cells were mounted in Vectashield (Vector Laboratories). Immunostaining 
was performed as previously described (Matunis et al., 1998). Secondary antibodies were rabbit anti goat 
Alexa 594 and rabbit anti mouse Alexa 488 (Invitrogen). Proximity Ligation was performed as previously 
described (37, 38). Images were recorded on a Leica TCS/SP2 confocal microscope system using a 100x 
NA 1.4PL APO lens and were analyzed with Leica confocal software. 
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Figure S1 related to Figure 1 A. Overlap between our study and previous SUMO proteomics projects. 
We have identified 103 SUMOylation sites in 82 SUMO target proteins including 69 SUMO target proteins 
that were previously identified as potential human SUMO target proteins (1-14). Nine of the SUMO target 
proteins identified in this study have previously been identified as targets for Smt3; YFL039C, YKR092C, 
YKR008W, YJL148W, YEL026W, YLR335W, YDR390C, YOL006C and YNL088  (Denison et al., 2005; 
Panse et al., 2004; Wohlschlegel et al., 2004; Zhou et al., 2004). B. HCD MS/MS spectrum showing the 
SUMOylation of ZNF295 via an inverted SUMOylation consensus site. C and D. HCD MS/MS spectra 



























Figure S2 related to Figure 2. Control immunoblot for 
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Figure S3 related to Figure 3. A and B. CID MS/MS spectrum showing the phosphorylation-directed 
SUMOylation of NOP5/58. C and D. CID MS/MS spectrum showing the phosphorylation-directed 




































































































































Figure S4 related to Figure 4. A. CID MS/MS spectrum showing the SUMOylation of ZBTB1 via lysine 
328. B. SUMOylation analysis of YFP-ZBTB1 E267A, E330A single and double mutants. HeLa cells 
stably expressing His6-SUMO-2 (S2) and control HeLa (H) cells were transfected with expression 
constructs encoding YFP-ZBTB1 wild type, E267A, E330A single and double mutants. Cells were lysed 
24 hours after transfection and His6-SUMO-2 conjugates were purified by IMAC. Total lysates (input) 
and purified fractions (pull down) were separated by SDS-PAGE, transferred to a membrane and probed 
using an antibody to detect YFP. C. The ZBTB1 K328 SUMOylation site does not consist of an integrated 
SUMO Interaction Motif (SIM) and a SUMOylation site. SUMO-SIM interactions are depending on large 
hydrophobic residues in the SIM. We mutated the isoleucines in ZBTB1 on positions 325 and 326 to 
alanines and compared the SUMOylation efficiencies of the mutants to the wild-type protein. No reduction 
in SUMOylation was observed for the mutants, indicating that the K328 SUMOylation site in ZBTB1 does 









































Figure S5 related to Figure 6. A and B. GAL4-ZBTB1- E267A-E330A luciferase activity and immunoblot.
HeLa cells were grown on 24-well dishes and transfected with 500 ng of Gal4(DBD)-fusion expression 
plasmids and 500 ng of the reporter construct 5xGal4-Tk-Pgl3. Cells were lysed in reporter lysis 
buffer and luciferase activity was measured. (A) The transcriptional activities of Gal4-ZBTB1 wild type 
and SUMOylation mutants were determined. The error bars indicate one standard deviation from the 
average; results are representative of five independent experiments. (B) Transfection mixtures were split 
and one set of wells was lysed in LDS sample buffer to verify the expression levels of the Gal4-ZBTB1 
proteins by immunoblotting using an antibody directed against Gal4. (C) GFP-ZBTB1-K265R-K328R 
PLA negative control. HeLa cells were transfected with an expression construct encoding GFP-ZBTB1-
K265R-K328R, fixed and the PLA was performed using affinity purified peptide anti SUMO-2/3 antibodies 
and a monoclonal antibody directed against GFP. Secondary antibodies were labeled with specific 




Supplemental Table S1 Detailed list of the SUMOylation sites that were identified in our screen.
Available onlline at: http://www.sciencedirect.com/science/article/pii/S1097276510005733
Supplementary Materials
Plasmids
Lysine-deficient SUMO-2 was previously described (11). Lysine-deficient SUMO2-Q87R was generated 
by QuickChange site-directed mutagenesis (Stratagene) using oligonucleotides 5’- CATCGACGTGTTC-
CGGCAGCAGACGGGAG-3’  and 5’-CTCCCGTCTGCTGCCGGAACACGTCGATG-3’ and lysine-
deficient SUMO2-T90R was generated using oligonucleotides 5’-GTGTTCCAGC AGCAGAGGGGA-
GGTTAGGAATTCTG-3’ and 5’-CAGAATTCCTAACCTCCCCTCTGCTGCTGGAACAC-3’
The cDNA encoding the ZBTB1 protein was obtained from the Mammalian Gene Collection (MGC 
code 60335; Image ID 6141266; supplied by MRC geneservice, Cambridge, UK) and amplified by a 
two-step PCR reaction using the following primers: 5’-AAAAAGCAGGCTATATGGCAAAGCCCAGC-
CAC-3’ and 5’-AGAAAGCTGGGTCTCAGGTTCTTTTCAAATGC-3’ for the first reaction and 5’-GGGGA-
CAAGTTTGTACAAAAAAGCAGGCT-3’ and 5’-GGGGACCACTTTGTACAAGAAAGCTGGGT-3’ for the 
second reaction. The forward primer for the mutant lacking the BTB domain was 5’-AAAAAGCAGGCTA-
TATGCAGGATGCAGATTGTTC-3’. The cDNA was inserted into pDON207 employing standard Gateway 
technology (Invitrogen) and subsequently transferred to multiple different destination vectors to generate 
a T7-ZBTB1 expression construct and EYFP-, ECFP- EGFP- and GAL4(DBD)-tagged ZBTB1 expression 
plasmids. The fusions were made to the N-terminus of ZBTB1. EYFP-, ECFP- and EGFP-destination 
vectors were constructed by Dr. M. Posch (Wellcome Trust Biocentre, Dundee, UK). The Gal4(DBD)-
destination vector was obtained by ligation of the Gateway cassette reading frame B (Invitrogen) into the 
EcoRI digested pCG4 plasmid (15), which was a kind gift of Dr. N.D. Perkins (Wellcome Trust Biocentre, 
Dundee, UK). T7-ZBTB1 was constructed using destination vector pDEST14 (Invitrogen). 
To generate ZBTB1 SUMOylation site mutants, the consensus SUMOylation sites,  lysine 265 and 
lysine 328, were mutated to arginine residues by QuickChange site-directed mutagenesis (Stratage-
ne) using oligonucleotides 5’-GACAGTAACATCAGAGCTGAATTTGGTG-3’ and 5’-CACCAAATTCAG 
CTCTGATGTTACTGTC-3’ for the K265R mutation, 5’-GGATTATTATTAGGATGGAGCCAGAAG-3’ and 
5’-CTTCTGGCTCCATCCTAATAATAATCC-3’ for the K328R mutation, 5’-GACAGTAACATCAAAGCT-
GCATTTGGTGAAAAAG-3 and 5’-CTTTTTCACCAAATGCAGCTTTGATGTTACTGTC-3’ for the E267A 
mutation and 5’-GGATTATTATTAAGATGGCTCCAGAAGATATTCCTAC-3’ and 5’-GTAGGAATATCTTCT-
GGAGCCATCTTAATAATAATCC-3’ for the E330A mutation. 
To generate mutations in the hydrophobic cluster preceding the SUMOylated lysine K328, we 
replaced isoleucines on positions 325 and 326 for the corresponding amino acids preceding the SU-
MOylated lysine 265, serine and asparagine respectively using oligonucleotides 5’-CTGAGAGGAAAAG-
GAGTATTATTAAGATGGAG-3’ and 5’-CTCCATCTTAATAATACTCCTTTTCCTCTCAG-3’ for the I325S 
mutation and oligonucleotides 5’-GAGAGGAAAAGGATTAATATTAAGATGGAGCC-3’ and 5’-GGCTC-
CATCTTAATATTAATCCTTTTCCTCTC-3’ for the I326N mutation. The I325A mutation was generated 
using oligonucleotides 5’-CTGAGAGGAAAAGGGCTATTATTAAGATGGAG-3’ and 5’-CTCCATCTTAATA 




GAAAAGGATTGCTATTAAGATGGAGCC-3’ and 5’-GGCTCCATCTTAATAGCAATCCTTTTCCTCTC-3’. 
The BTB domain (aa1-141) of ZBTB1 was amplified using oligonucleotides 5’-ACAACGGATCCATGG-
CAAAGCCCAGCCAC-3’ and 5’-GCCGCGGAATTCTTACCCAAATATCATTTTGCTG-3’ and inserted into 
pGEX-2T.
Phosphorylation site mutants in NOP5/58-EGFP (a kind gift from Dr. Westman, Dundee, U.K.) 
were generated by site directed mutagenesis. The S502A mutant was generated using oligonucle-
otides 5’-GGAAGAACCACTTGCTGAGGAAGAACCA TG-3’ and 5’-CATGGTTCTTCCTCAGCAAG-
TGGTTCTTCC-3’. The S502D mutant was generated using oligonucleotides 5’-GGAAGAACCACTT-
GATGAGGA AGAACCATG-3’ and 5’-CATGGTTCTTCCTCATCAAGTGGTTCTTCC-3’.
The HA-RanGAP1 expression construct was a kind gift from Dr. Melchior (Heidelberg, Germany). 
The Δ523_524 mutant was generated using oligonucleotides 5’-GGCTCCTCGTGCACATGCTCAAG-
AGTGAAGACAAG-3’ and 5’-CTTGTCTTCACTCTTGAGCATGTGCACGAGGAGCC-3’. The G523H-
L524H mutant was generated using oligonucleotides 5’-GGCTCCTCGTGCACATGCATCACCTCAAG-
AGTGAAGACAAGG-3’ and 5’-CCTTGTCTTCACTCTTGAGGTGATGCATGTGCACGAGGAGCC-3’. 
The G523N_L524N mutant was generated using oligonucleotides 5’-CAGGCTCCTCGTGCACATGAAT-
AACCTCAAGAGTGAAGACAAGG-3’ and 5’-CCTTGTCTTCACTCTTGAGGTTATTCATGTGCACGAG-
GAGCCTG-3’. 
pCMX-SMRTe (16, 17) was a kind gift of Dr. E.J. Park and Dr. J.D. Chen (University of Massachu-
setts Medical School, Worcester, MA). The SMRT cDNA was amplified by PCR using pCMX-hSMRTe as 
template and oligonucleotides 5’-GGGGACAAGTTTGTACAAAAAAGCAGGCTCCATGTCGGGCTCCA-
CACAGCCTGT-3’ and 5’-GGGGACCACTTTGTACAAGAAAGCTGGGTGTCACTCGCTGTCGGAGAG-
TGTCTCGTA-3’. The amplified fragment was subsequently inserted into pDON207, and the EYFP-SMRT 
expression construct was obtained using standard Gateway technology. Constructs were verified by se-
quencing.
In vivo SUMO conjugation assays
HeLa cells stably expressing His6-SUMO-2 and control HeLa cells were grown on 15cm culture dishes 
and transfected. Cells were isolated by trypsinization 24 hours after transfection, washed twice with ice-
cold PBS and lysed in 1 ml lysis buffer containing 8 M urea, 100 mM Na2HPO4/NaH2PO4 and 10 mM Tris/
HCl pH 7.0 at room temperature. After removal of DNA clumps, samples were sonicated 4x 5 secs on ice. 
Imidazole (5mM) was added where indicated and His6-SUMO-2 conjugates were purified on 50 µl Co2+ 
TALON beads (BD Biosciences) at room temperature. After washing the beads four times with 1 ml urea 
lysis buffer, SUMO-2 conjugates were eluted from the beads in 60 µl urea lysis buffer containing 200 mM 
imidazole. Alternatively, cells were solubilized in lysis buffer (6 M Guanidinium-HCl, 100 mM Na2HPO4/
NaH2PO4, 10 mM Tris/HCl, pH 8.0, 20 mM Imidazole, 10 mM β mercapto-ethanol) and sonicated to redu-
ce the viscosity. His6-SUMO conjugates were enriched on Ni-NTA Agarose beads (Qiagen) and washed 
using wash buffers A-D. (Buffer A: 6 M Guanidinium-HCl, 100 mM NaH2PO4 /Na2HPO4, 10 mM Tris/HCl 
pH 8.0 and 0.2% Triton-X-100. Buffer B: 8 M Urea, 100 mM NaH2PO4 /Na2HPO4, 10 mM Tris/HCl pH 8.0 
and 0.2% Triton-X-100. Buffer C: 8 M Urea, 100 mM NaH2PO4 /Na2HPO4, 10 mM Tris/HCl pH 6.3 and 




Triton-X-100). These wash buffers also contained 10 mM β mercapto-ethanol. Samples were eluted in 6.4 
M Urea, 80 mM NaH2PO4/Na2HPO4, 8 mM Tris/HCl pH 7.0, 200 mM imidazole.
Electrophoresis and immunoblotting
Protein samples were size fractionated on Novex 4-12% Bis-Tris gradient gels using MOPS running buf-
fer (Invitrogen) or on regular SDS-PAGE gels with a tris-glycine buffer. Note that these different methods 
cause slight differences in the running behavior of proteins (Invitrogen). Size fractionated proteins were 
subsequently transferred onto Hybond-C extra membranes (Amersham Biosciences) using a submarine 
system (Invitrogen). Blots were stained for total protein using Ponceau S (Sigma). After blocking with PBS 
containing 0.1% Tween-20 and 5% milk powder, the membranes were incubated with primary antibodies 
as indicated. 
Electrophoresis, Coomassie Staining and In-gel digestion
The purified His6-SUMO-2 conjugates were separated by SDS-PAGE using Novex 4-12% gradient gels 
and MES SDS running buffer (Invitrogen), followed by staining with Colloidal Blue Kit (Invitrogen). Bands 
in the molecular range of 15-38 kDa were excised from the gel, cut into 2-mm3 cubes and in-gel digested 
with trypsin (Promega) essentially as described (18). The reduction and alkylation steps were performed 
before Lys-C digestion and therefore skipped during trypsin in-gel digestion. The peptides extracted from 
the gel after digestion were cleaned, desalted, concentrated and enriched on C18 reverse phase StageTips 
(19). In-solution digested samples were analyzed on an LTQ-Orbitrap XL mass spectrometer whereas the 
analysis of in-gel digested samples was performed on an LTQ-Orbitrap Velos instrument  (20). 
Liquid Chromatography-Mass spectrometry
Mass spectrometric analysis was performed by nanoscale LC-MS/MS using LTQ-Orbitrap XL and LTQ-
Orbitrap Velos instruments (Thermo Fisher Scientific, Germany) coupled to an EASY-nLC system (Proxe-
on Biosystems, Denmark) via a Proxeon nanoelectrospray interface. Peptides eluted from StageTips 
were separated on a 75 μm inner diameter reverse phase C18 column packed in-house with 3 µm C18 
beads (Dr. Maisch, Germany) with a 140 or 240 min gradient. 
Data were acquired in data-dependent mode. In the case of the LTQ-Orbitrap XL, full scan spectra 
were acquired in the 300-1600 m/z range (R = 60,000  and target value of 1’000’000); 400-1000 m/z range 
was used in the ‘single range’ method; ‘multiple ranges’ experiments used mass regions m/z 300-500, 
m/z 450-650, m/z 600-900, m/z 850-1,250, m/z 1,200-1,800. Injection waveforms option was enabled in 
all survey scans to eject all ions outside of the specified mass range. For ‘full range’ and ‘single range’ 
orbitrap measurements the “lock mass” option was used to improve the mass accuracy of precursor ions 
(21). The ten most intense ions were fragmented by collision-induced dissociation (CID) with normalized 
collision energy of 35% and recorded in the linear ion trap (target value of 5,000) based on the survey 
scan and in parallel to the orbitrap detection of MS spectra. 
In the case of the LTQ-Orbitrap Velos, survey scan acquisition was performed in the orbitrap with a 
resolution of 30,000 at m/z 400. Ten most intense ions were fragmented by higher-energy collisional dis-




7,500 at m/z 400 (target value of 50,000). The HCD experiments were performed in the ‘full range’ mode 
(300-1700 m/z: target value of 1’000’000) and ‘multiple ranges’ mode (mass ranges of 400-650 m/z, 600-
900 m/z and 850-1300 m/z; target value of 500’000). Survey and HCD fragment spectra were acquired in 
profile mode, whereas the acquisition of CID MS/MS spectra was done in centroid mode. 
Data Processing and Analysis
Raw MS data files were processed with the MaxQuant software (version 1.0.14.3) (22) as previously 
described (23). Enzyme specificity was set to trypsin, allowing for cleavage N-terminal to proline residues 
and up to four missed cleavages. Cysteine carbamidomethylation was considered as a fixed modification, 
and methionine oxidation, protein N-acetylation and phosphorylation on serine, threonine and tyrosine 
residues were set as variable modifications in all experiments. In addition, mass addition of 114.0429 
(GG signature tag derived from SUMO2-T90R) on lysine for the T90R experiment, and mass addition of 
471.2078 (QQTGG signature tag remnant of SUMO2-Q87R) on lysine for the Q87R experiment, were 
considered as variable modifications. MS/MS peak list generated by MaxQuant were searched by the 
Mascot database search engine (Matrix Science, London, UK, version 2.1.04) against the human Interna-
tional Protein Index (IPI) database (version 3.37)  (Kersey et al., 2004). The initial maximum allowed mass 
deviation was set to 7 ppm for peptide masses, 0.5 Da for low resolution CID fragment ions and 0.02 Da 
for high resolution HCD fragment ions.
Manual validation of Peptide Identifications
The best MS/MS spectra of all identified SUMOylated peptides were manually validated using the Viewer 
module of MaxQuant and Xcalibur Qual browser instruments (Thermo Fisher Scientific, Germany). The 
peptide matches were filtered by the following criteria: (i) maximum mass deviation smaller than 5 ppm; 
(ii) only peptides containing an internal SUMOylated lysine were accepted; (iii) reasonable coverage of 
b- and/or y- ions series; (iv) peptides containing prolines were required to show pronounced cleavage 
amino-terminal to the proline residue; (v) preferential cleavage C-terminally from aspartate and glutama-
te; (vi) presence of a2/b2 pairs. Additionally, Q87R HCD spectra were required to show QQTGG signature 
fragment ions in the low mass region: m/z 257.125 (QQ), m/z 240.097 (QQ with loss of ammonia) and 
m/z 239.114 (QQ with loss of water). 
In vitro expression of proteins
In vitro transcription/translation of proteins was performed using 1 µg of plasmid DNA (T7-ZBTB1) and 
a wheat germ-coupled transcription/translation system in 25 µl reaction volumes according to the in-
structions provided by the manufacturer (Promega). [35S]Methionine (17.5 µCi per labeling) (Amersham 
Biosciences) was used in the reactions to generate radiolabeled proteins.
In vitro SUMO conjugation assays
In vitro SUMO conjugation assays were performed in 10 μl volumes containing 120 ng SAE1/2, 500 ng 
SUMO-2, 50 mM Tris/HCl pH 7.5, 5 mM MgCl2, 2 mM ATP, 10 mM creatine phosphate, 3.5 U/ml creatine 




was carried out using 1 μl of the in vitro transcribed and translated [35S] labeled ZBTB1 or 30 μM peptide. 
Reactions were incubated for 3 hours at 37°C. After termination of the reaction with LDS sample buffer 
(Invitrogen), reaction products were fractionated by SDS-PAGE using Novex 4-12% Bis-Tris gradient gels 
and MOPS running buffer (Invitrogen). Dried gels were exposed to X-Omat AR (XAR) autoradiography 
films (Kodak) to detect radiolabeled proteins.
Luciferase assays
HeLa cells were grown on 24-well tissue culture plates and transfected with 500 ng of Gal4-DBD or 
Gal4(DBD)-fusion expression plasmids and 500 ng of the reporter construct 5xGal4-Tk-Pgl3 (24). 24 
hours after transfection, cells were washed with ice-cold PBS and lysed in 100 μl reporter lysis buffer 
(Promega). As a control, the luciferase activity of the known transcriptional repressor thyroid hormone 
receptor (TR) was determined (25). Luciferase activity relative to Gal4-DBD was depicted. Equal expres-
sion of Gal4(DBD)-fusion plasmids was verified by immunoblotting. Transfection mixtures were split over 
two wells. Samples for immunoblotting were prepared in LDS sample buffer (Invitrogen).
Proximity Ligation Assay
Proximity Ligation was performed as previously described (26, 27). Cells were fixed for 15 minutes with 
3.7% paraformaldehyde in PBS at 37°C and permeabilized for 15 minutes at room temperature with 0.1% 
Triton X-100 in TBS. After washing, cells were blocked for 10 minutes using 0.5% milk powder in TBST. 
Antibody incubations using monoclonal anti GFP antibody (Roche) and affinity purified rabbit anti SUMO-
2/3 antibody (Eurogentec) were carried out overnight in blocking solution at room temperature. Subse-
quent steps were carried out at 37°C. Secondary antibodies were incubated for 1 hour. Hybridization was 
performed for 30 minutes in a humid chamber. This chamber was also used for ligation for 30 minutes, for 
amplification for 90 minutes and for detection for 30 minutes. Dot-like structures are an intrinsic characte-
ristic of PLA signals and do not necessarily represent nuclear bodies.
Supplementary References 
 
 1.  Blomster, H. A., Hietakangas, V., Wu, J., 
Kouvonen, P., Hautaniemi, S., and Sistonen, 
L. (2009) Novel proteomics strategy brings 
insight into the prevalence of SUMO-2 target 
sites. Mol. Cell Proteomics 8, 1382-1390
 2.  Ganesan, A. K., Kho, Y., Kim, S. C., Chen, 
Y., Zhao, Y., and White, M. A. (2007) Broad 
spectrum identification of SUMO substrates 
in melanoma cells. Proteomics 7, 2216-2221
 3.  Gocke, C. B., Yu, H., and Kang, J. (2005) 
Systematic identification and analysis of 
mammalian small ubiquitin-like modifier 
substrates. J. Biol. Chem. 280, 5004-5012
 4.  Golebiowski, F., Matic, I., Tatham, M. H., 
Cole, C., Yin, Y., Nakamura, A., Cox, J., 
Barton, G. J., Mann, M., and Hay, R. T. 
(2009) System-wide changes to SUMO 
modifications in response to heat shock. Sci. 
Signal. 2, ra24
 5.  Li, T., Evdokimov, E., Shen, R. F., Chao, 
C. C., Tekle, E., Wang, T., Stadtman, E. 
R., Yang, D. C., and Chock, P. B. (2004) 
Sumoylation of heterogeneous nuclear 
ribonucleoproteins, zinc finger proteins, and 
nuclear pore complex proteins: a proteomic 
analysis. Proc. Natl. Acad. Sci. U. S A 101, 
8551-8556
 6.  Li, T., Santockyte, R., Shen, R. F., Tekle, 
E., Wang, G., Yang, D. C., and Chock, P. B. 
(2006) A general approach for investigating 
enzymatic pathways and substrates for 
ubiquitin-like modifiers. Arch. Biochem. 
Biophys. 453, 70-74
 7.  Manza, L. L., Codreanu, S. G., Stamer, S. L., 
Smith, D. L., Wells, K. S., Roberts, R. L., and 
Liebler, D. C. (2004) Global shifts in protein 




oxidative stress. Chem. Res. Toxicol. 17, 
1706-1715
 8.  Matafora, V., D’Amato, A., Mori, S., Blasi, 
F., and Bachi, A. (2009) Proteomic analysis 
of nucleolar SUMO-1 target proteins upon 
proteasome inhibition. Mol. Cell Proteomics
 9.  Pungaliya, P., Kulkarni, D., Park, H. J., 
Marshall, H., Zheng, H., Lackland, H., 
Saleem, A., and Rubin, E. H. (2007) 
TOPORS functions as a SUMO-1 E3 
ligase for chromatin-modifying proteins. J. 
Proteome Res. 6, 3918-3923
 10.  Rosas-Acosta, G., Russell, W. K., Deyrieux, 
A., Russell, D. H., and Wilson, V. G. (2005) 
A universal strategy for proteomic studies 
of SUMO and other ubiquitin-like modifiers. 
Mol. Cell Proteomics 4, 56-72
 11.  Schimmel, J., Larsen, K. M., Matic, I., van 
Hagen, M., Cox, J., Mann, M., Andersen, J. 
S., and Vertegaal, A. C. (2008) The ubiquitin-
proteasome system is a key component of 
the SUMO-2/3 cycle. Mol. Cell Proteomics 7, 
2107-2122
 12.  Vertegaal, A. C., Ogg, S. C., Jaffray, E., 
Rodriguez, M. S., Hay, R. T., Andersen, J. 
S., Mann, M., and Lamond, A. I. (2004) A 
proteomic study of SUMO-2 target proteins. 
J. Biol. Chem. 279, 33791-33798
 13.  Vertegaal, A. C., Andersen, J. S., Ogg, 
S. C., Hay, R. T., Mann, M., and Lamond, 
A. I. (2006) Distinct and overlapping sets 
of SUMO-1 and SUMO-2 target proteins 
revealed by quantitative proteomics. Mol. 
Cell Proteomics 5, 2298-2310
 14.  Zhao, Y., Kwon, S. W., Anselmo, A., Kaur, 
K., and White, M. A. (2004) Broad spectrum 
identification of cellular small ubiquitin-
related modifier (SUMO) substrate proteins. 
J. Biol. Chem. 279, 20999-21002
 15.  Chapman, N. R., and Perkins, N. D. (2000) 
Inhibition of the RelA(p65) NF-kappaB 
subunit by Egr-1. J. Biol. Chem. 275, 4719-
4725
 16.  Park, E. J., Schroen, D. J., Yang, M., Li, 
H., Li, L., and Chen, J. D. (1999) SMRTe, 
a silencing mediator for retinoid and thyroid 
hormone receptors-extended isoform that 
is more related to the nuclear receptor 
corepressor. Proc. Natl. Acad. Sci. U. S. A 
96, 3519-3524
 17.  Wu, X., Li, H., Park, E. J., and Chen, 
J. D. (2001) SMRTE inhibits MEF2C 
transcriptional activation by targeting HDAC4 
and 5 to nuclear domains. J. Biol. Chem. 
276, 24177-24185
 18.  Shevchenko, A., Tomas, H., Havlis, J., Olsen, 
J. V., and Mann, M. (2006) In-gel digestion 
for mass spectrometric characterization of 
proteins and proteomes. Nat. Protoc. 1, 
2856-2860
 19.  Rappsilber, J., Mann, M., and Ishihama, 
Y. (2007) Protocol for micro-purification, 
enrichment, pre-fractionation and storage 
of peptides for proteomics using StageTips. 
Nat. Protoc. 2, 1896-1906
20.  Olsen, J. V., Schwartz, J. C., Griep-Raming, 
J., Nielsen, M. L., Damoc, E., Denisov, E., 
Lange, O., Remes, P., Taylor, D., Splendore, 
M., Wouters, E. R., Senko, M., Makarov, A., 
Mann, M., and Horning, S. (2009) A dual 
pressure linear ion trap orbitrap instrument 
with very high sequencing speed. Mol. Cell 
Proteomics 8, 2759-2769
21.  Olsen, J. V., de Godoy, L. M., Li, G., Macek, 
B., Mortensen, P., Pesch, R., Makarov, A., 
Lange, O., Horning, S., and Mann, M. (2005) 
Parts per million mass accuracy on an 
Orbitrap mass spectrometer via lock mass 
injection into a C-trap. Mol. Cell Proteomics 
4, 2010-2021
22.  Cox, J., and Mann, M. (2008) MaxQuant 
enables high peptide identification rates, 
individualized p.p.b.-range mass accuracies 
and proteome-wide protein quantification. 
Nat. Biotechnol. 26, 1367-1372
23.  Cox, J., Matic, I., Hilger, M., Nagaraj, N., 
Selbach, M., Olsen, J. V., and Mann, M. 
(2009) A practical guide to the MaxQuant 
computational platform for SILAC-based 
quantitative proteomics. Nat. Protoc. 4, 698-
705
24.  Kalkhoven, E., Teunissen, H., Houweling, A., 
Verrijzer, C. P., and Zantema, A. (2002) The 
PHD type zinc finger is an integral part of 
the CBP acetyltransferase domain. Mol. Cell 
Biol. 22, 1961-1970
25.  Tone, Y., Collingwood, T. N., Adams, M., and 
Chatterjee, V. K. (1994) Functional analysis 
of a transactivation domain in the thyroid 
hormone beta receptor. J. Biol. Chem. 269, 
31157-31161
 26.  Soderberg, O., Leuchowius, K. J., Gullberg, 
M., Jarvius, M., Weibrecht, I., Larsson, L. G., 
and Landegren, U. (2008) Characterizing 
proteins and their interactions in cells and 
tissues using the in situ proximity ligation 
assay. Methods 45, 227-232
27.  Soderberg, O., Gullberg, M., Jarvius, M., 
Ridderstrale, K., Leuchowius, K. J., Jarvius, 
J., Wester, K., Hydbring, P., Bahram, F., 
Larsson, L. G., and Landegren, U. (2006) 
Direct observation of individual endogenous 
protein complexes in situ by proximity 
ligation. Nat. Methods 3, 995-1000
5
Uncovering SUMOylation 
dynamics during cell 
cycle progression reveals 
FoxM1 as a key mitotic SUMO 
target protein
 
Joost Schimmel*, Karolin Eifler*, Jón Otti Sigurðsson*, 
Sabine A.G. Cuijpers, Ivo A. Hendriks, Matty Verlaan – de 
Vries, Christian D. Kelstrup, Chiara Francavilla, René H. 
Medema, Jesper V. Olsen, Alfred C.O. Vertegaal
Molecular Cell 2014 53(6):1053-66
*These authors contributed equally to this work. 






Chapter 5. Uncovering SUMOylation dynamics during 
cell cycle progression reveals FoxM1 as a key mitotic 
SUMO target  protein
Abstract
Loss of SUMO modification in mice causes genomic instability due to the 
missegregation of chromosomes. Currently, little is known about the identity of 
relevant SUMO target proteins that are involved in this process and about global 
SUMOylation dynamics during cell cycle progression. We performed a large-scale 
quantitative proteomics screen to address this and identified 593 proteins to be 
SUMO-2 modified, including the Forkhead transcription factor FoxM1, a key regulator 
of cell cycle progression and chromosome segregation. SUMOylation of FoxM1 
peaks during G2 and M phase, when FoxM1 transcriptional activity is required. We 
found that a SUMOylation deficient FoxM1 mutant was less active compared to wild-
type FoxM1, implicating that SUMOylation of the protein enhances its transcriptional 
activity. Mechanistically, SUMOylation blocks the dimerization of FoxM1, thereby 
relieving FoxM1 autorepression. Cells deficient for FoxM1 SUMOylation showed 
increased levels of polyploidy. Our findings contribute to understanding the role of 
SUMOylation during cell cycle progression.
Introduction
Cell cycle progression is extensively controlled via complex networks of reversible 
post-translational modifications (PTMs), including small chemical modifications like 
phosphorylation and modifications by ubiquitin and small ubiquitin-like proteins 
(1-3). Deregulation of these signaling cascades can result in uncontrolled cell 
cycle progression, causing genome instability and cancer (4-6). Cell cycle signal 
transducers represent major anti-cancer drug targets that are exploited to halt cell 
cycle progression in tumor cells (7).
More recently, mass spectrometry (MS)-based proteomics has enabled 
global analyses of different post-translational modification networks, including 
phosphorylation, ubiquitination and lysine acetylation (8). Interestingly, nuclear 
proteins and proteins involved in regulating metabolic processes showed significant 
cell cycle dynamics with notably high phosphorylation site occupancy in mitosis (9).
Initial studies on the small ubiquitin-like modifier (SUMO) system revealed a key 
role for this modification in cell cycle progression (10-13). A failure to conjugate the 
single SUMO form in S. cerevisiae, Smt3, to target proteins due to a deletion of Ubc9 
resulted in a G2/M block (14). Conversely, a failure to remove Smt3 from a subset 




also resulted in a G2/M block (15) and Ulp2 is essential for spindle dynamics and 
cell cycle progression (16). Mice deficient for Ubc9 failed to progress through 
embryonic development and died at the early post-implantation stage due to DNA 
hypocondensation and genome instability (17). 
Multiple SUMO target proteins were identified that play key roles during 
cell cycle progression including the trimeric replication clamp PCNA (18, 19), 
DNA topoisomerase IIα (20), CENP-E (Zhang et al., 2008), CENP-I (21) and the 
chromosomal passenger complex subunit Borealin (22). Despite these interesting 
findings, we are lacking global insight in the regulation of cell cycle progression via 
SUMOylation. To address this, we have optimized the biochemical purification of 
SUMO target proteins and used a SILAC approach (23) to compare SUMOylation 
levels of these targets at different cell cycle stages. Follow-up experiments revealed 
that SUMOylation was needed for full transcriptional activation of the Forkhead 
box transcription factor FoxM1 and for counteracting polyploidy. Mechanistically, 
SUMOylation counteracts autorepression of FoxM1. 
Results
Knockdown of UBA2 and Ubc9 in HeLa cells leads to decreased cell proliferation
To study the role of SUMOylation in cell cycle progression in a mammalian system, 
we infected HeLa and U2OS cells with lentiviruses encoding shRNAs against UBA2, 
Ubc9 or for a non-coding control shRNA. Western blot analysis confirmed that UBA2 
and Ubc9 protein levels as well as the amount of SUMO conjugates were reduced 
but not abrogated after virus infection, whereas the pool of free SUMO was increased 
(Figure 1A). Colony formation of cells treated with UBA2 and Ubc9 knockdown 
viruses was compared to the control nine days after infection. Knockdown of UBA2 
and Ubc9 limited colony formation to only about 1-2 % in HeLa cells and 4-22 % in 
U2OS compared to the control population (Figure 1B and Figure S1A). We further 
confirmed these findings by testing cell proliferation of Ubc9 depleted cells four days 
after infection. Ubc9 knockdown decreased proliferation by 24-45% both in HeLa 
and U2OS cells (Figure 1C and Figure S1B). 
Surprisingly, flow cytometry on day four after virus infection did not reveal any 
significant differences between mock treated cells and cells treated with UBA2 and 
Ubc9 knockdown viruses (Figure 1D and Figure S1C) in contrast to the G2/M block 
observed in yeast cells lacking Ubc9 (14). From this we conclude that the decrease 
in colony formation after UBA2 and Ubc9 knockdown is neither caused by arresting 
the cells in a specific phase of the cell cycle nor by an increase in the apoptotic cell 
pool. These findings are consistent with recently reported results (24). Using BrdU 
pulse labeling, we could demonstrate a delay in cell cycle progression in response 




Figure 1. SUMOylation is required for cell proliferation A) HeLa cells were infected with lentiviruses 
expressing an shRNA against UBA2 (shRNA1) and two different shRNAs against Ubc9 (shRNA2 and 
shRNA3), or with a control virus respectively. A decrease in UBA2 and Ubc9 expression and SUMO 
conjugation levels and an increase in free SUMO was confirmed by immunoblotting four days after virus 
infection using antibodies against UBA2, Ubc9 and SUMO-2/3. B) Colony formation was determined nine 
days after infection by staining with Giemsa solution and counting colonies using the ImageJ Version 
1.47v software. The values were normalized to the control. Error bars represent the standard deviation 
from the average obtained from three independent experiments. ** p < 0.001. C) The proliferation rate 
of cells treated with Ubc9 knockdown virus was compared to cells treated with control virus four days 
after infection by adding the cell metabolic activity reagent WST-1 to the growing cells and measuring 
the absorbance at 450 nm after two hours incubation. The values were normalized to the control and the 
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** p < 0.001. D) The graph depicts the percentage of HeLa cells in each cell cycle phase measured 
by flow cytometry four days after virus infection. Error bars represent the standard deviation from the 
average obtained from three independent experiments. E) BrdU pulse chase experiments demonstrate a 
decelerated passage through the cell cycle for HeLa cells treated with shRNA1 for four days and released 
from the BrdU pulse for four hours or eight hours. See also Figure S1.
A quantitative proteomics approach to study global SUMOylation dynamics 
throughout the cell cycle
Subsequently, we were interested in identifying global SUMOylation dynamics during 
cell cycle progression using a quantitative proteomics approach. SUMOylation 
proteomics is challenging since SUMOylation levels of most proteins are low and 
SUMO proteases can rapidly cleave SUMOs from target proteins (25). To be able 
to purify SUMO targets from cells, we generated a HeLa cell line stably expressing 
Flag-tagged SUMO-2 bearing a Q87R mutation in order to shorten the peptide 
branch remaining after tryptic digestion to enable SUMO acceptor site mapping (26). 
SUMO-2 was chosen for these experiments since SUMO-2/3 are the most abundant 
SUMO family members (27), displaying cell cycle dynamics (28) and mature SUMO-
2 and SUMO-3 are virtually identical. Moreover, these SUMO forms are able to 
form SUMO chains (29, 30) that play an important role in SUMOylation dynamics 
(31). Co-expression of GFP, linked to the Flag-SUMO-2 cDNA via an IRES, allowed 
sorting by flow cytometry of a homogeneous population of low expressing cells to 
avoid overexpression artifacts. 
Analysis of the cells by confocal microscopy revealed that Flag-SUMO-2 was 
predominantly located in the nucleus as expected (Figure 2A). Immunoblotting 
analysis confirmed the relatively low expression of Flag-SUMO-2 compared to 
endogenous SUMO-2/3 levels in HeLa cells and the efficient enrichment of SUMO-2 
conjugates by immunoprecipitation (IP) (Figure 2B). 
For quantitative proteomic analysis, three different populations of HeLa cells 
expressing Flag-SUMO-2 were SILAC labeled with three distinct sets of isotopic 
variants of lysine and arginine. Cells were blocked with thymidine or the CDK1 
inhibitor RO-3306 and either directly lysed or released from the blockage for different 
amounts of time as indicated in Figure 2C. Flow cytometry analysis confirmed the 
enrichment of synchronized cell populations at the respective cell cycle stages (Figure 
2C). Cells released from the RO-3306 block for 8 hours were an exception due to 
the prolonged presence of G2/M arrested cells. Thus, G1 effects identified in this 
sample might be underestimated. For subsequent Flag-IP, lysates of synchronized 
cells were mixed with lysates obtained from asynchronous cells labeled with heavy 
amino acids as indicated in Figure 2C, resulting in three independent experiments 
(I.A, II.A and III.A). In addition, we obtained two different M phase-enriched samples 
(Figure 2D, 2F and S2B). Results obtained via flow cytometry confirmed enrichment 
of arrested cells in the respective cell cycle stage (Figure 2D). Asynchronous cells 
































































G1 S G2/M apoptotic
asynchronous 67.5 19.4 11.1 2.0
Thymidine,
no release
45.4 44.2 9.4 1.0
Thymidine,  
2.5 h release
17.2 71.0 11.3 0.5
Thymidine, 
5.5 h release 
4.5 71.2 24.1 0.2
Thymidine,
7.5 h release
7.5 17.5 74.4 0.6
RO-3306, 
no release
2.9 19.6 75.6 2.0
RO-3306, 
8 h release

































































































































































AS early M late M
Exp. K0R0 K4R6 K8R10
IV.A early M late M AS
IV.B late M AS early M
V.A - HeLa Flag-S2
V.B - Flag-S2 HeLa
% cells
G1 S G2/M apoptotic
AS, K4R6 56.7 29.3 7.5 6.3
AS, K8R10 59.9 25.8 7.2 6.9
RO-3306, 30 min 
release, K0R0
4.8 39.7 52.2 3.0
RO-3306, 30 min 
release, K8R10
6.0 42.6 43.1 8.2
RO-3306, 2h 
release, K0R0
11.4 35.4 50.4 2.6
RO-3306, 30 min 
release, K4R6


























Figure 2. Global SUMO-2 conjugate dynamics during cell cycle progression A) HeLa cells were 
infected with a lentivirus encoding Flag-tagged SUMO-2-Q87R_IRES_GFP, and low expressing cells 
were sorted by flow cytometry. Flag-SUMO-2 was predominantly located in the nucleus. Scale bars are 
25 µM. B) Expression levels of total SUMO-2/3 and Flag-SUMO-2 conjugates in HeLa cells and Flag-
SUMO-2 (Flag-S2) expressing stable cells were compared by immunoblotting. Flag-SUMO-2 conjugates 
were efficiently purified by IP. C) Strategy to identify SUMO-2 conjugates at different cell cycle stages 
using a quantitative proteomic approach. HeLa cells stably expressing Flag-SUMO-2 were SILAC-labeled 




different phases of the cell cycle. For the Flag-IP, equal amounts of a light labeled and a medium labeled 
synchronized lysate were mixed with a heavy labeled asynchronous sample resulting in three samples 
(I.A, II.A and III.A) comprising six different cell cycle stages. Cell cycle synchronization was confirmed 
by propidium iodide staining and flow cytometry and the percentage of cells in each cell cycle phase is 
depicted in the table. D) The left table depicts the combination of samples mixed for experiments IV and V: 
HeLa cells expressing Flag-SUMO-2 were SILAC-labeled and synchronized with RO-3306 in G2/M. Cells 
were released from the block for 30 minutes (early M-phase) and 2 hours (late M-phase), respectively. 
In addition, asynchronous HeLa cells and HeLa cells expressing Flag-SUMO-2 were SILAC-labeled and 
mixed as indicated in the table to obtain a parental control sample with the according label swap for mass 
spectrometric analysis. Synchronization of cells was confirmed via flow cytometry. The right table shows 
the percentage of apoptotic cells and of cells in G1, S and G2/M phase, respectively. E and F) Total cell 
lysates of the different synchronized cell pools and purification of Flag-SUMO-2 conjugates by IP were 
analyzed by immunoblotting using anti-Flag antibody. This was done for experiment I.A, II.A, III.A (E) and 
experiment IV.A, IV.B, V.A and V.B. (F). See also Figure S2.
To determine the amount of background binders obtained in this screen, we 
compared medium labeled asynchronous HeLa cells as a parental control to 
asynchronous heavy labeled HeLa cells expressing Flag-SUMO-2 (Figure 2D, 2F 
and S2B, experiment V.A). In addition, we performed a complete label-swap control 
for all samples (Figure 2F and Figure S2, experiment I.B-V.B), which corrects for 
experimental errors and false positive hits due to light labeled contaminants. 
Flag-IP was performed for all ten experiments described and immunoblotting 
analysis was performed to determine total levels of Flag-SUMO-2 in each input 
fraction and to confirm highly efficient enrichment for SUMO-2 conjugates by IP 
(Figures 2E, 2F, S2D and S2E). Final eluted fractions of the Flag-IPs were separated 
by SDS-PAGE, stained with Coomassie, cut in ten gel slices and in-gel digested with 
trypsin. The Coomassie stained gel of Experiment I.B is shown as an example in 
Figure S2F. A total of 69,921 unique peptide variants covering 5180 proteins were 
identified by mass spectrometry at FDR<0.01 and their corresponding SILAC triplets 
were automatically quantified (Figure 3A, Table S1). 
To deem a protein SUMOylated, we required a SILAC ratio of at least two 
between the FLAG-SUMO-2 HeLa cells and the parental control (Figure 3B, Table 
S2). Given the relatively low percentage of cells in G2/M in these control experiments 
we wanted to avoid excluding SUMO-2 target proteins that peak specifically in G2/M, 
therefore proteins with a SILAC ratio of at least two in G2/M enriched samples were 
also included in Table S2. A total of 249 proteins were significantly SUMO-2 up- or 
downregulated over the cell cycle, as well as 159 with a log2 dynamic range larger 
than 1.0 (Figure 3C, Figure S3A).
SUMOylation dynamics for a subset of the identified SUMO-2 target proteins 
might be explained by similar dynamics of non-modified forms of these proteins. 
Therefore, we have analyzed the dynamics of proteins at the total protein level. We 
have obtained quantitative information at the total protein level for 361 of the SUMO-
2 target proteins, including 27 with a log2 dynamic range larger than 1.0 at the total 
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Up-and downregulated protein per condition
Figure 3. Global SUMOylation dynamics throughout the cell cycle; bioinformatics results
A) Overview of the proteomic experiments. Out of the 5180 proteins identified, 593 proteins were 
considered as SUMO targets based on SILAC filtering. A total of 356 peptides were identified carrying 
the QQTGG and/or pyroQQTGG modification, representing 203 unique SUMO-2 acceptor lysines. B) 
SILAC ratio reproducibility plot. Pearson correlation was calculated between both sets of experiments 
to determine the experimental reproducibility between biological replicates. The Flag-SUMO-2 HeLa cell 




targets. SUMO target proteins with a log2 ratio>1 are indicated in purple, intermediate ratios between 
0.5-1 are indicated in grey, whereas non-SUMOylated proteins with log2 ratio <0.5 are colored in dark 
blue. C) Overview of upregulated and downregulated SUMOylated proteins in each cell cycle condition. 
Proteins were filtered for presence in both label-swapped experiments and an average log2 ratio of 
>0.5 for upregulated targets and <-0.5 for downregulated targets. D) Gene Ontology (GO) enrichment 
analysis of SUMO modified proteins versus non–SUMOylated proteins. The bar plot shows the most 
significantly over-represented GO terms for biological process, cellular component and molecular function 
for SUMO regulated proteins (Log2 ratio>1) and for non-SUMOylated proteins (Log2 ratio <0.5). E) SUMO-
2 acceptor lysine motif analysis. Weblogo visualization of the amino acid frequencies at each position +/- 
6 amino acids from the SUMO-2 acceptor site lysine residues. The size and sorting order of each amino 
acid indicates its specific frequency at each position and they are colored according to their chemical 
properties. F) Functional protein interaction network analysis based on the STRING database. The most 
significantly interconnected cluster within the total SUMO network visualized by Cytoscape. The cluster 
is found using the MCODE plug-in and has a MCODE score of 24.4. The functional interactions between 
proteins are displayed as edges between the proteins (nodes). The cluster has 26 proteins with a total of 
305 interactions. The nodes are colored by their estimated cell-cycle peak-time according to the indicated 
color-scheme and their node size by their highest SILAC log2 ratio. See also Figure S3.
Gene ontology (GO) enrichment analysis of the SUMO-2 target proteins 
compared to a background of non-SUMOylated proteins from our dataset revealed 
a strong overrepresentation of nuclear proteins among the SUMO-2 targets. In 
particular SUMO modified proteins were highly enriched for sequence-specific DNA 
transcription factors (Figure 3D). Our dataset also contains 356 SUMO-2 modified 
peptides (Table S3) covering 203 unique SUMO acceptor sites (Table S4). Sequence 
motif analysis of the identified sites revealed a strong bias for the SUMO consensus 
motif ΨKxE (142 sites, Figure 3E). We also found 24 sites situated in the previously 
described inverted SUMO consensus motif (26). 
Functional protein interaction network analysis of the SUMO-2 regulated proteins 
based on the STRING database revealed a highly interconnected protein network 
(Figure S3B). The most significantly connected sub-clusters were identified using 
the MCODE plug-in for Cytoscape. The most significant cluster with an MCODE 
score of 24.4 contains 26 SUMO-2 regulated proteins that are color-coded according 
to their cell cycle peak-time (Figure 3F). SUMOylation of the different members of 
this network is predominantly peaking at that part of the cell cycle where they are 
functionally most active. For example, FANCI SUMOylation is peaking in S-phase 
where FANCI is involved in interstrand DNA crosslink repair during replication. ASPM, 
Aurora-A and –B, PLK1, BUB1B and FoxM1 are peaking in M-phase where they 
play roles in chromosome condensation and alignment, mitotic spindle formation, 
and segregation. Two additional functional protein clusters were highlighted by the 
MCODE analysis (Figures S3C and S3D). We demonstrate SUMOylation dynamics 





Figure 4. Confirmation of SUMO target proteins by immunoblotting HeLa cells stably expressing 
Flag-tagged SUMO-2 were synchronized at different stages of the cell cycle as described and Flag-
SUMO-2 conjugates were purified via IP. Input samples and Flag-SUMO-2 purified fractions were 
analyzed by immunoblotting with antibodies as indicated. SUMOylation dynamics throughout the cell 
cycle was demonstrated for eleven different SUMO targets identified in the mass spectrometry screen 
and RanGAP1 was used as a control. Equal levels of SUMO conjugates in all samples were verified via 
immunoblotting using anti-Flag antibody. See also Figure S4.
FoxM1 is extensively SUMOylated
The Forkhead box transcription factor M1 (FoxM1) is essential for proper cell cycle 
progression by regulating a cluster of genes needed for the execution of mitosis 
(32). FoxM1 is essential for genome stability since FoxM1 deficiency resulted in 
aneuploidy. A related phenotype was also observed in a SUMOylation-deficient 
mouse model, however little is known about relevant SUMO target proteins (17). We 
selected FoxM1 for follow-up experiments to study the regulation of this important 
transcription factor by SUMOylation. 
Interestingly, we found an increase in FoxM1 SUMOylation during M-phase 
in our proteomics project (Table S2). Immunoblotting analysis of Flag-SUMO-2 
purified fractions showed that SUMOylation of FoxM1 strongly increased mainly in 
cells blocked at the G2/M border (Figure 5A). In asynchronous cells and eight hours 
after a release from the block, when most cells are in G1 phase (Figure 2C) we 
observed considerably lower FoxM1 SUMOylation levels. Increases in SUMOylation 
of FoxM1 can at least partly be explained by increases in total levels of FoxM1 upon 
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Figure 5. FoxM1 is extensively regulated via SUMOylation A) HeLa cells stably expressing Flag-
SUMO-2 were synchronized with thymidine or RO-3306 and released for different time-points as depicted. 
Total lysates (left panel) or Flag-SUMO-2 enriched fractions (right panel) were separated by SDS-PAGE, 
transferred to a membrane, and probed using antibodies to detect FoxM1 or Flag. Asynchronous HeLa 
cells were used as a negative control for the Flag-SUMO-2 enrichment. B) Cartoon depicting Forkhead 
box protein M1 (FoxM1). FoxM1 is composed of 763 amino acids and harbors an N-terminal repressor 
domain (NRD), a Forkhead winged helix domain (FKH) and a C-terminal transactivation domain (TAD). 
FoxM1 contains 8 SUMOylation consensus sites and 4 additional SUMOylation sites identified by mass 
spectrometry. C) U2OS cells stably expressing His-SUMO-2 (S2) and control U2OS (U) cells were 
transfected with an expression construct encoding either HA-FoxM1 wild type or HA-FoxM1 lacking the 




His-SUMO-2 conjugates were purified by IMAC. Total lysates and purified fractions (His pulldown) were 
separated by SDS-PAGE, transferred to a membrane, and probed using an antibody to detect HA. Total 
SUMO-2/3 levels in the purified fractions were detected with a SUMO-2/3 antibody. D) The experiment 
described in (C) was repeated in U2OS cells stably expressing His-Ubiquitin (Ub) and control U2OS (U) 
cells. Ubiquitination of HA-FoxM1 was detected using an antibody directed against the HA-tag. Total 
ubiquitin levels in the purified fractions were detected by probing immunoblots with an antibody directed 
against ubiquitin. E) U2OS cells were transfected with an empty vector (Ctrl), Flag-FoxM1 wild type 
(WT) or Flag-FoxM1 12KR. Asynchronous cells or cells released for 5.5 hours from a thymidine block 
were used for Flag-FoxM1 enrichment by Flag-IP. Total lysates (lower panels) and Flag-FoxM1 enriched 
fractions (upper panels) were separated by SDS-PAGE, transferred to a membrane, and probed using 
antibodies to detect SUMO-2/3, methylated lysines or Flag. See also Figure S5.
To study the functional relevance of FoxM1 SUMO modification, we have 
mapped the SUMO acceptor sites of this protein. FoxM1 has an N-terminal repressor 
domain (NRD), a Forkhead winged helix DNA binding domain (FKH) and a C-terminal 
transactivation domain (TAD) (Figure 5B). The protein contains seven lysines that 
are situated in the SUMOylation consensus motif ΨKxE (lysines 201, 218, 356, 
440, 460, 478 and 495) and one lysine that is situated in the inverted SUMOylation 
consensus motif E/DxKΨ (lysine 443). Four additional SUMO acceptor sites that 
do not represent the classical consensus site were identified by mass-spectrometry 
analyses of SUMOylated recombinant FoxM1 proteins (Figure S5B). 
To analyze the SUMOylation of FoxM1, a mutant was generated where these 
twelve lysines were mutated to arginines (12KR). Wild type and 12KR FoxM1 
constructs were expressed in U2OS cells or in U2OS cells stably expressing a His 
tagged SUMO-2 construct. Analysis of the SUMO enriched fraction confirmed that 
SUMOylation of FoxM1 was abolished by these mutations (Figure 5C). Since FoxM1 
is also regulated by ubiquitination (33), we demonstrated that ubiquitination of the 
12KR mutant is similar to wild-type FoxM1 (Figure 5D). 
Enrichment of Flag-FoxM1 wild type and Flag-FoxM1 12KR from U2OS cells 
showed the modification of FoxM1 wild type by endogenous SUMO-2/3 and the 
increase in SUMOylation of FoxM1 in thymidine released cells (Figure 5E). We did 
not observe modification of the FoxM1 12KR mutant by endogenous SUMO-2/3, 
further validating our SUMOylation deficient mutant. This experiment was used to 
confirm that in addition to ubiquitination, also methylation of FoxM1 is not affected 
by mutating these twelve lysines, by analyzing Flag-FoxM1 wild type and Flag-
FoxM1 12KR enriched fractions by immunoblotting with an antibody directed against 
methylated-lysine. Nevertheless, some competition between the different PTMs 
could be observed (Table S5). 
SUMOylation positively regulates FoxM1 transcriptional activity
To study the effect of SUMOylation on the function of FoxM1, we have compared 
the transcriptional activities of wild-type and SUMOylation-deficient (12KR) FoxM1. 










































































































































































































































Figure 6. SUMOylation is required for FoxM1 transcriptional activity A) U2OS cells were (co)
transfected with an empty vector, HA-FoxM1 wild type (WT) or HA-FoxM1 12KR, a luciferase reporter 
containing six FoxM1 DNA binding domains (6x FoxM1 DB-Luciferase, left panel) or a luciferase reporter 
containing the CENP-F promoter region (right panel) and a LacZ reporter. Cells were lysed in reporter 
lysis buffer 48 hours after transfection and luciferase activity and β-galactosidase activity (β-Gal) were 
measured. Results are representative of six independent experiments and corrected for transfection 
efficiency using β-Gal activity; the error bars indicate the standard deviation from the average. Results 
are shown as a relative fold induction compared to cells transfected with the empty vector. ** p < 0.001
B) Expression levels of HA-FoxM1 wild-type and HA-FoxM1 12KR proteins in the luciferase experiments 
were verified by immunoblotting using an antibody directed against the HA-tag. C) Quantitative PCRs 
were performed on U2OS cells, U2OS cells stably expressing Flag-FoxM1 wild type or U2OS cells stably 
expressing Flag-FoxM1 12KR. Primers for Aurora kinase B, Cyclin-B1,CENP-F and SAP30 were used 
to quantify specific gene expression. The average expression levels of triplicates were normalized for 
the expression levels of the housekeeping gene CAPNS1. Results for the stable cell lines are shown as 
relative expression levels compared to U2OS cells (expression level set to 1). ** p < 0.001, * p < 0.05
D) The expression levels of HA-Flag-FoxM1 wild type and HA-Flag-FoxM1 12KR proteins in the 
quantitative PCR experiments were verified by immunoblotting using an antibody directed against FoxM1. 
See also Figure S6.
FoxM1 DNA binding sites (6x FoxM1 DB-luciferase) and one containing the promoter 
region of the known FoxM1 target gene CENP-F (32). We found that SUMOylation-
deficient FoxM1 was less active compared to wild-type FoxM1, indicating that 
SUMOylation enhances FoxM1 transcriptional activity (Figures 6A and 6B). This 
observation was further supported by quantitative PCRs (qPCRs) on FoxM1 target 
genes. Relative mRNA expression levels for Aurora kinase B, Cyclin-B1, CENP-F 
and SAP30 were lower in cells stably expressing Flag-FoxM1 12KR compared to 




To analyze whether loss of SUMOylation on all twelve lysines of FoxM1 was 
needed for the reduced activity, we made domain specific FoxM1 SUMOylation 
mutants in the NRD domain (4KR) or in the undefined domain between the Forkhead 
and the TAD of FoxM1 (8KR). A small reduction in SUMOylation levels for both 
mutants indicated modification of both FoxM1 domains (Figure S6A and S6B). 
Consistently, a decreased FoxM1 activity was only observed in the 12KR mutant 
(Figure S6C and S6D). We conclude that FoxM1 is extensively SUMOylated, to 
increase its transcriptional activity. 
Cells expressing SUMOylation-deficient FoxM1 are prone to develop polyploidy
Depletion of FoxM1 expression causes chromosome misalignment and malfunction 
of cytokinesis, giving rise to the accumulation of tetraploid and polyploid cells (32). To 
test whether SUMOylation of FoxM1 is functionally relevant, we set up knockdown 
and complementation experiments. The stable cell lines described in figure 6C and 
6D were used for these assays. Silent mutations were introduced in the Flag-FoxM1 
constructs to make them resistant to two independent FoxM1 shRNAs. Cells were 
infected with a non-targeting control shRNA or with one of the two FoxM1 shRNAs 
and analyzed three days after infection. Western blot analysis confirmed the efficient 
knockdown of endogenous FoxM1 in U2OS cells and stable expression of wild-type 
and SUMOylation-deficient Flag-FoxM1 (Figure 7A). Microscopy confirmed that both 
wild type and SUMOylation-deficient FoxM1 were localized in the nucleus (Figure 
S7A). A similar experiment was performed using GFP tagged FoxM1 to confirm 
that only endogenous FoxM1 was depleted in the stable cell lines without affecting 
exogenous FoxM1 (Figure S7C). These cells were however not suitable for rescue 
experiments due to interference of the large GFP tag with FoxM1 protein function. 
Cell cycle analysis of the different cell populations confirmed that FoxM1 knockdown 
resulted in increased populations of tetraploid and polyploid cells. Expression of 
both FoxM1 wild type and FoxM1 12KR could rescue the knockdown effects on the 
tetraploid cell population to a similar extent (Figure S7B). Also, no obvious differences 
were found in G1 phase and S phase cell populations when we compared FoxM1 wild 
type to the SUMOylation-deficient FoxM1 (Figure S7B). Interestingly, we observed a 
significant increase in polyploid cells when comparing cells expressing FoxM1 12KR 
to FoxM1 wild type cells (Figure 7B). Thus, cells deficient for FoxM1 SUMOylation 
were more sensitive to develop polyploidy. 
SUMOylation inhibits the negative regulatory domain of FoxM1
Subsequently, we searched for a mechanistic explanation for the activation of FoxM1 
by SUMOylation. In previous studies it was shown that FoxM1 is inhibited in G1 phase 
via direct interaction between the N-terminal repressor domain and the C-terminal 




Figure 7. SUMOylation inhibits the negative regulatory domain of FoxM1 and is required to 
counteract polyploidy A and B) U2OS cells stably expressing Flag-FoxM1 wild type or Flag-FoxM1 
12KR or parental U2OS cells were infected with two individual FoxM1 shRNA lentiviruses (shRNA #1 
and shRNA #2) or a non-targeting shRNA (ctrl). Three days after infection cells were harvested for 
immunoblotting analysis with a FoxM1 antibody (A) and for propidium iodide staining and flow cytometry 
(B). Average values from three independent experiments are shown in percentages for the polyploid cell 
population. The error bars indicate the standard deviation from the average. * p < 0.05 C) Recombinant 
His-FoxM1 proteins were SUMOylated in vitro and SUMO-2 proteins were removed from His-FoxM1 by 
incubating the proteins with recombinant SENP2. Glutathione beads only or glutathione beads bound to 
a GST-FoxM1 N-terminal protein fragment (Nterm) were incubated with SUMOylated His-FoxM1 proteins 
or His-FoxM1 proteins treated with SENP2. Inputs, elution of the GST pulldown and the unbound fraction 
after the GST pulldown were analyzed by immunoblotting using an antibody directed against the His-tag. 
The amount of GST-FoxM1 proteins in the elution and the unbound fraction were verified by staining the 
membrane with Ponceau-S. D) The experiment described in (C) was repeated using His-FoxM1 wild type 
(WT) proteins SUMOylated in vitro with SUMO-1 and with 3 different His-FoxM1 mutants SUMOylated 
in vitro with SUMO-2; His-FoxM1 4KR, 8KR and 12KR. Inputs and elutions of the GST pulldown were 
analyzed by immunoblotting and compared to interaction levels of His-FoxM1 WT in vitro SUMOylated 
with SUMO-2. E) Our data indicate that SUMOylation of FoxM1 during G2 and M phase inhibits the 
formation of the inactive FoxM1 dimer. This contributes to the increased transcriptional activity of FoxM1 
in these phases of the cell cycle. See also Figure S7.
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interaction, an in vitro interaction assay was performed. A GST tagged N-terminal 
FoxM1 protein fragment was coupled to glutathione beads and incubated with a 
mixture of unmodified and SUMOylated His-FoxM1 or unmodified His-FoxM1 proteins 
only. We observed that only unmodified full-length FoxM1 proteins interacted with 
the N-terminal part of FoxM1, while SUMOylated FoxM1 did not detectably interact 
with the protein (Figure 7C). By using the domain specific FoxM1 mutants previously 
described (4KR and 8KR) in this assay, we found that SUMOylation on both the NRD 
and on the undefined domain of FoxM1 blocks the interaction with the GST tagged 
NRD protein (Figure 7D). His-FoxM1 proteins SUMOylated with SUMO-1 were also 
unable to interact with the NRD, showing that extensive mono-SUMOylation on the 
twelve lysines is sufficient to block the interaction since SUMO-1 is impaired for 
polymerization (30). Interestingly, even a single modified form of FoxM1 no longer 
formed dimers. This leads us to propose a model where SUMOylation increases 
FoxM1 transcriptional activity by inhibiting the interaction between the repressor and 
activation domain of FoxM1 (Figure 7E). 
Discussion
We have addressed the role of SUMOylation in cell cycle progression using a 
proteomics approach to purify and identify hundreds of SUMO target proteins. Co-
regulation of these large sets of targets throughout the cell cycle enables orchestration 
of cell cycle progression via SUMOylation. All aspects of cell cycle progression are 
influenced by SUMOylation since these target proteins play roles in replication, 
DNA condensation, chromosome alignment and segregation and cytokinesis. We 
have also identified 203 SUMO-2 acceptor lysines. Functional analysis of the key 
mitotic SUMO target protein FoxM1 revealed a role for SUMO-modified FoxM1 in 
counteracting polyploidy.
Protein group modification
STRING analysis revealed complex interactions between the identified sets of 
SUMO-2 target proteins (Figures 3F and S3B). Half of the SUMOylated proteins 
depicted in Figure 3F have a known function in mitosis according to their GO 
biological process term. Interestingly, five of the proteins with SUMOylation peaking 
in G1/S are established players in the DNA replication pathway. The second most 
significant MCODE cluster (Figure S3C) consists of 11 SUMO-2 regulated proteins 
that are all involved in mRNA splicing via the spliceosome. The third significant 
MCODE cluster (Figure S3D) consists of 41 SUMOylated proteins of which 16 have 
transcriptional co-activator activity and seven of them are part of the MLL1 Histone-
lysine N-methyltransferase complex. 
These results are consistent with previous findings on the role of SUMOylation 




are SUMOylated and additionally contain SIMs for non-covalent interactions with 
SUMO. SUMOylation was proposed to act like a molecular glue to enhance group 
interaction. The networks identified in our screen could similarly be glued together 
by SUMOylation. 
Regulation of FoxM1 via SUMOylation
The Forkhead box (Fox) transcription factor FoxM1 was selected for follow up 
experiments since this protein links the two major SUMO-regulated biological 
processes, transcription and the maintenance of genome stability. FoxM1 plays a 
key role in mitotic progression via transcriptional regulation of a network of genes 
including Aurora kinase B, CENP-F, Cdc25B, Cyclin-B1 and Survivin. Deregulating 
the transcription of these genes by depleting FoxM1 expression resulted in a delay 
in G2 phase, reduced cell proliferation and defects in mitosis. Together these defects 
in FoxM1 depleted cells resulted in an increased population of cells with a 4n DNA 
content and the formation of aneuploid cells due to missegregation of chromosomes 
(32, 37). Previously, Ubc9 deficient cells were shown to have a related phenotype, 
but relevant SUMO target proteins were still missing (17). Our data indicate that 
FoxM1 is one of the SUMO target proteins relevant for explaining the phenotype of 
SUMOylation deficient cells. 
SUMOylation of transcription factors frequently results in transcriptional inhibition 
with some exceptions (13, 38, 39) . This is thought to occur via the recruitment of 
inhibitory complexes. In contrast, SUMOylation is required for activation of FoxM1 
(Figure 6). Mechanistically, the bulky SUMO modifications prevent the negative 
regulatory domain from binding to the activation domain, blocking the formation of 
inactive dimers (Figure 7). Consequently, SUMOylated FoxM1 is thought to activate 
transcription in a monomeric form. Previously, phosphorylation of FoxM1 was 
proposed to counteract dimer formation (35), but the small size of this modification 
might be insufficient for full activation of the protein. Phosphorylation and 
SUMOylation could cooperate to activate FoxM1 via the phosphorylation-dependent 
SUMOylation motif (PDSM) ΨKxExxS (40), since downstream of K218 in FoxM1, a 
serine is located at position 223. However, phosphorylation of this serine has so far 
not been reported (35). 
During the revision of our project, another paper was published on the regulation 
of FoxM1 by SUMOylation (41). In this paper, the authors claim that the mutation 
of five SUMOylation consensus motifs in FoxM1 abolished SUMOylation. Using 
our sensitive method to detect SUMOylation, we found that mutating SUMOylation 
consensus motifs in FoxM1 was not sufficient to abolish SUMOylation (Figure 
S5C). Whereas Myatt et al. found that SUMOylation inhibited FoxM1, we found 
that SUMOylation was required for full activity of FoxM1. This discrepancy could be 




employed to boost SUMOylation and was surprisingly located in the cytoplasm, which 
might explain its lower transcriptional activity. Furthermore, Myatt et al. enhanced 
SUMOylation of FoxM1 by transiently overexpressing Ubc9. Using a sensitive 
method to detect SUMOylation, there was no need for Ubc9 overexpression or the 
use of a FoxM1-Ubc9 fusion protein in our hands. 
FoxM1 plays an important role in cancer and is thought to act as a classical 
oncogene (42, 43). Gene expression studies of primary tumors have revealed that 
FoxM1 is frequently upregulated in solid tumors. High expression levels of FoxM1 have 
been found in different types of solid tumors including lung, breast, colon, prostate 
and liver cancer (44, 45). These hallmarks of elevated FoxM1 expression established 
the idea that targeting FoxM1 in cancer may have therapeutic advantages (46, 47). 
Since SUMOylation of FoxM1 increases FoxM1 transcriptional activity, interfering 
with FoxM1 SUMOylation might be a potential interesting addition to FoxM1 based 
cancer therapies. However, currently little is known about the SUMOylation status of 
FoxM1 in cancer; this is a topic for future studies.
Conclusions and future perspective
Dynamic regulation of a large set of target proteins by SUMOylation plays an 
important role in cell cycle progression. In this study, we have identified hundreds of 
dynamically regulated SUMO-2 target proteins in all stages of the cell cycle using 
a quantitative proteomics approach and an optimized purification procedure that 
inactivates SUMO proteases and results in a high yield. The small Flag tag minimally 
impacts SUMO-2 and is expected not to interfere with SUMOylation dynamics, in 
contrast to large tags such as GFP that reduce the conjugation rate (48). Whereas 
valuable strategies to purify endogenous SUMOs are being developed (49), the yield 
of these methods is limited compared to the method that we have described here. 
Optimal yield is required to obtain global insight in SUMOylation dynamics. 
Detailed functional analysis of SUMO targets requires the identification of the 
SUMO acceptor lysines in these proteins to create mutants deficient in SUMOylation. 
Currently, large-scale site-specific SUMOylation proteomics is still challenging (25, 
26, 50). The set of SUMO acceptor lysines identified in this project is the largest 
set identified in a single study today, but is still modest and many SUMO-targeted 
lysines still need to be identified. The site-specific aspect of SUMOylation proteomics 
still needs further optimizing as it is clearly behind compared to phosphorylation 
and ubiquitination. Nevertheless, we believe that the dynamic set of SUMO target 
proteins identified in this study and the subset of SUMO acceptor sites represents a 





Cell lines, Cell culture, SILAC labeling and transfections
HeLa and U2OS cells were cultured in Dulbecco’s modified Eagle’s medium (Gibco Invitrogen Corporation, 
Grand Island, NY, USA) supplemented with 10% FCS (Gibco) and 100 U/ml penicillin and 100 μg/
ml streptomycin (Gibco). For SILAC analysis, cells were essentially labeled as described before (23). 
Transfections were carried out using 2.5 μl polyethylenimine (PEI, 1 mg/ml, Alpha Aesar) per μg DNA.
SUMO target protein purification
Cells were lysed in four pellet volumes of lysis buffer (1% SDS, 0.5% NP-40 in PBS including phosphatase 
- and protease inhibitors). Chloroacetamide was added freshly at 70 mM and samples were sonicated 
and equalized. An equal volume of dilution buffer (2% Triton X-100, 0.5% sodium deoxycholate, 1% BSA 
in PBS including phosphatase - and protease inhibitors and freshly added 70 mM choroacetamide) was 
added to the lysates and they were centrifuged for 45 minutes at 13.2 krpm at 4ºC. The supernatants were 
mixed with Flag-M2 beads (Sigma). After 90 minutes incubation, the beads were washed 5 x with wash 
buffer (50 mM Tris, 150 mM NaCl, 70 mM choroacetamide, 0.5% NP-40, phosphatase - and protease 
inhibitors) and bound proteins were eluted. 
Mass spectrometry analysis
Purified proteins were size separated by SDS-PAGE, in-gel digested, extracted, desalted, concentrated 
and analyzed by mass spectrometry using an EASY-nLC system (Proxeon, Odense, Denmark) connected 
to the LTQ-Orbitrap Velos or to the Q-Exactive (both from Thermo Fisher Scientific, Germany) through 
a nano-electrospray ion source. Raw mass spectrometry (MS) files were processed with the MaxQuant 
software suite (version 1.4.0.3, Max Planck Institute of Biochemistry, Department of Proteomics and 
Signal Transduction, Munich, Germany).  
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Figure S1 related to Figure 1: Cell cycle profile after UBA2 and Ubc9 knockdown. A) Colony formation 
of U2OS cells was determined nine days after infection with a control shRNA, shRNA1 (UBA2), shRNA2 
or shRNA3 (both Ubc9) by staining with Giemsa solution and counting colonies using the ImageJ Version 
1.47v software. The values were normalized to the control. Error bars represent the standard deviation 
from the average obtained from three independent experiments. ** p < 0.001. B) The proliferation rate 
of U2OS cells treated with Ubc9 knockdown virus was compared to cells treated with control virus four 
days after infection by adding the cell proliferation reagent WST-1 to the growing cells and measuring 
the absorbance at 450 nm after two hours incubation. The values were normalized to the control and the 
standard error of the mean was determined from ten values obtained from three independent experiments. 
* p < 0.05. C) Four days after infection with UBA2, Ubc9 and control viruses, U2OS cells were stained with 
propidium iodide and subjected to flow cytometry analysis. The graph depicts the percentage of cells in 
each cell cycle phase. Error bars represent the standard deviation from the average obtained from three 
independent experiments. D) HeLa cells treated with control shRNA and shRNA1 for four days were 
pulse-labeled with BrdU and released for four hours or  eight hours before staining them with propidium 
iodide. The graphs depict the amount of DNA (mCherry-A) in BrdU labeled cells (blue) and non-labeled 
cells (red) at the respective time-points demonstrating a faster passage through the cell cycle for the 






G1 S G2/M apoptotic
async 64.1 16.2 14.6 4.4
Thymidine,
no release
47.5 39.5 7.3 4.7
Thymidine,  
2.5 h release
16.7 71.4 9.1 2.0
Thymidine, 
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Figure S2 related to Figure 2: Loading controls and label swap of SILAC-labeled cells synchronized 
in different cell cycle stages and purification of SUMO conjugates. A) HeLa cells stably expressing 
Flag-SUMO-2 were SILAC-labeled with three different isotopic variants of lysine and arginine. Three 
independent pools of light labeled (K0R0) cells and one pool of medium labeled (K4R6) cells were blocked 
with thymidine. Two pools of medium labeled cells were blocked with RO-3306. The light labeled cells 
were released from the thymidine block and lysed at three different time points (2.5 hours, 5.5 hours and 
7.5 hours after release). Two pools of medium labeled cells were lysed directly after the thymidine block 
or the RO-3306 block. The third medium labeled pool was released from the RO-3306 block for eight 
hours and then lysed. Three pools of asynchronous cells were heavy labeled (K8R10) and served as an 
internal standard during the subsequent analysis. Total cell lysates of the different synchronized cell pools 
were size separated by SDS-PAGE and levels were analyzed by Ponceau S staining (left panel). For the 
Flag-immunoprecipitation, equal amounts of lysates from light-labeled and heavy-labeled synchronized 
cells were mixed with an equal amount of lysate from medium-labeled asynchronous cells, resulting in 
three samples (I.B, II.B and III.B) comprising six time points in cell cycle progression. Inputs, unbound 
fractions and immunoprecipitated samples were analyzed by Ponceau S staining (right panel). B) HeLa 
cells expressing Flag-SUMO-2 were SILAC-labeled and synchronized with RO-3306 in G2/M. Cells 
were released from the block for 30 minutes (early M-phase) and 2 hours (late M-phase), respectively 
(experiment IV.A and label swap experiment IV.B). In addition, asynchronous HeLa cells and asynchronous 
HeLa cells expressing Flag-SUMO-2 were SILAC-labeled and mixed to obtain a parental control sample 
for mass spectrometric analysis (experiment V.A and label swap experiment V.B). Total cell lysates of the 
different cell pools were size separated by SDS-PAGE and levels were analyzed by Ponceau S staining 
(left panel). Inputs, unbound fractions and immunoprecipitated samples were analyzed by Ponceau S 
staining (right panel). C) Label swap for the experiment described in (A). Cell cycle synchronization 
was confirmed by flow cytometry. Flow cytometry profiles are shown next to the respective samples 
and the percentage of cells in each cell cycle phase is depicted in the table. D) Lysates of the different 
synchronized cell pools from the experiment described in (C) were size-separated by SDS-PAGE and 
protein levels were analyzed by Ponceau S staining (left panel), levels of Flag-SUMO-2 conjugates 
were compared by immunoblotting using an antibody directed against the Flag epitope (right panel). E) 
Purification of Flag-SUMO-2 conjugates by immunoprecipitation in the experiment described in (C) was 
confirmed by immunoblotting for all three experiments. Inputs, unbound fractions and immunoprecipitated 
samples were size-separated by SDS-PAGE and levels were analyzed by Ponceau S staining (left panel). 
Levels of Flag-SUMO-2 conjugates were analyzed by immunoblotting using an antibody directed against 
the Flag epitope (right panel). F) The Flag-IP samples of all three experiments described in (C) were 
size separated by SDS-PAGE and stained with Coomassie. Each sample was divided into ten different 
gel slices according to the molecular weight of the purified proteins. These sections were further cut into 
small gel fragments, proteins were digested by trypsin, extracted and analyzed by mass spectrometry. 
















































































































































































































































































































































Figure S3, related to Figure 3. Global SUMOylation dynamics throughout the cell cycle. 
A) A standardized heat map of SUMOylated proteins. Red indicates a low SILAC Log2 ratio while 
green indicates a high SILAC Log2 ratio of the SUMO target proteins at the different time points in the 
experiment. B) The total functional SUMO protein network. The STRING network including 474 nodes 
with 2538 edges was acquired and visualized in Cytoscape. The MCODE plugin for Cytoscape was used 
to find highly interconnected clusters within the network. The three most interconnected clusters in the 
total network are highlighted. C) The second most significantly interconnected cluster within the total 
SUMO network. The cluster contains 11 proteins with a total of 55 interactions. The nodes are colored 
by their estimated cell-cycle peak-time according to the indicated color-scheme and their node size by 
their highest SILAC log2 ratio. D) The third most significantly interconnected cluster within the total SUMO 
network. The cluster contains 41 proteins with a total of 120 interactions. The nodes are colored by 
their estimated cell-cycle peak-time according to the indicated color-scheme and their node size by their 
highest SILAC log2 ratio.
% cells
G1 S G2/M apoptotic
asynchronous 55.8 20.8 23.0 0.4
Thymidine,
no release
33.2 58.8 7.1 0.9
Thymidine,  
2.5 h release
5.6 83.2 10.9 0.3
Thymidine, 
5.5 h release 
5.6 70.8 23.2 0.4
Thymidine,
7.5 h release
11.1 28.9 59.6 0.4
RO-3306, 
no release
1.2 21.5 75.3 2.0
RO-3306, 
8 h release
62.2 5.5 29.4 2.9
Figure S4, related to Figure 4. Flow cytometry analysis of 
cell cycle synchronization. HeLa cells stably expressing Flag-
SUMO-2 were synchronized in different stages of the cell cycle as 
previous described. Cell cycle synchronization was confirmed by 
flow cytometry, the percentage of cells in each cell cycle phase is 


























































































Figure S5, related to Figure 5. Endogenous FoxM1 SUMOylation and identification of SUMO-2 
acceptor sites in FoxM1. A) U2OS cells were exposed to heat shock at 43°C for 1 hour to destabilize 
SUMO proteases and subsequently lysed for immunoprecipitation with a mouse monoclonal SUMO-2/3 
antibody or a Flag antibody as a control. Input and IP samples were size separated by SDS-PAGE and 
analyzed by immunoblotting using FoxM1 antibody (upper panel) or SUMO-2/3 antibody (lower panel). 
Heavy Chains (H.C) and Light Chains (L.C) of the antibodies are indicated. B) MS/MS spectra for the 
SUMO acceptor sites in FoxM1. K132, K144 and K368 were found to be SUMO-2 modified in human 
FoxM1. Additionally K415 was found to be SUMO-1 modified in mouse FoxM1; this lysine is conserved 
in human FoxM1. C) U2OS cells stably expressing His-SUMO-2 were transfected with expression 
constructs encoding mouse V5-FoxM1 WT or V5-FoxM1 6EA (E201A, E218A, E356A, E461A, E479A 
and E496A). The six consensus sites mutated in this construct are conserved in human FoxM1. U2OS 
cells were transfected with a V5-FoxM1 WT construct as a control. Cells were lysed 48 hours after 
transfection in 6 M Guanidine-HCL, and His-SUMO-2 conjugates were purified by immobilized metal ion 
affinity chromatography. Total lysates and purified fractions (His pulldown) were separated by SDS-PAGE, 
transferred to a membrane, and probed using an antibody to detect V5. Total SUMO-2/3 levels in the 













FoxM1 WT NRD FKH TAD
1 234 321 600 763
FoxM1 12KR NRD FKH TAD
1 234 321 600 763
FoxM1 4KR NRD FKH TAD
1 234 321 600 763
FoxM1 8KR NRD FKH TAD








































































































































































































Figure S6, related to Figure 6. Analysis of domain specific FoxM1 SUMOylation mutants. A) 
Different FoxM1 mutants were generated. The four lysines in the N terminal repressor domain (4KR) 
or the eight lysines in the undefined domain between the Forkhead and the C terminal transactivation 
domain (8KR) were mutated to arginines. These mutants were compared to wild-type (WT) FoxM1 
and the 12KR mutant of FoxM1. B) U2OS cells stably expressing His-SUMO-2 were transfected with 
expression constructs encoding HA-FoxM1 WT, HA-FoxM1 12KR, HA-FoxM1 4KR or HA-FoxM1 
8KR. U2OS cells were transfected with HA-FoxM1 WT as a control. Cells were lysed 48 hours after 
transfection in 6 M Guanidine-HCL, and His-SUMO-2 conjugates were purified by immobilized metal 
ion affinity chromatography. Total lysates and purified fractions (His pulldown) were separated by SDS-
PAGE, transferred to a membrane, and probed using an antibody to detect HA. Total SUMO-2/3 levels 
in the purified fractions were detected with an antibody directed against SUMO-2/3. C) U2OS cells were 




8KR and a luciferase reporter containing six FoxM1 DNA binding domains (6x FoxM1 DB-Luciferase, 
upper panel) or a luciferase reporter containing the CENP-F promoter region (lower panel) and a LacZ 
reporter. Cells were lysed in reporter lysis buffer 48 hours after transfection and luciferase activity and 
β-gal activity were measured. Results are representative of four independent experiments and corrected 
for transfection efficiency using β-gal activity; the error bars indicate the standard deviation from the 
average. Results are shown as a relative fold induction compared to cells transfected with the empty 
vector. ** p < 0.001 D) Expression levels of the different HA-FoxM1 proteins in the luciferase experiments 
were verified by immunoblotting using an antibody directed against the HA-tag. 




















































































































Figure S7, related to Figure 7. FoxM1 knockdown and complementation experiments. A) U2OS 
cells, U2OS cells stably expressing Flag-FoxM1 wild type or Flag-FoxM1 12KR were infected with a 
non-targeting shRNA lentivirus, or two independent lentiviruses encoding FoxM1 shRNAs (shRNA #1 and 
#2). Cells were fixed three days after infection, stained with antibodies to detect FoxM1 and analyzed 
by confocal microscopy. Scale bars are 10 µM. B) FACS analysis of G1 phase, S phase and tetraploid 
cells for the rescue experiment described in figures 7A and 7B. Average values from three independent 
experiments are shown in percentages; the error bars indicate the standard deviation from the average.
 C) U2OS cells, U2OS cells stably expressing GFP-FoxM1 wild type or GFP-FoxM1 12KR were infected 
with a non-targeting shRNA lentivirus, or two independent lentiviruses encoding FoxM1 shRNAs (shRNA 
#1 and #2). Three days after infection cells were harvested for immunoblotting analysis with a FoxM1 
antibody.
Supplemental Table Legends
- Table S1. List of all Identified Proteins in This Study, Related to Figures 2 and 3.
 This table lists all the proteins that were identified by mass-spectrometry in all the SILAC   
 experiments described in this study.
- Table S2. List of all SUMO Targets, Related to Figures 2 and 3.
 This table contains all the proteins that have been classified as SUMO targets. 
- Table S3. List of Identified SUMO-Acceptor Sites, Related to Figure 3.
 List of SUMO-modified peptides that have been identified in this study, carrying the QQTGG  
 and/or pyroQQTGG modification.
- Table S4. List of Unique Identified SUMO-Acceptor Sites, Related to Figure 3.
 This table indicates the unique SUMO-modified sites that were identified in this study.
- Table S5. Post-Translational modification of FoxM1, Related to Figure 5.
 This table contains methylation, acetylation, ubiquitination and phosphorylation sites on   
 FoxM1 identified by mass spectrometry. 
Tables available onlline at: http://www.sciencedirect.com/science/article/pii/S1097276514001154
Supplementary Materials
Plasmids
The mature protein that we refer to as SUMO-2-Q87R has the following amino acid sequence: MSEEKP-
KEGVKTENDHINLKVAGQDGSVVQFKIKRHTPLSKLMKAYCERQGLSMRQIRFRFDGQPINETDTPA-
QLEMEDEDTIDVFRQQTGG (Tatham et al., 2001). The open reading frame of this protein was amplified 
with the following primers: 5’-TTACTGCAGATGGACTACAAGGACGACGATGACAAGACTAGTATGTCC-
GAGGAGAAGCC-3’ and 5’- AATCTCGAGCTAACCTCCCGTCTGCTGCCG-3’ to introduce an N-terminal 
Flag-tag. This PCR product was cloned in between the PstI and XhoI site of the plasmid pLV-CMV-IRES-
eGFP (Vellinga et al., 2006) for lentiviral infection.
The cDNA encoding the human FoxM1 protein was obtained from the Mammalian Gene Collection (MGC 
code 9577; Image ID 3881055; supplied by Source Bioscience) and amplified by a two-step PCR re-
action using the following primers: 5’-AAAAAGCAGGC TTAATGAAAACTAGCCCCCGTCG-3’ and 5’-A 
GAAAGCTGGGTTCTACTGTAGCTCA GGAATAAAC-3’ for the first reaction and 5’-GGGGACAAGTTTG-
TACAAAAAAGCAGG CT-3’ and 5’-GGGGACCACTTTGTACAAGAAAGCTGGGT-3’ for the second re-
action. The cDNA was inserted into pDON207 employing standard Gateway technology (Invitrogen). 




pDON207-FoxM1 wild type and pDON207-FoxM1-12KR were introduced by QuickChange site-direc-
ted mutagenesis (Stratagene) using oligonucleotides 5’- CTAAGAGATCCCCTGCACAGCAAGAATC-
CAACCAGGCAGAGG CCTCCAAG-3’ and 5’-CTTGGAGGCCTCTGCCTGGTTGGATTCTTGCTG-
TGCAGGGG ATCTCTTAG-3’ for resistance to FoxM1 shRNA #1 and 5’- GTTTCTGGCCTTGCAGCA 
AACCGGTCCCTAACTGAGGGCCTGGTCCTG-3’ and 5’- CAGGACCAGGCCCTCAGT TAGGGAC-
CGGTTTGCTGCAAGGCCAGAAAC-3’ for resistance to FoxM1 shRNA #2. To generate pDON207-
FoxM1-4KR and 8KR we have swapped regions of the wild type and 12KR constructs by restriction 
of these plasmids with BssSI and XcmI and subsequent ligation. These cDNAs were subsequently 
transferred to multiple different destination vectors to generate T7-6His-FoxM1 expression constructs, 
HA-tagged FoxM1 expression plasmids (pMT2-HA-Dest, a kind gift of Drs. Petra de Graaf and Marc 
Timmers, Utrecht, The Netherlands) or GFP- tagged FoxM1 (pBabe-GFP-puro-DEST, also a kind gift 
of Drs. Petra de Graaf and Marc Timmers, Utrecht, The Netherlands). cDNA of FoxM1 wild type and 
FoxM1-12KR was cloned into the SpeI and XhoI cloning sites of a pLV-Flag-IRES-GFP construct using 
the following primers: 5’- ttaactagtATGAAAACTAGCCCCCG-3’ and 5’- aatctcgagCTACTGTAGCTCAG 
GAATAAAC-3’ to generate Flag-tagged, GFP sortable FoxM1 constructs. All fusions were made to the 
N-terminus of FoxM1. The cDNA encoding the mouse FoxM1 protein was obtained from the Mamma-
lian Gene Collection (Image ID 6417437; supplied by Source Bioscience) and amplified by a two-step 
PCR reaction using the following primers: 5’- AAAAAGCAGGCTCGATGAGAACCAGCCCCCGCCG-3’ 
and 5’- AGAAAG CTGGGTGCTAAGGGATGAACTGAGAC-3’ for the first reaction and 5’-GGGGA-
CAAGT TTGTACAAAAAAGCAGGCT-3’ and 5’-GGGGACCACTTTGTACAAGAAAGCTGGGT-3’ for 
the second reaction. The cDNA was inserted into pDON207 employing standard Gateway technology 
(Invitrogen). Mutations were introduced by QuickChange site-directed mutagenesis using the following 
oligonucleotides: 5’-CAGCGTTAAGCAGGCA CTGGAAGAGAAG-3’ and 5’- CTTCTCTTCCAGTGCCT-
GCTTAACGCTG-3’ (E201A), 5’-CGGGTTAAGGTTGCGGAGCCCTCAGGAG-3’ and 5’-CTCCTGA-
GGGCTCCGCAA CCTTAACCCG-3’ (E218A), 5’-CCATCAA AACTGCAATCCCACTGGG-3’ and 5’-
CCCA GTGGGATTGCAGTTTTGATGG-3’ (E356A), 5’-CCATTAAGGAAGCAGAAATGCAGC CTG-3’ 
and 5’- CAGGCTGCATTTCTGCTTCCTTAATGG-3’ (E461A), 5’-CCTATCAAA GTGGCGAGCCCTCCCT 
TG-3’ and 5’-CAAGGGAGGGCTCGCCACTTTGATAGG-3’ (E479A), 5’-CGCTCAAAGAGGCGCTATC-
CAACTC-3’ and 5’-GAGTTGGATAGCGCCT CTTTGAGCG -3’ (E496A). Wild type and 6EA mouse 
FoxM1 cDNAs were subsequently transferred to the pcDNA3.1/nV5-DEST expression vector (Invitrogen). 
The 6x-FoxM1 DB-Luciferase, CENP-F promoter Luciferase and the GST tagged N terminal FoxM1 con-
structs were described previously (Laoukili et al., 2005; Laoukili et al., 2008). The CMV-LacZ reporter con-
struct used in Luciferase assays was a kind gift of Dr. Erik Meulmeester. The SUMO-1 and SUMO-2 ex-
pressing constructs pE1E2S1 and pE1E2S2 were a kind gift of Dr. Hisato Saitoh (Uchimura et al., 2004).
Antibodies
The primary antibodies used were as followed: mouse anti-Ubc9 (BD Biosciences), mouse anti-UBA2 
(Transduction Laboratories) mouse anti-Bromodeoxyuridine-Fluorescein (Roche Applied Science), mou-
se monoclonal anti-Flag M2, rabbit anti-HMGN5, mouse anti-polyHistidine Clone HIS-1 (All from Sigma), 




D. Baker, Leiden, The Netherlands), rabbit anti-FoxP1 (Abcam), rabbit anti-FoxM1, mouse anti-Ubiquitin 
P4D1 (both from Santa Cruz Biotechnology), mouse monoclonal anti-HA.11 (Covance),  mouse mono-
clonal anti-Methylated lysine (Abcam), mouse monoclonal anti-polyHistidine Clone HIS-1 (Sigma), rabbit 
anti-GTF21RD1, rabbit anti-JARID1B, rabbit anti-MDC1, rabbit anti-MYBL2, rabbit anti-SATB2, rabbit an-
ti-RanBP2 (all from Bethyl laboratories), rabbit anti-MCM4 (Epitomics), mouse anti-RanGAP1 (Life Tech-
nologies), rabbit anti-V5 (Abcam),  rabbit anti-SUMO-2/3 as previously described (Vertegaal et al., 2004). 
SILAC labeling
For SILAC labeling, cells were grown in medium supplemented with [12C6,
14N4]arginine (referred to as R0), 
[13C6,
14N4]arginine (referred to as R6), [
13C6,
15N4]arginine (referred to as R10), [
12C6
14N2]lysine (referred to 
as K0), [2H4,
12C6,
14N2]lysine (referred to as K4), or [
13C6,
15N2]lysine (referred to as K8) as indicated.
Lentiviral shRNA experiments
HeLa cells were infected at MOI 3 with lentivirus encoding shRNA TRCN0000007472 (shRNA1), shRNA 
TRCN0000007205 (shRNA2) or shRNA TRCN0000007206 (shRNA3). The medium was changed the 
next day and three days after infection, cells were transferred to different plates to proceed with FACS 
analysis, WST-1 analysis and colony formation assay. U2OS cells and U2OS cells stably expressing Flag-
FoxM1 wild type or Flag-FoxM1 12KR were infected at MOI 2 with lentiviruses encoding shRNA TRCN 
0000015544 (shRNA #1) or shRNA TRCN0000015546 (shRNA #2) against FoxM1. Cells were split one 
day after infection and processed three days after infection for FACS analysis, immunoblotting and micro-
scopy. In all shRNA experiments, a non-targeting shRNA SHC002 was used as a control virus. All shRNA 
constructs belong to the Mission shRNA library from Sigma-Aldrich. 
WST-1 analysis
On day three after lentivirus infection, cells were transferred (three wells per lentivirus construct in the first 
and second experiment, four wells per construct in the third experiment) to a 96-well plate at a density of 
3000 cells per well. After another 24 hours, the old medium was removed and 100 µl of medium mixed 
10:1 with WST-1 cell metabolic activity reagent (Roche) was added to each well. The absorbance at 450 
nm was measured two hours after addition of the reagent in a microplate reader Victor 3 (Perkin Elmer).
Colony formation assay
For the colony formation assay, cells were transferred to 10 cm dishes on day three after the lentivirus 
infection at a density of 10,000 cells per dish. Colonies were grown until day nine after the infection and 
fixed with methanol and acetic acid (3:1) for 15 minutes at room temperature. After drying the dishes, co-
lonies were stained with Giemsa solution (Merck). Colony formation was quantified using ImageJ Version 
1.47v software.
Synchronization of cells
Cells were blocked with 4 mM thymidine (Sigma) for 16 hours or 10 µM RO-3306 (Calbiochem) for 20 hours 




of thymidine blocking was performed to limit DNA damage associated with this treatment. After the indica-
ted time of release, cells were harvested by a mild trypsin treatment, one fifth of the sample was fixed for 
FACS analysis and the remaining sample was lysed in 4 pellet volumes of Flag-IP lysis buffer (1% SDS, 
0.5% NP-40, 50 mM sodium fluoride, 1 mM sodium orthovanadate, 5 mM β-glycerol phosphate, 5 mM so-
dium pyrophosphate, 0.5 mM EGTA, 5 mM 1,10-phenanthroline, protease inhibitor including EDTA (Roche; 
1 tablet per 10 ml buffer) in PBS). Lysates were frozen in liquid nitrogen and, if needed, stored at -80ºC. 
Immunoprecipitation
Flag-IP lysates described above were thawed at 30ºC and 70 mM Chloroacetamide was added freshly. 
Samples were sonicated and incubated for 30 minutes at room temperature. Afterwards, samples were 
equalized using BCA and 30 µl of each lysate were kept as an input sample. An equal volume of dilution 
buffer (2% Triton X-100, 0.5% sodium deoxycholate, 1% BSA, freshly added 70 mM chloroacetamide, 5 
mM sodium fluoride, 1 mM sodium orthovanadate, 5 mM β-glycerol phosphate, 5 mM sodium pyrophosp-
hate, 0.5 mM EGTA, 5 mM 1,10-phenanthroline, protease inhibitor including EDTA (Roche; 1 tablet per 
10 ml buffer) in 1x PBS) was added to the lysates and they were subsequently centrifuged for 45 minutes 
at 13.2 krpm at 4ºC. The supernatant was mixed with prewashed Flag-M2 beads (Sigma; 30 µl beads per 
1 ml of diluted sample) and incubated at 4ºC for 90 minutes. Afterwards, the beads were washed 5 x with 
wash buffer (50 mM Tris, 150 mM NaCl, 70 mM chloroacetamide, 0.5% NP-40, 5 mM sodium fluoride, 1 
mM sodium orthovanadate, 5 mM β-glycerol phosphate, 5 mM sodium pyrophosphate, 0.5 mM EGTA, 5 
mM 1,10-phenanthroline, protease inhibitor including EDTA (Roche; 1 tablet per 10 ml buffer)) including 
three tube changes. Flag-SUMO-2 conjugates or Flag-FoxM1 proteins were eluted with one bead volume 
of 5% SDS and 1 mM Flag M2 epitope peptide in wash buffer. For SUMO-2/3 IPs, mouse monoclonal 
SUMO-2/3 antibodies were coupled to protein G sepharose (GE Healthcare). Cell lysis and the IP were 
performed as described above. SUMO-2/3 conjugates were eluted with one bead volume 1x Nupage LDS 
sample buffer (Invitrogen).
Fluorescence-activated cell sorting analysis and BrdU labeling
Cells were harvested by a mild trypsin treatment, washed two times with PBS and resuspended in 1.5 ml 
of PBS. Afterwards, 3.75 ml of 100% ethanol was added and the cells were fixed at 4ºC at least overnight. 
On the day of flow cytometry analysis, the cells were first centrifuged at 1200 rpm for 2 minutes, the 
supernatant was removed and the cells were washed with PBS and 2% calf serum. Then, the cells were 
pelleted again and resuspended in 500 µl of PBS complemented with 2% calf serum, 25 µg/ml propidium 
iodide (Sigma) and 100 µg/ml RNAse A (Sigma). Cellular DNA content was determined by flow cytometry 
with the BD LSRII system and BD FACS DIVA Software (BD Biosciences Clontech). Newly synthesized 
DNA was labeled by replacing the cell medium with medium containing 20 µM BrdU (Sigma). After 30 
minutes of incorporation, the cells were released for 0, 4 or 8 hours. Cells were harvested by a mild 
trypsin treatment, washed once with PBS and resuspended in 0.5 ml of PBS. Subsequently, 5 ml of 70% 
ethanol was added and the cells were fixed at 4°C at least overnight. Next, the cells were washed with 
PBS and resuspended in 200 µl RNase A (0.5 mg/ml). After a 30 minute incubation at 37°C, the RNase A 




(5 M HCl and 0.5% Triton in MQ) and incubated for 20 minutes at room temperature. After neutralizing the 
solution by adding 10 ml of 1 M Tris pH 7.5, the cells were washed once with wash buffer 1 (0.5% Tween 
and 1% BSA in PBS). Subsequently, the cells were resuspended in FITC-conjugated anti-BrdU antibody 
(Roche) solution and incubated for 30 minutes at room temperature in the dark. Finally, the cells were 
washed twice with wash buffer 2 (0.5% Tween and 2% FCS in PBS), resuspended in PBS containing 20 
µg/ml propidium iodide and analyzed by flow cytometry as described above.
Electrophoresis and immunoblotting
Protein samples were either separated via regular SDS-PAGE using a Tris-glycine buffer or on Novex 
4-12% Bis-Tris gradient gels (Invitrogen) using MOPS buffer. Fractionated proteins were transferred onto 
Hybond-C extra membranes (Amersham Biosciences) using a submarine system (Invitrogen). Membra-
nes were stained for total protein amounts with Ponceau S (Sigma) and blocked with PBS containing 5% 
milk powder and 0.1% Tween-20 before incubating with the primary antibodies as indicated.
Coomassie staining and in-gel digestion
Proteins were fractionated on Novex 4-12% gradient gels (Invitrogen) and stained with the Colloidal Blue 
Kit (Invitrogen) according to the manufacturer’s protocol. Gel-lanes were divided into ten different slices 
as indicated and each slice was cut into 1 mm3 cubes. Gel slices were destained with 50% ethanol in 25 
mM ammonium bicarbonate solution and dehydrated with absolute ethanol. Proteins were digested with 
sequencing-grade modified trypsin (Sigma) overnight. Trypsin activity was quenched by acidification with 
TFA and peptides were extracted from the gel plugs with increasing concentrations of acetonitrile in 0.5% 
acetic acid. Organic solvent was evaporated in a vacuum centrifuge (Lundby and Olsen, 2011).
Mass Spectrometry Analysis
The resulting peptides from in-gel digestion were desalted and concentrated on STAGE-tips with two 
C18 filters  and eluted two times with 10 μl 40% acetonitrile in 0.5% acetic acid prior to online nanoflow 
liquid chromatography-tandem mass spectrometry (nano LC-MS/MS). All the experiments were perfor-
med on an EASY-nLC system (Proxeon, Odense, Denmark) connected to the LTQ-Orbitrap Velos or to 
the Q-Exactive (both from Thermo Fisher Scientific, Germany) through a nano-electrospray ion source. 
Peptides were separated in a 15 cm analytical column in-house packed with either 1,9 or 3 µm C18 beads 
(Reprosil-AQ, Pur, Dr. Manish, Ammerbuch-Entringen, Germany) with a 80 minutes gradient from 8% to 
75% acetonitrile in 0.5% acetic acid at a flow rate of 250 nl/minute. The mass spectrometers were opera-
ted in data-dependent acquisition mode with a top 10 method. For Q-Exactive measurements, full-scan 
MS spectra were acquired at a target value of 1 x 106 and a resolution of 70,000, and the Higher-Collisio-
nal Dissociation (HCD) tandem mass spectra (MS/MS) were recorded at a target value of 1 x 106 and with 
a resolution of 35,000 with a normalized collision energy of 25%. For LTQ-Orbitrap Velos measurements, 
full-scan MS spectra were acquired at a target value of 1 x 106 and a resolution of 30,000, and the Higher-
Collisional Dissociation (HCD) tandem mass spectra (MS/MS) were recorded at a target value of 5 x 104 




Peptide and protein identification
Raw mass spectrometric (MS) files were processed with the MaxQuant software suite (version 1.4.0.3, 
Max Planck Institute of Biochemistry, Department of Proteomics and Signal Transduction, Munich, Ger-
many) by which the precursor MS signal intensities were determined and SILAC triplets were automati-
cally quantified. HCD-MS/MS spectra were deisotoped and filtered such that only the 10 most abundant 
fragments for each 100 mass/charge ratio (m/z) range were retained (Cox et al., 2011). Proteins were 
identified by searching the HCD-MS/MS peak lists against a target/decoy version of the complete human 
Uniprot database supplemented with commonly observed contaminants such as porcine trypsin and bo-
vine serum proteins. Tandem mass spectra were matched with an initial mass tolerance of 4.5 ppm on 
precursor masses and 20 ppm for fragment ions. Cysteine carbamidomethylation was searched as a fixed 
modification. Protein N-acetylation, N-pyroglutamine, oxidized methionine and SUMOylation (QQTGG) 
with monoisotopic mass of 471.20776 Da and pyroSUMOylation (pyroQQTGG) with monoisotopic mass 
of 454.18121 Da on lysine residues as variable modifications for the experiment. QQTGG and pyroQQT-
GG modified lysines were required to be located internally in the peptide sequence. Site localization pro-
babilities were determined by MaxQuant using the PTM scoring algorithm (Cox and Mann, 2008; Olsen et 
al., 2006). The data set was filtered by posterior error probability to achieve a false discovery rate (FDR) 
below 1%. Only peptides with Andromeda score > 25 (unmodified and modified) were included in the total 
peptide list. Protein/peptides were considered as SUMOylated if they had a SILAC ratio > 2 between the 
Flag-SUMO-2 cell line and the parental control cells. 
Bioinformatics analysis
Protein interaction network analysis was performed using interaction data from the STRING database 
version 9.05 (Szklarczyk et al., 2011). Only interactions with a STRING score above 0.4 are represented 
in the networks. Cytoscape (version 3.0.1) was used for visualization of protein interaction networks 
(Smoot et al., 2011). Clusters in that network were identified with MCODE (version 1.4.0 beta2) with 
MCODE score >6. MCODE is a Cytoscape plugin that finds clusters (highly interconnected regions) in a 
network. Clusters mean different things in different types of networks. For instance, clusters in a protein-
protein interaction network are often protein complexes and parts of pathways, while clusters in a protein 
similarity network represent protein families (Bader and Hogue, 2003). Proteins in MCODE clusters were 
color-coded according to their cell-cycle peak-time using the cell-cycle color-scheme method previously 
described (Jensen et al., 2006). Significantly enriched Gene Ontology annotation terms were determined 
using Fisher’s exact test from InnateDB (Lynn et al., 2008). P values were corrected for multiple hypothe-
ses testing using the Benjamini and Hochberg FDR.
Purification of His-SUMO and His-Ubiquitin conjugates
U2OS cells expressing His-SUMO-2 or His-Ubiquitin were washed and collected in ice-cold PBS. Small 
aliquots of cells were lysed in 1x LDS for input samples. Guanidinium lysis buffer (6 M guanidinium-HCl, 
0.1 M Na2HPO4/NaH2PO4, 0.01 M Tris/HCl, pH 8.0 and competing imidazole) was added to the cell pellet 
to lyse the cells, after which the lysates were sonicated to reduce the viscosity. These lysates were used 




were equalized and His-SUMO-2 or His-Ubiquitin conjugates were enriched on nickel-nitrilotriacetic acid-
agarose beads (Qiagen) after which the beads were washed using wash buffers A to D. Wash buffer A: 
6 M guanidinium-HCl, 0.1 M Na2HPO4/NaH2PO4, 0.01 M Tris/HCl, pH 8.0, 10 mM β-mercaptoethanol, 
0.3% Triton X-100. Wash buffer B: 8 M urea, 0.1 M Na2HPO4/NaH2PO4, 0.01 M Tris/HCl, pH 8.0, 10 mM 
β-mercaptoethanol, 0.3% Triton X-100. Wash buffer C: 8 M urea, 0.1 M Na2HPO4/NaH2PO4, 0.01 M Tris/
HCl, pH 6.3, 10 mM β-mercaptoethanol, 0.3% Triton X-100. Wash buffer D: 8 M urea, 0.1 M Na2HPO4/
NaH2PO4, 0.01 M Tris/HCl, pH 6.3, 10 mM β-mercaptoethanol, 0.1% Triton X-100. Samples were eluted in 
7 M urea, 0.1 M Na2HPO4/NaH2PO4, 0.01 M Tris/HCl, pH 7.0, 500 mM imidazole.
Luciferase assays
U2OS cells were grown on 24-well tissue culture plates and cotransfected with 100 ng of the luciferase 
reporter construct, 100 ng of the LacZ reporter construct and 300 ng expression plasmid as indicated. 48 
hours after transfection, cells were washed with ice-cold PBS and lysed in 100 µl of Reporter Lysis Buf-
fer (Promega) for luciferase activity measurement or in SNTBS (2% SDS, 1% NP-40, 150 mM NaCl, 50 
mM Tris pH 7.5) for immunoblotting. Experiments were carried out in quadruplicate and all values were 
corrected for β-gal activity. 
RNA isolation, RT-PCR and quantitative PCR
Total RNA was purified from 6 cm dishes using the SV total RNA isolation system (Promega) according 
to the manufacturer’s protocol. Total RNA was amplified and converted into double-stranded cDNA by 
reverse transcription using ImProm-II Reverse Transcriptase (Promega) and Random Hexamers (Invi-
trogen). Real-time quantitative PCR was performed using a CFX384 Touch Real-Time PCR detection 
system (Bio-Rad) in which PCR reactions were performed in a 10 µl volume containing cDNA, FastStart 
Universal SYBR Green Master mix (Roche) and specific primers. The PCR was carried out with an initial 
denaturation at 95°C for 3 minutes, followed by 40 cycles of 95°C for 20 seconds, 55°C annealing for 
20 seconds and 60°C elongation for 30 seconds. The following sense (S) and antisense (AS) primer se-
quences were used: Aurora kinase B, S 5’-ATTGCTGACTTCGGCTGGT-3’, AS 5’-GTCCAGGGTGCCA-
CACAT-3’, Cyclin-B1, S 5’-TTTCGCCTGAGCCTATTTTG-3’, AS 5’-GCACATCCAGATGTTTCCATT-3’, 
CENP-F, S 5’-GAGTCCTCCAAACCAACAGC-3’, AS 5’-TCCGCTGAGCAACTTTGAC-3’, SAP30, S 5’- 
CGAGCTGGATAAGAGCGCAA-3’, AS 5’- TGGTCTGGTTGGTAGCTTGA-3’, CAPNS1, S 5’-ATGGTTTT-
GGCATTGACACATG-3’, AS 5’- GCTTGCCTGTGGTGTCGC-3’. Data were analyzed with the Bio-Rad 
CFX3 Manager software, average expression levels of triplicates were normalized for CAPNS1 expres-
sion levels.
Recombinant proteins
His-FoxM1 recombinant proteins were purified essentially as described previously (Schimmel et al., 2010). 
Briefly, BL21 cells were cotransformed with a His-FoxM1 expression construct and the SUMO-2 expres-
sion vector pE1E2S2 or SUMO-1 expression vector pE1E2S1. Cells were grown to an OD600 of 0.6. 
Cells were then grown overnight at 24°C in the presence of 0.1 mM isopropyl-β-D-thiogalactopyranoside 




His-FoxM1 proteins were affinity-purified on Talon beads (BD Biosciences). 32 µg of SUMOylated His-
FoxM1 protein was incubated with 0.7 µg of SENP2cd (BostonBiochem) at room temperature for 1 hour 
to remove the SUMO-2 moieties. GST tagged N-terminal FoxM1 was produced in E. coli and purified as 
described previously (Tatham et al., 2001). 
In vitro interaction assay
GST-Nterm-FoxM1 protein fragments bound to Glutathione Sepharose (GE Healthcare) or beads only 
were incubated with 5 µg of His-FoxM1 proteins for 1 hour at 4°C in NETN buffer (150 mM NaCl, 1 mM 
EDTA, 20 mM Tris pH 8.0, 0.5% NP-40). After incubation, beads were washed 5 times in NETN buffer. 
Beads were eluted in NETN buffer in the presence of 20 mM Glutathione (Sigma) at room temperature. 
The bound and unbound proteins were analyzed by immunoblotting. 
Microscopy
Cells were grown on microscopy coverslips and fixed with 3.7% formaldehyde in PBS for 15 minutes at 
room temperature. Afterwards, cells were permeabilized with 1% Triton X-100 in PBS for 15 minutes and 
washed twice with PBS and once with PBS plus 0.05% Tween (PBS-T). Slides were blocked with 0.5% 
blocking reagent (Roche) in 0.1 M Tris, pH7.5 and 0.15 M NaCl for 10 minutes and the primary antibody 
was added for one hour. Coverslips were washed five times with PBS-T and incubated with the secondary 
antibody for one hour. Again, the coverslips were washed five times with PBS-T and dehydrated washing 
once with 70%, once with 90% and once with 100% ethanol. After drying the cells, the coverslips were 
mounted onto a microscopy slide using citifluor/DAPI solution (500 ng/ml) and samples were analyzed 
using a LEICA CTR6500 microscope.
Statistical Analysis
All the experiments have been performed at least in triplicate. Results shown are mean ± s.d and the p-
value was calculated by Student’s two tailed t-test.
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Chapter 6. The Cockayne Syndrome-B protein is 
SUMOylated upon UV induced DNA damage
 
Abstract
Post translational modification of proteins by ubiquitin and Small Ubiquitin-Like 
Modifiers plays an essential role in various pathways of the DNA damage response. 
To get more insight in the involvement of SUMOylation in two of these pathways, we 
used a proteomics approach to identify regulated SUMO2 targets upon treatment 
with ultraviolet light (UV) or ionizing radiation (IR). The Cockayne Syndrome-B (CSB) 
protein was found to be SUMOylated specifically after UV induced DNA damage. 
CSB plays a key role during transcription coupled nucleotide excision repair (TC-
NER) by recruiting a cluster of proteins essential for DNA repair. We found that CSB 
is SUMOylated on lysine 32 and lysine 205, this process is however not essential 
for cell survival after UV irradiation. Studying the dynamics of CSB SUMOylation 
revealed that this is an early response upon DNA damage. The recruitment of the 
Cockayne Syndrome-A (CSA) ubiquitin E3 ligase complex initiates the removal of 
SUMOylated CSB at a later stage in the DNA damage response. This can potentially 
be explained by the ubiquitination of the RNA polymerase II complex by CSA which 
leads to the dissociation of CSB from chromatin and subsequently to the loss of 
SUMOylation. 
Introduction
The genetic code of cells is continuously under threat from exogenous and endogenous 
DNA-damaging agents such as ionizing radiation (IR), ultraviolet radiation (UV) and 
reactive oxygen species. To guarantee genomic stability, cells are equipped with 
a set of repair pathways that recognize and repair different kinds of DNA lesions. 
Deregulation of these DNA damage responses (DDRs) results in genomic instability 
which in turn often leads to the development of cancer, neurodegenerative diseases 
and many other syndromes (1, 2). During DDRs, DNA lesions are recognized by 
proteins, which induces a cascade of recruitment and activation of proteins that 
facilitate DNA repair. 
 Proteins involved in DNA repair are regulated upon DNA damage by 
posttranslational modifications such as ubiquitination and SUMOylation (3). 
Ubiquitin and Small Ubiquitin-like Modifiers (SUMOs) are covalently attached via 
an enzymatic cascade to lysines in target proteins to regulate the function of these 
proteins. Ubiquitin and SUMO specific proteases can reverse those modifications by 
catalytic cleavage, providing the cell with a highly dynamic and controllable system 




 Since its discovery in the mid-1990s (4), SUMOylation has emerged as a 
regulator of many, mainly nuclear, cellular processes (5, 6). SUMOylation is regulating 
proteins in many ways; it can change the subcellular localization of proteins, induce 
complex formation and regulate the activity of enzymes. Furthermore, SUMOylation 
can have both positive and negative effects on protein stability, by either blocking 
ubiquitination of lysines or by targeting proteins for proteasomal degradation via the 
recruitment of SUMO targeted ubiquitin ligases (STUBLs) respectively (7, 8). 
 The first link between SUMOylation and DNA repair was revealed in studies on 
Base Excision Repair (BER), where SUMOylation induces a conformational change 
in the Thymine-DNA glycosylase protein and thereby stimulates the repair process 
(9, 10). Furthermore it has been shown that two SUMO specific E3 ligases, PIAS1 
and PIAS4, accumulate at sites of double strand breaks (DSBs). At DSBs, these E3 
ligases SUMOylate BRCA1 to induce its activity and SUMOylation is required for the 
accumulation of repair proteins to facilitate repair of DSBs (11). 
 SUMO and ubiquitin also act together during the DDR, best exemplified 
by the modification of the homotrimeric, ring shaped protein Proliferating Cell 
Nuclear Antigen (PCNA). PCNA encircles DNA where it acts as a processing 
factor for DNA polymerases and as an interaction platform for proteins involved in 
DNA metabolism. Monoubiquitination of PCNA on lysine 164 upon DNA damage 
induces the recruitment of polymerases needed for translesion synthesis, whereas 
SUMOylation on the same lysine inhibits recombination during DNA synthesis by 
recruiting the anti-recombinogenic helicase Srs2 (12, 13). The role of SUMO and 
ubiquitin crosstalk in DNA repair was further emphasized by the observation that the 
SUMO-dependent recruitment of RNF4, a well-studied STUBL, to DSBs induces an 
ubiquitination signal that is essential for efficient repair of DSBs (14, 15). 
 Here we have identified the Cockayne Syndrome-B (CSB) protein as a novel 
SUMO2 target protein. Cockayne syndrome is a severe autosomal-recessive 
disease caused by mutations in either the CSB or CSA gene. Patients suffer from 
UV sensitivity, premature aging and neurodevelopmental abnormalities; these 
phenotypes are partly explained by a defect in transcription-coupled nucleotide 
excision repair (TC-NER) (16). The CSB protein plays a key role in TC-NER. A DNA 
lesion in the actively transcribed strand of a gene causes the stalling of the elongating 
RNA polymerase machinery. This stalling induces the strong interaction between 
RNA polymerase II (RNAPII) and CSB; subsequently CSB initiates the recruitment 
of NER specific proteins that facilitate the proper repair of the DNA lesion (17). Using 
a SILAC based proteomic approach we found that CSB is specifically SUMOylated 
upon DNA damage induced by UV irradiation. We show that SUMOylation of CSB 
on two lysines is an early response to DNA damage and that the recruitment of 
the Cockayne-Syndrome-A (CSA) ubiquitin E3 ligase complex results in the 





A quantitative proteomics approach to study SUMOylation dynamics in 
response to UV and IR treatment
It has been well established that SUMOylation of proteins plays an important role in the 
DNA Damage Responses (DDR) in cells (3). We were interested to analyze the global 
changes in SUMOylation in two different sub pathways of this response. We choose 
to use Ultraviolet C (UV-C) irradiation which is known to induce thymine dimers and 
6,4-photoproducts. These types of DNA damage are repaired by Nucleotide Excision 
Repair (NER). For the second type of DNA damage we used Ionizing Radiation (IR). 
IR mainly results in double strand breaks in DNA, which are repaired by either Non 
Homologous End Joining (NHEJ) or Homologous Recombination (HR) (18). 
 To be able to quantify changes in SUMOylation patterns after these types of 
DNA damage we used a SILAC (Stable Isotope Labeling by Amino acids in Culture) 
approach to label three different populations of U2OS cells expressing Flag-SUMO2 
with three distinct sets of isotopic variants of lysine and arginine (Figure 1A). These 
cells were either treated with 4 gray (GY) (IR, Heavy labeled), 20 J/m2 UV (Medium 
labeled) or left untreated (Light labeled). Cells were allowed to grow for an additional 
hour after the induction of DNA damage, subsequently cells were lysed and mixed 
before enrichment of SUMOylated proteins by a Flag-SUMO2 immunoprecipitation 
(IP) (Figure 1B). In addition we performed a duplicate with swapped SILAC labels to 
correct for experimental errors and false positive hits. Eluted fractions of the Flag-IPs 
were separated by SDS-PAGE, stained with Coomassie, cut in ten gel slices and in-
gel digested with trypsin. These tryptic digests were analyzed by nano-scale reversed 
phase liquid chromatography combined with high-resolution mass spectrometry. 
 A summary of the results can be found in Figure 1C. Western blot analysis 
confirmed the UV specific increase in SUMOylation of CSB and XPC, while 
SUMOylation of Senataxin and MDC1 was increased after both UV and IR treatment. 
SUMOylation of RanGap1 and SART1 was not affected by the two types of DNA 
damage (Figure 1D). Total SUMO levels in the same experiment were analyzed by 
an anti-SUMO-2/3 Western (Figure 1E). CSB and XPC seem to be very efficient 
SUMO target proteins after UV treatment since the modified forms are already visible 
on Westerns for total lysates. Visualizing SUMOylated forms of a protein without 
any pre-enrichment of SUMOs is quite rare due to the low stoichiometry of SUMO 
modification on proteins (19).
The Cockayne Syndrome-B protein is extensively SUMOylated on lysine 32 
and lysine 205 after UV treatment
Because of its emerging role in TC-NER, we decided to further analyze the 
SUMOylation on CSB upon UV induced DNA damage. CSB has an acidic domain, 
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= UV + IR upregulated
D
Gene name UV/Ctrl exp1 UV/Ctrl exp2 IR/Ctrl exp1 IR/Ctrl exp2
ERCC6 / CSB 2.58 2.26 0.21 0.25
XPC 1.57 1.21 0.35 0.17
SCAF1 0.93 0.83 0.27 0.53
ZNF444 0.63 0.73 -0.07 -0.10
CEBPB 0.98 0.59 0.12 0.50
NAB1 0.64 0.57 0.35 0.60
RIF1 0.40 0.33 0.62 1.13
INTS3 0.30 0.10 0.54 0.63
SETX 0.99 0.98 0.59 1.36
DLD 0.77 0.90 1.09 0.56
MDC1 1.41 0.80 1.16 1.74
RanGap1 0.21 0.23 0.10 0.02































































Figure 1. SUMOylation dynamics in response to UV and IR treatment A) Strategy to identify SUMO-
2 conjugates in response to UV and IR using a quantitative proteomic approach. U2OS cells stably 
expressing Flag-SUMO-2 were SILAC-labeled with three different isotopic variants of lysine and arginine 
and treated as indicated. For the Flag-IP, equal amounts of the three different lysates were mixed and 
SUMO2 conjugates were enriched using a Flag IP. B) Total cell lysates of the three cell populations Flag-
SUMO2 conjugates were analyzed by immunoblotting using anti-Flag antibody. C) Table summarizing the 
results from the mass spectrometry analysis. The normalized log2 ratio is shown for 13 targets, experiment 
1 (exp1) and experiment (exp2) refers to the label swap. D) U2OS cells or U2OS cells stably expressing 
Flag-SUMO2 were treated as in (A) and Flag-SUMO2 conjugates were purified via IP. Total lysates and 
Flag-SUMO-2 (Flag-IP) purified fractions were analyzed by immunoblotting with antibodies as indicated. 





ubiquitin binding domain (UBD) (21). Analysis of the amino acid sequence revealed 
that five lysines of CSB are situated in the SUMOylation consensus motif ΨKxE 
(Lysines 32, 205, 481, 1359 and 1489) (Figure 2A). 
 To analyze whether these lysines are used for SUMOylation lysine to arginine 
mutations were made for all five consensus sites (5KR). U2OS or U2OS Flag-SUMO2 
cells stably expressing GFP tagged wild type (WT) or 5KR CSB were generated 
and SUMOylation of these proteins in untreated or UV treated (20 J/m2) cells were 
analyzed. Flag-SUMO2 enrichment confirmed the UV dependent SUMOylation of 
WT-CSB, and similar to endogenous CSB we could detect the modified CSB bands 
also on total lysate samples. SUMOylation of CSB is completely abolished in the 
5KR mutant, thus CSB is indeed SUMOylated on the SUMO consensus sites (Figure 
2B). 
 Next we wanted to know whether all five consensus sites are used for 
SUMOylation. To analyze this we made a lysine 1489 (1KR), a lysine 1489, 1359 
(2KR), a lysine 1489, 1359, 481 (3KR) and a lysine 1489, 1359, 481, 205 (4KR) 
mutant and compared SUMOylation levels of these different proteins. Interestingly, 
no reduction in SUMOylation was observed in the first three mutants, suggesting 
that SUMOylation mainly takes place on the two N-terminal SUMO consensus sites. 
Indeed adding lysine 205 to the 3KR mutant decreased SUMOylation of CSB (Figure 
1C) and mutating only lysine 32 and 205 (2KR) seem to be sufficient to abolish 
SUMOylation (Figure 1D). Western blots for SUMO-2/3 or XPC were included to 
confirm efficient and equal purification of SUMOylated proteins in all Flag-SUMO2 
IPs. 
 Previously, it has been shown that CSB accumulates at local UV-damaged 
subnuclear areas (22). We analyzed and compared the subcellular localization of 
WT and the SUMO deficient 5KR CSB proteins in U2OS cells stably expressing GFP 
tagged CSB proteins. Local UV lesions were induced by using a porous UV-blocking 
membrane (23). 1 hour after UV irradiation cells were fixed and analyzed for GFP 
expression. Cells were stained with a XPC antibody to visualize the damaged areas 
in the nucleus. Both wild type and the SUMO deficient CSB proteins accumulated 
at the locally damaged areas in the cell together with XPC (Figure 2E). Thus, 
SUMOylation of CSB does not affect the localization of the protein at sites of DNA 
damage. 
SUMOylation of CSB is not essential for cell survival after UV
To study the functional relevance of SUMOylation of CSB upon DNA damage we 
made use of a CSB-deficient cell line derived from a Cockayne syndrome patient 
(CS1AN) (24). These cells are hypersensitive to UV irradiation (25, 26) and fail to 
recover RNA synthesis after UV irradiation (27, 28). 
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Figure 2. CSB is SUMOylated on lysine 32 and lysine 205 after UV treatment A) Cartoon depicting 
Cockayne Syndrome-B (CSB). CSB is composed of 1493 amino acids and harbors an acidic region, 
multiple ATPase motifs and an Ubiquitin binding domain (UBD). CSB contains 5 SUMOylation consensus 
sites. B) U2OS cells and U2OS cells stably expressing Flag-SUMO-2 were infected with retroviruses 
encoding either GFP-CSB wild type (WT) or GFP-CSB lacking the SUMOylation consensus sites (5KR). 
Cells were either treated with 20 J/m2 of UV or left untreated and cultured for an additional hour. Cells 
were lysed and SUMO2 conjugates were enriched by Flag IP. Total lysates and Flag purified fractions 
were analyzed by immunoblotting using anti-GFP antibody (left panel) or anti-Flag antibody (right panel, 
Flag-IP only). C) The experiment described in (B) was repeated with GFP-CSB mutants as indicated. 
Total lysates and Flag purified fractions were analyzed by immunoblotting using anti-GFP antibody or anti-
XPC antibody. D) The experiment described in (B) was repeated with GFP-CSB WT, a GFP-CSB mutant 
lacking lysine 32 and lysine 205 (2KR) and GFP-CSB 5KR. E) U2OS cells expressing either GFP-CSB 
WT or GFP-CSB 5KR were locally irradiated with 100 J/m2 UV and allowed to recover for one hour. Cells 
were fixed and stained using anti-XPC antibody. GFP and XPC expression was analyzed by confocal 
fluorescent microscopy. Differential interference contrast (DIC) was used to visualize the nuclei.
CSB to generate stable cell lines. The relative UV sensitivity of WT-CSB and 5KR-
CSB was determined by exposing the cells to different doses of UV and quantifying 
the clonal survival of these cells on day 14 after treatment. As published, CS1ANsv 
cells were very sensitive to UV irradiation, whereas normal human fibroblasts (VH10) 
showed significant resistance towards UV treatment. CS1ANsv cells expressing WT- 
or 5KR-CSB rescued the UV sensitivity of CS1ANsv cells to a similar extent (Figure 
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Figure 3. Clonal survival and RNA recovery assays (A) CS1ANsv cell lines stably expressing WT- or 
5KR-CSB were generated, expression levels of CSB were analyzed by immunoblotting using anti-CSB 
antibody. (B) The CS1ANsv stable cell lines and VH10sv cells were treated with different doses of UV 
as indicated. 14 days after UV treatment, cell survival was analyzed by counting colonies. Cell survival 
of untreated cells (0 J/m2) was set at 100% for each cell type. The error bars indicate the SD from the 
average. (C) VH10ht cells were infected with lentiviruses expressing either a non-targeting control shRNA 
(Ctrl) or two individual Ubc9 shRNAs (Ubc9 shRNA #1 or #2). Total SUMO-2/3 and Ubc9 levels were 
analyzed by immunoblotting with anti-SUMO-2/3 and anti-Ubc9 antibodies respectively. Equal protein 
levels were analyzed by immuno-blotting with anti-Actin. (D) Two days after lentiviral infection, cells were 
treated with 10 J/m2 UV. The RNA recovery was analyzed at 2, 6 and 24 hours after UV treatment. RNA 
synthesis in untreated cells was set at 100%; the error bars indicate the SD from the average. 
 Interestingly, knocking down the single known SUMO E2 enzyme Ubc9 with 
two independent shRNAs did significantly reduce RNA synthesis recovery after 
UV treatment in VH10 cells (Figure 3C en 3D). Preliminary results suggest that the 
transcriptional recovery is not affected in the SUMO deficient CSB cell line (data not 
shown); however this remains to be confirmed with additional experiments. Taken 
together, these results demonstrate that SUMOylation of CSB upon UV treatment is 
not essential for the cells to survive after DNA damage. However, global SUMOylation 
after DNA damage does seem to contribute to the efficient restart of transcription 




CSB SUMOylation dynamics reveals a novel link between the two 
complementation groups in Cockayne Syndrome
Since SUMOylation is a highly dynamic and reversible process, we wanted to 
investigate the timing and stability of CSB SUMOylation upon UV treatment. To 
establish this, we have set up an Elisa assay to be able to quantify the amount of 
CSB SUMOylation at different time-points after UV treatment. Anti-Flag coated well 
plates were incubated with lysates from U2OS Flag-SUMO2 cells. After extensive 
washing, the plates were incubated with SUMO-2 or CSB antibodies. The binding of 
these antibodies was detected by incubating with a secondary antibody coupled to 
Biotin. Biotin binding was detected by incubating with Streptavidin coupled to HRP, 
which in turn was visualized and quantified by incubating with peroxidase. 
 To validate this assay, CSB and SUMO-2 detection was analyzed in untreated 
or UV treated (20 J/m2) cell lysates prepared 1 hour after treatment. For CSB we 
observed an increase in signal after UV treatment, representing SUMOylated CSB, 
whereas the SUMO-2 signal is unchanged (Figure 4A). Next, U2OS Flag-SUMO2 
cells were treated with 20 J/m2 of UV and lysates were made at different time-points 
after treatment. The procedure described above was repeated and the CSB signal 
was quantified. We found that SUMOylation of CSB after induced DNA damage is an 
early event already visible after 15 minutes and peaking after 30 minutes. After 30 
minutes CSB SUMOylation slowly disappears again to almost undetectable levels 
after 24 hours (Figure 4B). 
 Removal of SUMOylated proteins is regulated by SUMO specific proteases (29) 
or by the activity of STUBLs (8). Upon DNA damage, CSB recruits the Cockayne 
Syndrome-A (CSA) protein as part of a Cullin-like E3 ligase complex for ubiquitin 
(30). We were interested to see whether the recruitment of this CSA-E3 complex is 
involved in the processing of SUMOylated CSB. Therefore we used a CSA deficient 
cell line derived from a Cockayne Syndrome patient (CS3BEsv) (25, 31). CS3BEsv 
cells and its derivative expressing His tagged CSA were used to make cell lines 
expressing Flag-SUMO2. These cells were treated with 20 J/m2 UV alone or in 
combination with proteasome inhibition by adding MG132 for 3 hours, subsequently 
SUMOylated proteins were enriched 1 hour after UV treatment using a Flag-IP. 
Efficient SUMOylation of CSB was observed in CS3BEsv cell, while complementing 
these cells with His-CSA strongly reduced the amount of SUMOylated CSB. This 
difference can be nullified by blocking proteasomal degradation with MG132 (Figure 
4C), indicating that the activity of the CSA-E3 ligase complex is needed for the removal 
of SUMOylated CSB. Because CSB SUMOylation is increasing the first 30 minutes 
after UV (Figure 4B), we expected that CSA would not play a role in destabilizing 
SUMOylated CSB in this time frame. Indeed when we compared SUMOylation of 
CSB in cell lysates made at different time-points after UV treatment, an effect on 































+ +- - + +- -+-
- -- - + ++ +++













+ +- - + +- -+-+-
No





































































































































Figure 4. CSB SUMOylation dynamics after UV treatment A) Anti-Flag coated well plates were incubated 
with different diluted lysates of U2OS Flag-SUMO2 cells that recovered for one hour after irradiation with 
20 J/m2 or lysates of untreated U2OS Flag-SUMO2 cells (blank). Plates were then incubated with anti-
SUMO-2/3 or anti-CSB antibody and the intensity of these signals was detected by Elisa. B) Anti-Flag 
coated well plates were incubated with lysates of U2OS Flag-SUMO2 cells that were allowed to recover 
for the indicated time-points after irradiation with 20 J/m2 UV. Plates were then incubated with anti-CSB 
antibody to detect SUMOylated CSB; the intensity of this signal was detected by Elisa. The error bars 
indicate the SD from the average. C) The CSA deficient cell line CS3BE was complemented by stable 
expression of His-CSA, CSA expression was analyzed by immunoblotting with anti-CSA antibody (left 




20 J/m2 of UV or left untreated and cultured for an additional hour. Another set of cells was treated in the 
same way in combination with MG132 treatment for 3 hours. Cells were lysed and SUMO2 conjugates 
were enriched by Flag IP. Total lysates and Flag purified fractions were analyzed by immunoblotting using 
anti-CSB antibody or anti-Flag antibody (Flag IP only). D) Cells described in (C) were allowed to recover 
for the indicated time-points after irradiation with 20 J/m2 UV. Cells were lysed and SUMO2 conjugates 
were enriched by Flag IP. Total lysates and Flag purified fractions were analyzed by immunoblotting 
using anti-CSB antibody (left panel) or anti-Flag antibody (Flag IP only). E and F) U2OS cells stably 
expressing Flag-SUMO2 were infected with lentiviruses expressing a non-targeting control shRNA (Ctrl), 
two independent shRNAs against CSA (E) or two independent shRNAs against DDB1 (F). Untreated cells 
or cells that were allowed to recover for 30 minutes or 8 hours after irradiation with 20 J/m2 UV were lysed 
and SUMO2 conjugates were enriched by Flag IP. Total lysates and Flag purified fractions were analyzed 
by immunoblotting using anti-CSB antibody (left panel) or anti-Flag antibody (Flag IP only). Knockdown of 
CSA and DDB1 was confirmed by immunoblotting using anti-CSA antibody (E) and anti-DDB1 antibody 
(F) on total lysates. 
Strikingly, while we still observed CSB SUMOylation after 24 hours in the CS3BEsv 
cell line, SUMOylation completely disappeared in the His-CSA complement cell line. 
The role of the CSA-E3 ligase complex in CSB SUMOylation stability was further 
confirmed by knock-down studies on CSA and DDB1. DDB1 is an adapter protein for 
Cullin-like ligases and directly interacts with CSA (32). Expression of both proteins 
was knocked-down by two independent shRNAs in U2OS Flag-SUMO2 cells. Cells 
were left untreated or were treated with UV and harvested after either 30 minutes or 
8 hours, SUMOylation of CSB in cells with CSA or DDB1 knockdown was compared 
to cells treated with a non-targeting control shRNA (Ctrl). While the SUMOylation 
of CSB was strongly reduced after 8 hours in the Ctrl treated cells, we observed a 
stabilizing effect on CSB SUMOylation with both CSA knockdown (Figure 4E) and 
DDB1 knockdown (Figure 4F). Interestingly, knocking down CSA seems to have 
an overall effect on total SUMOylation levels in this experiment (Figure 4E). This 
data shows that the recruitment of the CSA-E3 ligase complex after DNA damage 
regulates the stability of SUMOylated CSB.
CSA, a potential STUBL for SUMOylated CSB?
Because of its effect on SUMOylated CSB, we wondered whether the CSA-E3 
ligase could act as a STUBL. One of the features of a STUBL is the strong affinity 
for SUMOylated proteins (33). As CSA is specifically recruited by CSB bound to 
chromatin (34), a cellular fractionation assay (35) was used to enrich for chromatin 
associated proteins. UV induced DNA damage results in the strong binding of CSB 
to RNAPII on chromatin and in the SUMOylation of CSB, therefore we hypothesized 
that CSB SUMOylation is exclusive for the chromatin bound fraction. Using the 
fractionation assay we indeed found that modified CSB bands are only observed 
after UV treatment in total lysates and the chromatin enriched fraction, but not in the 
cytosolic fraction and soluble nucleus in U2OS cells (Figure 5A). 
 The previously described CSB deficient cell line CS1AN and the WT-CSB or 
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Time after UV 20J/m2
Figure 5. CSB SUMOylation is not essential 
for CSA recruitment A) U2OS cells were left 
untreated or were allowed to recover for 30 
minutes or 6 hours after irradiation with 20 J/
m2 UV. Cells were separated into a cytosolic 
fraction, soluble nucleus or chromatin fraction 
by biochemical fractionation of the cells. A 
small percentage of cells was directly lysed in 
SNTBS to obtain a total lysate. The different 
fractions and total lysates were analyzed by 
immunoblotting using anti-CSB antibody. 
A Ponceau S staining of the membrane is 
included as a loading control. B) CS1ANsv 
cells or CS1ANsv cells stably expressing 
WT- or 5KR-CSB were left untreated or were 
treated with 20 J/m2 UV and cultured for the 
indicated time. Cells were fractionated and the 
chromatin enriched fraction was analyzed by 
immunoblotting using anti-CSB antibody and 
anti-CSA antibody. The soluble nucleus was 
analyzed by immunoblotting using anti-CSA 
antibody. Ponceau S staining of immunoblots 
with the chromatin and nuclear enriched 
fractions are included as a loading control. 
C) The experiment described in (B) was 
repeated and CSA and CSB signals in the 
chromatin enriched fraction were quantified 
with the Odyssey system. The CSA to CSB 
ratio in the chromatin fractions was calculated 
for 15 and 30 minutes after UV treatment, the 
ratio for CS1AN WT-CSB cells was set to 1.0. 
The error bars indicate the SD from the average. D) Recombinant GST tagged N-terminal CSB protein 
fragments (GST-CSB Nterm) were in vitro SUMOylated with SUMO2. SUMOylated and unmodified GST-
CSB protein fragments were size-separated by SDS-PAGE and detected by Coomassie staining of the 
gel. E) Recombinant GST-CSB protein fragments and GST-SUMO2 proteins were SUMOylated in vitro 
and coupled to glutathione beads. SUMO2 conjugates were removed by incubating these proteins with 
recombinant SENP2. Glutathione beads only or beads bound to the described proteins were incubated 
with recombinant CSA-DDB1 protein complex. Input and elution of the GST pulldown were analyzed 
by immunoblotting using anti-DDB1 and anti-CSA antibodies. Ponceau S staining of the membrane is 




These cells were left untreated or were treated with 20 J/m2 of UV and harvested 
at different time-points. Analysis of the chromatin fraction confirmed that CSA 
recruitment depends on CSB, no recruitment was observed in the CS1AN cell line; 
instead CSA remained in the soluble nucleus upon UV treatment. CSA is specifically 
recruited to the chromatin after UV treatment in both the WT-CSB and the 5KR-CSB 
cell line (Figure 5B). To quantify the CSA recruitment in WT-CSB and 5KR-CSB 
cell lines, this experiment was repeated and the CSA/CSB ratio was calculated for 
both experiments. Although CSA recruitment might be slightly reduced in the 5KR-
CSB cells in chromatin fractions 15 minutes after UV treatment, the effects are quite 
modest and probably loose significance after 30 minutes (Figure 5C). 
 Furthermore, no difference in interaction between the CSA-DDB1 complex and 
unmodified or SUMOylated CSB proteins was observed in vitro. In this experiment 
GST tagged N-terminal CSB protein fragments were SUMOylated in vitro (Figure 5D) 
and SUMOs were removed by adding SENP2 to obtain unmodified N-terminal CSB 
fragments. These proteins were incubated with recombinant CSA-DDB1 complexes 
and subsequently purified using glutathione beads. Although the CSA-DDB1 complex 
strongly interacts with CSB, no difference was observed between SUMO modified 
and unmodified CSB (Figure 5E). Interestingly, we did observe a strong interaction 
between the CSA-DDB1 complex and both mono-SUMO2 as well as SUMO2 chains 
(Figure 5E). The GST-SUMO2 levels in this experiment were significantly higher 
than the GST-CSB levels. The interaction between the CSA-DDB1 complex and 
SUMO2 might thus be overestimated compared to the interaction with the N-terminal 
CSB protein fragments. We conclude that the CSA-E3 ligase complex does not act 
as a classical STUBL towards the binding of SUMOylated CSB. 
 To see whether the CSA-E3 ligase complex can ubiquitinate CSB, we repeated 
the experiment described in Figure 4C and replaced Flag-SUMO2 expression for 
Flag-Ubiquitin expression. Enrichment for ubiquitinated proteins with a Flag IP 
revealed that adding back His-CSA into CS3BE cells does induce CSB ubiquitination 
in untreated cells. However, ubiquitination of CSB was reduced after UV treatment 
and surprisingly even further reduced in combination with MG132 treatment (Figure 
6). The destabilization of SUMOylated CSB can therefore not be explained by the 
ubiquitination and proteasomal degradation via the CSA-E3 ligase complex. 
Identification of targets for CSA mediated ubiquitination
To identify other targets for CSA dependent ubiquitination, we set up another SILAC 
screen. For this experiment, the previously described CS3BE cell line and the 
complemented CS3BE cell line expressing CSA-Flag were used. A His-ubiquitin 
expression vector was introduced in these cell lines to enable the purification of 
ubiquitinated proteins. Four differently treated sets of medium and heavy labeled 




spectrometry (Figure 7A). Interestingly, we found an increase in ubiquitination of 
RNAPII subunit RPB1 in the CSA-Flag cell line in two experiments. An increased 
heavy/medium (CS3BE + CSA-Flag / CS3BE) ratio was found for RPB1 in cells 
that were treated with UV and either allowed to recover for 1 hour or for 6 hours in 
combination with MG132 (Figure 7A). By using an antibody for the active RNAPII 
subunit RPB1 (anti-phospho-RPB1), we confirmed that ubiquitination of this protein 
is increased in the CSA-Flag complement cell line after UV induced DNA damage 
(Figure 7B). We conclude that RNAPII is a target for CSA-dependent ubiquitination 
and degradation upon UV induced DNA damage. Potentially, this could lead to 
the dissociation of CSB from chromatin, leading to deSUMOylation of CSB in the 
nucleus (Figure 8). 
Experiment Medium labeled Heavy labeled UV Recovery MG132
1 CS3BE CS3BE + CSA-Flag No UV - -
2 CS3BE CS3BE + CSA-Flag 20 J/m2 1 hour -
3 CS3BE CS3BE + CSA-Flag 20 J/m2 6 hours -
4 CS3BE CS3BE + CSA-Flag 20 J/m2 6 hours +
Exp1 Exp2 Exp3 Exp4
RNA polymerase II, subunit RPB1 0 0.64 0 0.6
Normalized Log2 Ratio
A B
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Figure 7. Identification of targets for CSA mediated 
ubiquitination (A) Setup of SILAC experiment. CS3BE cells 
or CS3BE + CSA-Flag cells stably expressing His-ubiquitin 
were SILAC labeled and treated as indicated, His-ubiquitin 
conjugates were purified by IMAC and analyzed by mass 
spectrometry. The normalized log2 ratios in each experiment 
are depicted for the RNAPII subunit RPB1. (B) The experiment 
described in (A) was repeated, total lysates and His-ubiquitin 
purified fractions were analyzed by immunoblotting using anti-
phospho-RPB1 antibody or anti-His antibody (His pulldown 
only). CSA expression in total lysates was analyzed by 
immunoblotting using anti-CSA antibody
+ +- - + +- -+-
- -- - + ++ +++














Figure 6. CSA dependent ubiquitination of CSB is reduced after 
UV treatment. CS3BE cells or CS3BE cells stably expressing His-
CSA were infected with lentiviruses encoding Flag-ubiquitin. Cells 
were either treated with 20 J/m2 of UV or left untreated and cultured 
for an additional hour, another set of cells was treated in the same 
way in combination with MG132 treatment for 3 hours. Cells were 
lysed and ubiquitin conjugates were enriched by Flag IP. Total 
lysates and Flag purified fractions were analyzed by immunoblotting 





























































































0 - 30 minutes after UV
UV induced DNA damage
15 - 30 minutes after UV
> 30 minutes after UV
> 60 minutes after UV
Figure 8. Model During transcription, CSB interacts dynamically with RNAPII. UV induced DNA damage 
causes stalling of the RNAPII complex and this initiates a more stable interaction between CSB and 
RNAPII. CSB SUMOylation is an early event upon UV induced DNA damage. The recruitment of the CSA 
E3 ligase complex initiates the destabilization of SUMOylated CSB at later time points after DNA damage. 
The exact mechanism behind this destabilization is currently unknown; the recruitment of a STUBL or the 






CSB is a novel SUMO2 target protein 
We have studied the SUMOylation of the TC-NER factor CSB upon UV induced DNA 
damage. This protein was identified as a novel SUMO2 target protein in a SILAC 
based proteomics screen for SUMO2 targets upon UV and IR treatment. In addition 
to CSB, the previously published SUMO target XPC (36) was also identified as a 
‘UV-dependent’ SUMO target. XPC is another component of the TC-NER pathway 
(30) showing that at least two proteins that are essential for TC-NER are modified 
by SUMO2 upon DNA damage. This screen also showed that some targets are only 
SUMOylated upon the activation of specific DNA repair pathway (UV or IR specific), 
while other proteins are targets for SUMOylation in two separate repair pathways 
(UV + IR upregulated). Due to the harsh filtering of targets by using a label swap 
experiment, it is most likely that there are many more SUMO2 regulated targets in 
these DNA repair pathways that remain to be identified. 
CSB is SUMOylated on two lysines located in the N-terminus of the protein
SUMOylation often occurs on lysines located in the so called ‘SUMO consensus 
motif’ ψKxE, however SUMOylation of lysines not located in this motif is frequently 
reported (37). CSB has 5 lysines located in the SUMO consensus motif and mutational 
analysis of the CSB protein revealed that SUMOylation of CSB mainly takes place 
on lysine 32 and lysine 205. SUMOylation on these two lysines is exclusively and 
abundantly happening after DNA damage induced by UV irradiation, which raises 
the question what mechanism is responsible for this specificity? 
 Several studies revealed a strong link between chromatin and SUMOylation 
activity. It has been shown that SUMO proteins and components of the SUMOylation 
machinery often colocalizes and interacts with chromatin (38). In addition, it was 
recently found that active promoters of genes are areas with a high SUMOylation 
activity (39). Thus, chromatin seem to be contents of the nucleus that display an 
increased SUMOylation activity. Since CSB strongly binds to stalled RNAPII 
on chromatin (34) upon UV induced DNA damage, we wondered whether this 
translocation could explain the increase in SUMOylation. Indeed, we found that 
SUMOylation of CSB predominantly takes place in chromatin enriched fractions 
after UV treatment (Figure 5A), potentially explaining the UV specific SUMOylation. 
 Intriguingly, an ATP dependent conformational change in CSB is essential 
for stable CSB-chromatin association after UV irradiation (40). In this study, the 
authors suggest that a stable CSB-chromatin interaction under normal conditions is 
prevented by the N-terminal region of CSB that blocks the DNA interaction surface 
of the protein. In the presence of a lesion-stalled transcription, this autorepression 
is released by an ATPase induced conformational change of CSB. Since CSB is 




this conformational change is needed to induce CSB SUMOylation. Future research 
is also needed to investigate whether SUMOylation has an effect on the induction, 
stability and duration of the conformational change in CSB upon DNA damage. 
 Furthermore, it would be interesting to study the involvement of a specific 
SUMO E3 ligase in CSB SUMOylation. Potential candidates are PIAS1 and PIAS4; 
previously it was found that these E3 ligases are recruited to sites of DNA damage 
(41). Another interesting E3 ligase to study is CBX4, a family member of the 
chromatin-associated PcG proteins. CBX4 mediated SUMOylation of the polycomb 
complex protein BMI1 regulates its accumulation at sites of DNA damage (42).
CSB SUMOylation is dispensable for UV survival of cells
Clonal survival assays showed that SUMOylation of CSB is not essential for long 
term survival of cells after UV irradiation. Although it has been shown that interfering 
with global SUMOylation leads to serious cellular defects (43) (44), abolishing 
SUMOylation on single protein level often lacks notable phenotypes. Therefore it has 
been proposed that SUMOylation regulates cellular processes by modifying protein 
groups involved in a particular process (45). We found at least one other UV specific 
SUMO target that is involved in TC-NER, XPC, and it is most likely that SUMO 
modifies a whole set of proteins that are regulating the repair of UV induced lesions. 
 The role of SUMOylation in TC-NER could thus also be explained by group 
modification; indeed it has been published that two PIAS SUMO E3 ligases play 
an essential role in promoting NER in yeast (46). In agreement with this data, we 
found that knocking down the SUMO E2 enzyme Ubc9 significantly decreased the 
recovery in RNA synthesis after a UV induced block in transcription. Recovery of 
RNA synthesis by RNAPII depends on the efficient repair of a DNA lesion and is 
therefore a good readout for efficient DNA repair (47, 48). Whether SUMOylation of 
CSB has a direct effect on the transcriptional restart after UV induced DNA damage 
should be addressed by future research. In addition, the recent developed method to 
measure the kinetics of nucleotide excision repair (49) is an interesting tool to study 
the involvement of CSB SUMOylation in efficient repair of lesions.
Link between SUMOylated CSB and CSA recruitment
In Cockayne Syndrome there are two genetic complementation groups: CS-A and 
CS-B (50). Mutations in either CSA or CSB lead to similar phenotypes in CS patients 
and both proteins play key roles in TC-NER. Despite these similarities, the exact link 
between CSA and CSB and their cooperative function in DNA repair remains to be 
elucidated (51). Binding of CSB to stalled RNAPII upon DNA damage is essential 
for the recruitment of CSA. Subsequently, CSA is required for the recruitment of 
HMGN1, XAB2 and TFIIS but dispensable for the attraction of core NER factors (30). 




complex further consisting of DDB1, Cullin 4A and Roc1. At an early stage after UV 
irradiation, this E3 ligase is inactive due to the binding of the COP9 signalosome 
(CSN) to the complex which leads to the deneddylation of Cullin 4A. The CSN 
complex dissociates from the E3 ligase complex at later time points after UV and 
this potentially releases ubiquitination activity of the E3 ligase (52). 
 So far, it is unclear what the targets are for CSA dependent ubiquitination at sites 
of DNA damage. CSB has been suggested as a UV-specific target for CSA mediated 
ubiquitination and subsequent proteasomal degradation (32). Although we observed 
an increase in CSB ubiquitination in CSA complemented cell-lines, this was strongly 
reduced after UV treatment and even further reduced in combination with inactivation 
of the proteasome. Its important to note that the usage of tagged-ubiquitin constructs 
exlcudes the detection of potential linear ubiquitin chains on CSB. Neverthelles, in 
our hands it does not look like CSB is a target for UV-dependent degradation via the 
CSA E3 ligase complex. However, we did find that the recruitment of this complex is 
responsible for the destabilization of SUMOylated CSB at later time-points after UV. 
This observation provides a novel link between CSB and CSA but raises the question 
how CSA is regulating the destabilization of SUMOylated CSB. As mentioned above 
CSA does most likely not act as a STUBL, but potentially CSA could still recruit a 
STUBL to sites of DNA damage to ubiquitinate SUMOylated CSB. Recently, RNF111 
was identified as a STUBL that facilitates the DNA damage response by recognizing 
SUMOylated XPC (53). It would be interesting to study the effect of RNF111 on 
SUMOylated CSB, since both CSB and XPC are SUMO targets in the TC-NER 
pathway. 
 Another explanation for the destabilization of SUMOylated CSB by the CSA 
complex is the ubiquitination of TC-NER factors by this complex. Ubiquitination of 
RNAPII (and other TC-NER proteins) by the CSA complex could potentially induce 
the dissociation of CSB from chromatin and translocation to the nucleoplasm. Since 
CSB is exclusively SUMOylated on chromatin, this translocation could lead to the 
deSUMOylation of CSB in the nucleus by SUMO specific proteases (Figure 8). 
Intriguingly, RNA polymerase II ubiquitination and degradation is believed to be a 
‘last-resort’ respone to DNA damage in yeast. In this model, Cdc48 dissassembles 
ubiquitinated RNAPII from chromatin resulting in its proteasomal degradation (54). 
It would be interesting to see whether the mammalian Cdc48 homolog, VCP/p97 
has similar effects on human RNAPII. If this is the case, one could study the effect 
on SUMOylated CSB after repression of VCP/p97 expression to see whether 
the stability of SUMOylated CSB is indeed linked to the degradation of RNAPII. 
Furthermore, it was recently found that Cdc48 and its cofactor acts as a SUMO-
targeted segregase towards SUMOylated Rad52 during DNA double-strand break 
repair (55). Therefore it would be very interesting to see if VCP/p97 is also recruited by 





Cell culture, SILAC labeling and generation of cell lines
U2OS, CS3BEsv, CS1ANsv and VH10ht cells were cultured in Dulbecco’s modified Eagle’s medium 
(Gibco Invitrogen Corporation, Grand Island, NY, USA) supplemented with 10% FCS (Gibco) and 100 U/
ml penicillin and 100 μg/ml streptomycin (Gibco). For SILAC analysis, cells were essentially labeled as 
described before (56). Briefly, cells were grown in medium supplemented with [12C6,
14N4]arginine (referred 
to as Arg0), [13C6,
14N4]arginine (referred to as Arg6), [
13C6,
15N4]arginine (referred to as Arg10), [
12C6
14N2]
lysine (referred to as Lys0), [2H4,
12C6,
14N2]lysine (referred to as Lys4), or [
13C6,
15N2]lysine (referred to as 
Lys8) as indicated. U2OS cells stably expressing Flag-SUMO2 were previously described (57). U2OS 
cells stably expressing GFP-CSB proteins were generated by infecting cells with retroviruses encoding 
different GFP-CSB constructs and the Puromycin resistant gene. After infection, cells were selected for 
GFP-CSB expression by culturing in medium supplemented with 1 µg/ml of Puromycin (Calbiochem). 
CS1ANsv cells stably expressing WT- or 5KR-CSB were generated by infecting cells with lentiviruses en-
coding CSB and the Blasticidin resistant gene. After infection, cells were selected for CSB expression by 
culturing in medium supplemented with 400 µg/ml G418 (Roche). CS3BE cells stably expressing His-CSA 
or CSA-Flag were generated by infecting cells with lentiviruses encoding CSA and the Blasticidin resistant 
gene. After infection, cells were selected for CSB expression by culturing in medium supplemented with 
either 5 µg/ml Blasticidin (Invitrogen) (His-CSA) or 100 µg/ml G418 (CSA-Flag). All cells were cultured in 
CELLSTAR flasks (175cm2) and petri dishes (145 x 20 mm) (both from Greiner Bio-One).
Plasmids
The pLV-CMV-Flag-SUMO2-IRES-eGFP plasmid was previously described (57). Ubiquitin cDNA was 
cloned into pLV-CMV-Flag-IRES-eGFP vector. Wild type CSB cDNA was cloned into pDON207 (Invi-
trogen). This construct was used to make lysine to arginine mutations using the following primers: 5’-GAAG-
AAATGGCAATCAGGCAAGAAAGTGGTG-3’ and 5’-CACCACTTTCTTGCCTGATTGCATTTCTTC-3’ 
(K32R), 5’-GAGGAGCAGAGGTGAGAATTGAACTAGATCAC-3’ and 5’-GTGATCTAGTTCAATTC 
TCACCTCTGCTCCTC-3’ (K205R), 5’- CAAAGAGAAACGTCTGAGGCTGGAGGACGA TTC-3’ and 
5’-GAATCGTCCTCCAGCCTCAGACGTTTCTCTTTG-3’ (K481R), 5’-CAG GATGGCATCATGAGAAAG-
GAGGGAAAAG-3’ and 5’-CTTTTCCCTCCTTTCTCATGA TGCCATCCTG-3’ (K1359R), 5’- GAATTT-
GGAAACTCAGGCCAGAATACTGC-3’ and 5’-GCAGTATTCTGGCCTGAGTTTCCAAATTC-3’ (K1489R). 
The different CSB constructs were subsequently transferred to pBabe-puro-GFP-Dest (a kind gift of Petra 
de Graaf and Marc Timmers, Utrecht, The Netherlands) or pLenti-NEO-Dest (Addgene, number 17392) 
employing standard Gateway technology (Invitrogen). To create N-terminal CSB protein fragments, cDNA 
encoding amino acid 1 until 341 of CSB was cloned into pDON207. Subsequently, this cDNA was trans-
ferred to pDEST15 (T7-GST-Dest, Invitrogen) using standard Gateway technology. Synthetic oligos en-
coding either the 6His-StrepII-tag or the Flag-tag were inserted into pENTR4 (Invitrogen). Wild type CSA 
cDNA was subsequently cloned into these vectors and transferred to pLenti6.3 V5-DEST (Invitrogen) to 
obtain lentiviral vectors expressing His- or Flag-tagged CSA. The pGEX-2T-SUMO2gg vector was a kind 
gift of Prof. Dr. Ron Hay (58). The SUMO-2 encoding construct pE1E2S2 was a kind gift of Prof. H. Saitoh 





The primary antibodies used were as followed: mouse monoclonal anti-Flag M2, mouse anti-His, rab-
bit anti-Actin (all from Sigma), mouse monoclonal anti-SUMO-2/3, rabbit monoclonal anti-Ercc8 (CSA), 
goat anti-DDB1 (all from Abcam), mouse anti-Ubiquitin P4D1 (Santa Cruz Biotechnology), rabbit anti-
MDC1, rabbit anti-CSB, rabbit anti-XPC, rabbit anti-Senataxin (all from Bethyl laboratories), mouse anti-
RanGap1 (Life Technologies), rabbit anti-SUMO-2/3 and rabbit anti-SART1 were previously described 
(61, 62), mouse anti-GFP (Roche), mouse anti-Ubc9 (BD biosciences), rabbit anti-Phospho-Rpb1 CTD 
(Ser2/Ser5) (Cell signaling). 
Flag-SUMO2 and Flag-Ubiquitin immunoprecipitation
Flag-SUMO2 and Flag-Ubiquitin conjugates were enriched with a Flag immunoprecipitation as described 
before (57).
Electrophoresis and immunoblotting
Protein samples were either separated via regular SDS-PAGE using a Tris-glycine buffer or on Novex 
4-12% Bis-Tris gradient gels (Invitrogen) using MOPS buffer. Fractionated proteins were transferred onto 
Hybond-C extra membranes (Amersham Biosciences) using a submarine system (Invitrogen). Membra-
nes were stained for total protein amounts with Ponceau S (Sigma) and blocked with PBS containing 5% 
milk powder and 0.1% Tween-20 before incubating with the primary antibodies as indicated.
Coomassie staining, in-gel digestion and Mass Spectrometry analysis
This was essentially done as previously described (57). Briefly, Coomassie stained gel slices were des-
tained with 50% ethanol in 25 mM ammonium bicarbonate solution and dehydrated. Resulting peptides 
from in-gel digestion were desalted and concentrated on STAGE-tips with two C18 filters; eluted peptides 
were analyzed on an EASY-nLC system (Proxeon) connected to the Q-Exactive (Thermo Fisher Scien-
tific).
Global and local UV irradiation
UV irradiation of cell was essentially performed as described before (63). Briefly, cells were rinsed with 
phosphate-buffered saline (PBS) and exposed to UV-C (254 nm; TUV lamp; Philips). After irradiation cells 
were cultured in their original medium for time-points as indicated. For local irradiation PBS washed cells 
were covered with a micro-porous polycarbonate filter containing 5 µm pores (Millipore) and irradiated 
with 100 J/m2 UV. After irradiation cells were cultured in their original medium for one hour. 
Microscopy
Cells were fixed, stained and analyzed as described before (57).
UV survival
Survival of cells was determined essentially as described before (64). Briefly, cells were exposed to UV 




were counted and the amount of colonies was compared to untreated cells (0 J/m2) which was set to 100 
% survival. 
RNA recovery assay
48 hours after infection, VH10ht cells were plated on 96-well plates and UVC-irradiated (10J/m2), and sub-
sequently cultured in their original medium for different time-periods (0–24 h) to allow RNA synthesis re-
covery. Cells were then incubated for 1 h in medium supplemented with 1mM of EU (Invitrogen) to detect 
global RNA transcription. Image acquisition and data processing are automated. Typical RNA synthesis 
images were captured by the BD pathway 855 and analyzed by Cell profiler software. 
Elisa assay
Anti-Flag-M2 coated well plates (Sigma) were prewashed with PBS-T (0.05 % Tween-20 in PBS). Wells 
were incubated with lysates diluted in dilution buffer, according to the Flag immunoprecipitation procedure 
(57) for 1,5 hours at 4°C. Wells were washed with PBS-T (3 times) and incubated with rabbit anti-CSB 
or rabbit anti-SUMO-2/3 antibodies for 1,5 hours at 4°C and washed again with PBS-T (3 times). Subse-
quently, wells were incubated with swine anti-rabbit biotinylated antibody (DAKO) for 1,5 hours at 4°C and 
washed three times with PBS-T. Next, wells were incubated with Streptavidin-HRP (R&D systems) and 
incubate for 20 minutes at room temperature after which the plates were washed with PBS-T (3 times). 
HRP was detected by incubating with the Substrate Reagent Pack (R&D systems) for 20 minutes at room 
temperature; reactions were stopped by adding 1M H2SO4. Signal intensity was measured at 450 nm 
using a platereader.
Lentiviral shRNA experiments
U2OS cells were infected at MOI 3 with lentivirus encoding shRNA TRCN0000003720 (CSA shRNA 
#1), shRNA TRCN0000 003721 (CSA shRNA #2), shRNA TRCN0000082853 (DDB1 shRNA #1), shRNA 
TRCN0000082857 (DDB1 shRNA #2) or non-targeting shRNA SHC002 (Ctrl). The medium was changed 
the next day and four days after infection, cells were harvested. For the RNA recovery assay, VH10ht cells
were infected at MOI 3 with lentivirus encoding shRNA TRCN0000007205 (Ubc9 shRNA #1) or shRNA 
TRCN0000007206 (Ubc9 shRNA #2) or non-targeting shRNA SHC002 (Ctrl). 
Biochemical fractionation of cells
Cellular fractionation assays were essentially performed as described previously (35).
Recombinant proteins
The GST tagged N-terminal CSB fragment and GST tagged SUMO2 were produced in E. coli and purified 
as described previously (58). 10His-CSA-6His-DDB1 protein complex were essentially produced and 
purified as described previously (60). Briefly, Sf9 cell pellets expressing 10His-CSA-6His-DDB1 were 
lysed in lysis buffer (50 mM Tris pH 8.0, 20 mM Imidazole, 200 mM NaCl, 0.1 % Triton X-100, 5 mM 
β-mercaptoethanol, protease inhibitor minus EDTA (Roche)). Cell lysates were sonicated and centrifuged 




hours at 4°C. Subsequently, the beads were washed 4 times with lysis buffer supplemented with 30 mM 
Imidazole. Proteins were eluted with an Imidazole gradient (50 mM Imidazole to 500 mM Imidazole) for 15 
minutes at 4°C each elution. The 10His-CSA-6His-DDB1 complex from the elution with 300 mM Imidazole 
was used for the interaction experiments.
In vitro interaction experiment
Recombinant GST tagged proteins bound to Glutathione Sepharose (GE Healthcare) were left untreated 
or were incubated with 5 µg SENP2cd (BostonBiochem) at 4°C for 2 hours. Beads were washed twice 
with 0.5 M NaCl, 1 mM PMSF, protease inhibitor cocktail (Roche) in 1X PBS and three times with NETN 
buffer (150 mM NaCl, 1 mM EDTA, 20 mM Tris pH 8.0, 0.5% NP-40). These beads or beads only were 
incubated with 5 µg of 10His-CSA-6His-DDB1 protein complexes for 2 hours at 4°C in NETN buffer. After 
incubation, beads were washed 5 times in NETN buffer. Beads were eluted in NETN buffer in the pres-
ence of 20 mM Glutathione (Sigma) at room temperature for 15 minutes.
Purification of His-Ubiquitin conjugates
His-Ubiquitin conjugates were purified as described previously (57). 
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Chapter 7. Summary and Discussion
Post translational modifications (PTMs) are orchestrated by highly active and 
reversible enzymatic systems to regulate the functional diversity of proteins. Because 
of their dynamic nature, PTMs are used by the cell as a controllable system to 
regulate a wide variety of processes (1). Studying modifications of proteins will give 
us more insight in how the cell uses PTMs to regulate cellular processes and how 
different PTMs act together to adjust the function of proteins. The research described 
in this thesis focuses one of these PTMs, the Small ubiquitin-Like Modifier (SUMO). 
SUMOs are proteins that are covalently attached to lysines in target proteins. These 
studies have uncovered hundreds of SUMO target proteins and acceptor sites 
and revealed a role for SUMOylation in protein degradation, cell cycle progression 
and DNA repair. The results from the different studies presented in this thesis are 
summarized and discussed in this chapter.
7.1 Crosstalk between SUMO and ubiquitin
Proteasome regulated SUMO-2 target proteins
In chapter 2 we reported on the cooperation between SUMOylation and ubiquitination 
in the regulation of a subset of SUMO-2 target proteins. Abolishing proteasomal 
degradation by blocking the proteasome resulted in the increase in SUMOylation 
of 73 proteins. This increase seemed to be independent of the total levels of these 
proteins, suggesting that only the SUMOylated forms are subjected to proteasomal 
degradation. So far, SUMOylation on its own has never directly been linked to 
the proteasomal degradation of proteins, this seems to be exclusive for proteins 
modified with ubiquitin chains (2, 3). The degradation of these SUMOylated proteins 
can therefore only be explained by a system where SUMO marks these proteins for 
subsequent ubiquitination and degradation. 
In the same period as we published these findings, several reports came out on 
the identification of the so called ‘SUMO targeted ubiquitin ligases’ (STUBLs) SLX5/
SLX8 in yeast and RNF4 in mammalians (4-7). These studies provided mechanistic 
insight in how SUMOylated proteins are targeted for proteasomal degradation. 
STUBLs can bind non-covalently to SUMO via multiple SUMO interacting motifs 
(SIMs) in these ubiquitin E3 ligases, resulting in the ubiquitination and degradation 
of the SUMOylated proteins they bind. Interestingly, Tatham and coworkers found 
that RNF4 preferentially binds to polySUMO-chains in vitro through four SIMs in 
the N-terminus of the protein. We observed an increase in SUMO chains upon 
proteasomal degradation, supporting this model of recognition. Surprisingly, 




did not change the processing of SUMO-2 targets by the proteasome and had no 
effect on the co-purification of ubiquitin. Future research should point out whether 
monoSUMOylation on several lysines in a protein can also be recognized by RNF4 
and thus functionally replace polySUMOylation on single lysines. 
We also found direct evidence for the ubiquitination of SUMO-2/3 proteins. 
Currently, it is unclear whether crosstalk between SUMO and ubiquitin is regulated 
by the ubiquitination of SUMO or by the ubiquitination of adjacent lysines in target 
proteins. It would also be interesting to study whether unanchored SUMO proteins 
and SUMO chains are subjected to direct proteasomal degradation via ubiquitination. 
In our study we concluded that conjugated SUMOs are recycled by the proteasome 
since blocking the proteasome resulted in a lack of ‘free’ SUMO needed for the 
SUMOylation of another set of targets. It is unclear exactly how these SUMO 
proteins are recycled by the proteasome; future research should show whether this 
is regulated by the activity of SUMO specific proteases located at proteasomes or 
if proteasomes cannot distinguish between SUMO and ubiquitin and process both 
proteins in a similar way (8, 9). Ubiquitin polymers are recycled via deubiquitinating 
enzymes associated with the regulatory particle of the proteasome. 
The identification of another STUBL, RNF111, revealed that crosstalk between 
SUMO and ubiquitin is not limited to proteasomal degradation. RNF111 recognizes 
SUMOylated proteins and mainly induces lysine-63 linked ubiquitin chain formation; 
these types of chains are not processed by the proteasome and are mainly linked to 
a role in endocytosis and DNA repair (10-12). It is thus very likely that more STUBLs 
and other forms of crosstalk between SUMO and ubiquitin will be discovered in the 
near future. 
Identification of USP11 as a SUMO-targeted ubiquitin protease
In chapter 3 we found evidence that the RNF4 mediated ubiquitination of SUMOylated 
proteins is reversible via the activity of the ubiquitin specific protease USP11. By 
performing RNF4 purifications from cells we found an interaction between RNF4 and 
USP11, the nature of this interaction remains to be elucidated. Preliminary in vitro 
data suggest that RNF4 and USP11 do not interact directly; several Importin proteins 
co-purifying with RNF4 could potentially play a role in facilitating the interaction (data 
not shown). 
Interplay between ubiquitin E3 ligases and ubiquitin specific proteases are 
reported more often and are necessary to achieve a balanced system. This is best 
exemplified by studies on the deubiquitinating enzyme USP7. USP7 regulates several 
components of the ubiquitin machinery, including the E2 enzyme Ube2E1 and the 
E3 enzyme Hdm2 (13, 14). In these cases, USP7 protects these E3 enzymes from 
proteasomal degradation by regulating their deubiquitination. Although we did not 




an effect on RNF4 protein stability after USP11 knockdown, suggesting that USP11 
is not involved in regulating RNF4 protein levels.
Mechanistically, we showed that USP11 can counteract RNF4 activity towards 
the ubiquitination of SUMO-2 chains. In in vitro assays, USP11 can deubiquitinate 
hybrid SUMO2-ubiquitin chains that were produced by RNF4. Interaction studies 
revealed that USP11 has a low affinity for binding to SUMO2-ubiquitin chains 
as compared to RNF4; we did observe a strong interaction between USP11 and 
unanchored ubiquitin chains. Surprisingly, mutating four potential SIMs in USP11 did 
significantly reduce its deubiquitination activity towards SUMO2-ubiquitin. Therefore 
it is plausible that USP11 binds to SUMO2-ubiquitin chains through sequential 
interaction with ubiquitin, SUMO2 and perhaps also RNF4. 
In line with recent findings (15) we found that USP11 regulates the stability of PML 
nuclear bodies. RNF4 ubiquitinates SUMOylated PML, resulting in the destabilization 
of PML nuclear bodies; USP11 can counteract this by stabilizing SUMOylated PML. 
PML is a tumour suppressor and is often found to be downregulated in various types 
of cancer; this is potentially regulated by proteasomal degradation of PML (16, 17). 
Blocking PML degradation with the help of USP11 would therefore be a potential 
interesting approach in cancer treatment. Indeed Wu and coworkers found that 
USP11-mediated regulation of PML stability plays an important role in brain tumour 
pathogenesis (15). In addition, USP11 has been linked to DNA damage repair where 
it regulates DNA repair proteins including BRCA2 and p53. (18). It has been shown 
that interfering with USP11 levels reduces survival of cancer cells upon different 
drug treatments (19, 20). Whether this is linked to USP11’s deubiquitination activity 
towards SUMOylated proteins would be an interesting addition to future research on 
USP11. So far, we only observed an effect of USP11 on PML SUMOylation; USP11 
knockdown studies in combination with a SILAC approach could be useful to identify 
novel SUMO target proteins that are regulated by USP11.
7.2 Identification of SUMOylation sites
Although SUMOylation often takes place on the so called ‘SUMO consensus motif’ 
ψKxE/D (where ψ is a big hydrophobic amino acid and x can be any amino acid), not 
all of these motifs are necessarily used and SUMOylation often occurs on lysines 
situated in non-consensus motifs. Research on the effects of SUMOylation on 
individual targets is therefore often hampered by struggles to identify the acceptor 
lysines. 
To be able to identify SUMO acceptor lysines in proteins, we have developed 
a method which is described in chapter 4. By introducing an arginine close to the 
C-terminus of SUMO-2, we were able to identify 103 SUMOylation sites by tryptic 




of SUMO consensus motifs among the identified sites (+/- 70%), showing that the 
SUMO machinery has a high preference for this motif. This preference lays in the 
direct binding of the SUMO E2 enzyme Ubc9 to the consensus motif, which positions 
the catalytic site of Ubc9 towards the lysine that is subsequently SUMOylated (21, 
22). 
Apparently, the consensus site alone is in some cases not sufficient for efficient 
Ubc9 binding; several other features can induce the interaction with Ubc9 and 
thereby initiate SUMOylation. The identification of the so called ‘phosphorylation-
dependent SUMOylation motif’ (PDSM) and the ‘negatively charged amino acid-
dependent SUMOylation motif’ (NDSM) showed that site specificity can be regulated 
at additional levels (23-25). These studies showed that phosphorylation or negatively 
charged amino acids downstream of SUMO consensus sites results in a stronger 
interaction with Ubc9 and therefore induces SUMOylation. In our study we found 
the first direct evidence for PDSM regulated SUMOylation by identifying peptides for 
four proteins that were both SUMOylated and also phosphorylated downstream of 
the acceptor lysine. We also found a new additional type of extended SUMOylation 
motif, where the consensus motif is preceded by at least two more hydrophobic 
amino acids (the HCSM). The efficient SUMOylation of these kind of sites can 
probably also be explained by an enhanced binding of Ubc9, this was published 
before for the SUMO target protein RanGAP1 (22). 
Surprisingly, we also identified an inverted SUMO consensus motif, suggesting 
that Ubc9 can bind to these sites in two directions. So far, no studies have been 
reported on the significance of this inverted consensus motif. 
Finally, we also mapped SUMO acceptor lysines that did not fit to any form 
of SUMO consensus site; the question remains how specificity for these lysines is 
regulated. One potential explanation could be that these lysines are located in a 
‘SUMOylation motif’ only in the structured protein but not in the unstructured peptide 
surrounding the lysine. In line with this hypothesis, it was previously found that the 
ubiquitin conjugating enzyme E2-25K was SUMOylated on a non-consensus site 
only in the context of a folded protein; in unstructured peptides this site was not used 
for SUMOylation (26). Another explanation for the SUMOylation of non-consensus 
sites is the non-covalent interaction between the Ubc9-SUMO thioester and a SUMO 
interacting motif close to the modified lysine. This mechanism of SUMOylation was 
previously shown for the ubiquitin-specific protease 25 (27). A third option is the 
binding of a SUMO E3 ligase to non-consensus motifs to induce SUMOylation; PCNA 
SUMOylation on lysine 164 for example depends on binding of the E3 ligase Siz1 
(28). Analysis of the surrounding sequence in the identified non-consensus sites and 






7.3 SUMOylation in genome stability  
DNA damage and disorganization of chromosome segregation are two important 
sources of genome instability, an evolving hallmark of cancer (29). In chapter 5 and 
6 of this thesis we have focused on a potential role for SUMOylation in maintaining 
genome stability. 
FoxM1 SUMOylation is important for cell cycle progression
In chapter 5 we performed a large-scale proteomics screen to analyze global 
SUMOylation dynamics during cell-cycle progression. Among the 593 identified 
SUMO2 targets, we found a G2 and M phase specific increase in SUMOylation 
of the transcription factor FoxM1. Currently we lack insight in how this increase in 
SUMOylation is regulated. Potentially, it could just simply reflect the increase in total 
expression levels for FoxM1; this has been published to occur during S phase (30). 
Another explanation could be the increased binding of FoxM1 to DNA during these 
phases of the cell cycle; recently it was found that active promoters of genes are 
areas with a high SUMOylation activity (31). Interestingly, crystal structure analysis 
showed that the DNA-binding domain of FoxM1 has a relative low affinity for its 
consensus promoter sequence (32). Since SUMOylation can have both positive as 
well as negative effects on the binding of transcription factors to DNA, it would be 
interesting to study the effects of FoxM1 SUMOylation on its DNA binding abilities (33, 
34). A third possibility for the observed increase in FoxM1 SUMOylation during G2 
and M phase is the subcellular localization of the SUMO machinery. Colocalization 
of FoxM1 and either SUMO E3 ligases or SUMO specific proteases during a specific 
phase of the cell cycle could potentially regulate SUMOylation levels of FoxM1 (35). 
Follow-up experiments brought to light that SUMOylation of FoxM1 during G2 and 
M phase induces its transcriptional activity by blocking the auto-inhibitory interaction 
between the N-terminus and the C-terminus of the protein. SUMOylation on either 
the N-terminal repressor domain of FoxM1 alone or on the domain separating the 
Forkhead part from the transcriptional activation part of the protein was sufficient to 
block the inhibitory interaction in vitro. However, mutating SUMOylation sites in either 
domain separately had no effect on the transcriptional activity of FoxM1, suggesting 
that you need to block SUMOylation completely to release autorepression. Solving 
the crystal structure for the folded FoxM1 protein could provide more insight in how 
SUMOylation is blocking the interaction between two FoxM1 molecules.
FoxM1 transcriptional activity is essential for proper cell cycle progression by 
regulating a set of genes that are needed for the execution of mitosis. Previously, it was 
shown that deregulation of FoxM1 activity induces missegregation of chromosomes, 
resulting in aneuploidy and thus genomic instability (36). In line with these findings, 
we found that decreasing FoxM1 activity by abolishing its SUMOylation induced 




embryonic fibroblasts lacking Ubc9 expression (37) and can thus partly explain 
the observed defects in cells where overall SUMOylation is abolished. However, 
it is very unlikely that restoring FoxM1 SUMOylation alone would be sufficient to 
counteract these defects, since we found that SUMOylation modifies whole protein 
groups during cell cycle progression. 
In general, SUMOylation of transcription factors inhibits their activity; FoxM1 
is thus one of the exceptions to the rule (38). Inhibition of transcription factors by 
SUMOylation is often linked to complex formation through non-covalent interactions 
with SIM containing repressor complexes. The fact that FoxM1 acts as its own 
repressor and the observation that FoxM1 does not contain classical SIM motifs 
contributes to our conclusions that SUMOylation prevents the dimerization of 
FoxM1 proteins. A somewhat similar mechanism was previously published for the 
transcription factor Ikaros; SUMOylation of Ikaros induces its activity by preventing 
the interaction with a repressor complex (39). Interestingly, the p19ARF protein was 
previously identified as a negative regulator of FoxM1 activity. Binding of p19ARF to 
the C-terminus of FoxM1 results in inhibition of its activity by targeting FoxM1 to the 
nucleolus (40). It would be interesting to see whether FoxM1 SUMOylation can not 
only induce the relief of autorepression but also block the interaction with p19ARF. 
Because of its emerging role during cell cycle progression, FoxM1 is an important 
subject in cancer treatment studies. Although cells need a certain level of FoxM1 
activity to properly divide, high FoxM1 expression levels are often linked to many forms 
of human cancer (41). It is thus evident that cells need to balance FoxM1 activity to 
maintain genome stability. This balance is mainly kept by regulating the expression 
levels and by post translational modifications of FoxM1. Quickly after execution of 
mitosis, FoxM1 is inactivated by dephosphorylation and FoxM1 protein levels are 
decreased by ubiquitination and proteasomal degradation (42, 43). Intriguingly, we 
also identified FoxM1 as a proteasome regulated SUMO2 target in chapter 2. Since 
SUMOylation of FoxM1 peaks during mitosis, it would be interesting to see whether 
SUMOylation of FoxM1 targets the protein for ubiquitination and degradation during 
G1 phase. Unpublished data indeed showed that RNF4 can specifically bind to and 
ubiquitinate SUMOylated FoxM1 proteins in vitro. Knocking down RNF4 expression 
in cells did however not have any effect on the SUMOylation of FoxM1, suggesting 
a role for other, yet unknown, STUBLs. Surprisingly, FoxM1 was identified as a 
potential target for anticancer therapies with proteasome inhibitors. Treatment of 
cells with proteasome inhibitors such as MG132 decreased FoxM1 transcriptional 
activity and FoxM1 expression. It is unlikely that this effect is linked to the increased 
SUMOylation of FoxM1, since we found that this induces FoxM1 activity. The 
inhibitory effect of proteasome inhibition of FoxM1 can potentially be explained by 
the stabilization of transcriptional regulators and repressors of FoxM1 (44). 




function, mainly on expression levels (45). However, there are still a lot of 
challenges in FoxM1 targeting when it comes to the delivery of inhibitors to tumours 
and their specificity. Interfering with FoxM1 SUMOylation could provide a high 
level of specificity and result in the decrease of FoxM1 transcriptional activity in 
tumours. Future research could focus on analyzing SUMOylation levels of FoxM1 
in various cancers and should point out if it is possible to specifically target FoxM1 
SUMOylation in these cancers. So far, no technique has been described to interfere 
with SUMOylation of individual endogenous SUMO target proteins; this is a main 
challenge for the scientific SUMO community. 
DNA damage triggers the SUMOylation of CSB
Over the last years it became evident that SUMOylation of DNA repair proteins is 
an important process in the DNA damage response (46). Therefore we wanted to 
identify target proteins that are SUMOylated in two subpathways of the DNA damage 
response. In chapter 6 we have used a proteomics approach to identify proteins that 
are regulated by SUMO2 upon treatment with IR or UV. One of the most interesting 
findings in this screen, in our opinion, was the UV specific SUMOylation of CSB; this 
protein was therefore chosen for follow-up experiments. CSB belongs to the SWI2/
SNF2 family of DNA-dependent ATPases and plays an essential role in transcription 
coupled nucleotide excision repair (TC-NER). Stalling of the RNA polymerase II 
complex (RNAPII) upon encountering a lesion in the transcribed strand initiates the 
strong interaction between CSB and RNAPII on the chromatin. Subsequently, CSB 
facilitates the recruitment of proteins that regulate the repair of the lesion and the 
transcriptional restart after repair (47). Mutations in either the CSA or CSB gene 
results in the severe autosomal recessive disorder, Cockayne syndrome (CS). CS is 
at least partly caused by a defect in TC-NER; CS cells fail to quickly repair lesions 
in the transcribed strand of active genes and fail to resume RNA synthesis after UV 
induced DNA damage (48). 
By making point mutations in the SUMO consensus sites in CSB, we found 
that CSB is SUMOylated on two lysines in the N-terminus of the protein upon UV 
induced DNA damage. The UV-specificity of this modifications lies most likely in the 
increased recruitment of CSB to chromatin upon DNA damage, since chromatin are 
contents of the nucleus that display increased SUMOylation activity (49). Indeed, we 
only observed CSB SUMOylation in chromatin enriched fractions from cells exposed 
to UV and not in the soluble nucleus. It is important to note that a substantial fraction 
of the total CSB protein was already observed in the chromatin fraction in untreated 
cells. The increase in CSB levels in the chromatin fraction after UV treatment were 
modest; however, we did observe a strong depletion of CSB in the soluble nucleus 
shortly after UV treatment. Nevertheless, it is possible that other mechanisms 




SUMOylation of CSB in untreated cells. The colocalization with specific SUMO 
E3 ligases or conformational changes in CSB upon UV induced DNA damage are 
therefore interesting subjects for future research. 
So far, we lack insight in the role that CSB SUMOylation plays during DNA 
repair; follow up experiments are needed to unravel the downstream consequences. 
Interestingly, it was previously published that CSB undergoes a conformational 
change to release its N-terminal autorepression and enable the stable CSB-chromatin 
interaction after UV irradiation (50). Since SUMOylation of CSB takes place on the 
N-terminus after UV treatment, it would be interesting to see if SUMO is involved in 
this conformational change; potentially SUMO could have similar effects on CSB 
as we found for FoxM1 in chapter 5. Several proteins have been shown to interact 
with the N-terminus of CSB (51): the N-terminus of CSB stimulates the incision 
activity of NEIL1, thereby enhancing base excision repair (52); PARP1 binding to 
the N-terminus of CSB results in the poly(ADP-ribosyl)ation of CSB which inhibits 
its ATPase activity (53) and binding of the c-Abl kinase to the N-terminus of CSB 
upon oxidative stress initiates the phosphorylation of CSB (54). Since SUMOylation 
often enhances interactions through SIMs or blocks interactions by shielding binding 
domains, it would be interesting to see if SUMOylation of CSB has an effect on these 
or other interactions. Furthermore it would be interesting to analyze the effects of 
CSB SUMOylation on the RNAPII complex. In general it is believed that the assembly 
and binding of the NER complex does not need the displacement of RNAPII per se; 
backtracking and/or a conformational change of the complex might be sufficient to 
facilitate DNA repair (47). Future research should point out if SUMOylation of CSB 
is somehow involved in the regulation of the RNAPII complex upon DNA damage. 
Complement studies with wild type and SUMO deficient CSB in the Cockayne 
syndrome cell line CS1AN showed that SUMOylation of CSB is not essential for the 
long term survival of cells after UV irradiation. It is important to note that this cell 
line still expresses the N-terminal part of CSB (amino acids 1-336) and the CSB-
PGBD3 fusion protein (which contains the first 465 amino acids of CSB) (55, 56). 
It is currently unclear whether SUMOylation of these proteins in CS1AN cells can 
functionally complement the SUMOylation of full-length SUMO deficient CSB in 
this experiment. Long term survival of cells after DNA damage only reflects their 
ability to adapt to stress stimuli and does not give information on efficiency and 
timing of DNA repair. Additional experiments are therefore essential to see whether 
CSB SUMOylation plays a role in the quality and quantity of DNA repair and other 
cellular processes. First of all, the recovery of RNA synthesis after UV treatment 
should be compared between cells expressing wild type or SUMO deficient CSB; a 
fast and efficient transcriptional restart is a feature of proper DNA repair. We found 
that reducing overall SUMOylation by knocking down Ubc9 does slow down RNA 




is important for efficient repair. Furthermore we should investigate the effect of 
SUMOylation on CSBs ATPase activity, in vitro experiments have been developed in 
the past to address this (57). By using a method to measure nucleotide excision repair 
kinetics we could analyze and quantify the efficiency of repair between wild type and 
SUMO deficient CSB expressing cells (58). Besides its emerging role in TC-NER, 
CSB has also been implicated in general transcription regulation upon stress stimuli 
(48). Because SUMOylation is particularly important in regulating transcription, it 
would be interesting to perform transcriptome analysis in cells expressing wild type 
or SUMO deficient CSB. 
Crosstalk between SUMOylation and ubiquitination could potentially also play 
an important role in TC-NER. Analysis of CSB SUMOylation dynamics revealed that 
this is an early event after UV treatment and that the recruitment of the CSA ubiquitin 
E3 ligase complex initiates the destabilization of SUMOylated CSB. In contrast to a 
previously published paper (59), we think that the CSA complex is not regulating the 
direct ubiquitination of CSB after UV but induces the ubiquitination and degradation 
of the RNAPII complex. This results in the dissociation of CSB from chromatin, 
which potentially induces the deSUMOylation of CSB in the nucleus by SUMO 
specific proteases. These results are in conflict with a previous published project 
where researchers stated that RNAPII is ubiquitinated by Nedd4 but not by CSA 
upon DNA damage (60). Interestingly, BRCA1 has been linked to CSB ubiquitination 
and BRCA1 was identified as a SUMO regulated ubiquitin ligase (61, 62). Whether 
SUMOylation of CSB is important for its ubiquitination by BRCA1 remains to be 
elucidated. 
Recently, it was found that another NER factor, XPC, is SUMOylated in response 
to DNA damage and that XPC SUMOylation initiates the recruitment of the STUBL 
RNF111 (10). Potentially, CSB SUMOylation could also recruit a STUBL to induce 
(auto)ubiquitination at sites of DNA damage. Ubiquitination of CSB upon UV induced 
DNA damage can be antagonized by the recruitment of the UVSSA-USP7 complex 
(63-65). Future research should point out whether CSB SUMOylation is involved in 
and/or affected by the recruitment of this complex. 
Concluding remarks
The results presented in this thesis showed that SUMOylation, sometimes in 
coordination with other PTMs, plays an important role in protein stability, cell cycle 
progression and DNA repair. Regulation of proteins by a coordinated SUMOylation / 
deSUMOylation system is thus essential to maintain genome stability; deregulation 
of this balance has been linked to the development of several human cancers (66). 
Restoring this balance in these cancer types is therefore an attractive entry point for 
therapeutic interventions and could provide a high level of specificity. 




cellular processes can sometimes only be explained by the simultaneous modification 
of groups of proteins involved in a process. Improvement of mass spectrometry 
based research in the near future should give a complete coverage of the SUMO 
landscape in different cellular processes. In addition, site specific identification of 
SUMO target proteins will facilitate the studies on individual SUMOylated proteins. 
This will help us understand whether SUMOylation of individual proteins can have 
clear and significant downstream consequences; in a lot of cases it is more likely that 
individual modifications only add up to the adequate regulation of a particular process. 
A combination of mass spectrometry based research and follow up experiments 
on identified SUMOylated proteins will help us to understand the emerging role of 
SUMOylation in eukaryotic life. 
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Chapter 8. Nederlandse samenvatting
 
Cellen worden beschouwd als de basale bouwstenen van het leven. Celdeling zorgt 
ervoor dat één enkele cel uiteindelijk uitgroeit tot een compleet organisme. Door cel 
specialisatie ontstaan groepen cellen met een specifieke structuur die uiteindelijk 
vorm geven aan verschillende weefsels en organen. Alle cellen bevatten de erfelijke 
informatie die nodig is voor het uitvoeren van celdeling en specialisatie, deze 
informatie is opgeslagen in de vorm van DNA gelegen in chromosomen. DNA bestaat 
uit twee lange strengen van vier verschillende nucleotiden, de erfelijke informatie ligt 
besloten in de specifieke volgorde van deze nucleotiden. Een gen is zo’n specifiek 
stuk DNA, hiervan wordt een kopie gemaakt in de vorm van RNA, een proces dat we 
kennen als transcriptie. De code op het RNA wordt vervolgens vertaald in eiwitten 
(translatie) door een specifieke volgorde van aminozuren aan elkaar te koppelen; drie 
aaneensluitende nucleotiden in het RNA coderen voor één van de twintig bestaande 
aminozuren. De gevormde eiwitten reguleren allerlei biologische processen in de cel 
die nodig zijn voor een efficiënte celdeling en specialisatie. 
Het menselijk genoom bevat tussen de 20.000 en 25.000 genen; theoretisch 
gezien zou dit dus resulteren in dezelfde hoeveelheid eiwitten die in een cel gemaakt 
kunnen worden. Er zijn echter verschillende processen in de cel die ervoor zorgen 
dat één gen kan resulteren in verschillende varianten RNA transcripten. De totale 
set van eiwitten die gemaakt wordt in de cel, het proteoom, is dus velen malen 
groter dan de hoeveelheid genen. De functionele diversiteit van het proteoom wordt 
verder uitgebreid door post-translationele modificaties (PTMs) van eiwitten; PTMs 
bestaan uit kleine chemische veranderingen, of de binding van kleine eiwitten aan 
aminozuren. Modificaties van eiwitten worden gereguleerd door een set enzymen. 
PTMs kunnen worden gekoppeld aan aminozuren in eiwitten door enzymen die we 
ligases noemen, een andere set enzymen (proteases) kunnen deze modificaties 
weer verwijderen. Deze dynamische modificaties worden door de cel gebruikt om de 
functie van eiwitten te veranderen om zo cellulaire processen te reguleren. 
Het onderzoek in dit proefschrift is gericht op één van deze PTMs, een eiwit 
genaamd Small Ubiquitin-like Modifier (SUMO). SUMOs behoren tot de familie van 
ubiquitine-achtige eiwitten, deze eiwitten binden aan één specifiek soort aminozuur 
(lysines) in andere eiwitten. Het proces waarin SUMO bindt aan een lysine in een 
ander eiwit noemen we SUMOylering. Voorafgaand onderzoek heeft aangetoond 
dat SUMOylering essentieel is voor de ontwikkeling en levensvatbaarheid van 
organismen. Desondanks hebben we nog maar weinig inzicht in welke eiwitten 
worden geSUMOyleerd onder bepaalde omstandigheden en wat de functionele 
consequentie is van deze modificatie. Daarom hebben we in dit proefschrift een 




worden, deze techniek heet massa spectrometrie (MS). Met opvolgende experimenten 
op enkele geïdentificeerde eiwitten hebben we geprobeerd meer inzicht te krijgen in 
de rol die SUMO speelt in verschillende cellulaire processen. 
Binding van ubiquitine aan andere eiwitten resulteert in veel gevallen in de 
degradatie van dat eiwit door een eiwitcomplex genaamd het proteasoom. Lange tijd 
werd gedacht dat SUMOylering en ubiquitinering twee onafhankelijke processen zijn 
en dat SUMOylering niet leidt tot eiwitafbraak. In hoofdstuk 2 tonen we echter aan 
dat SUMO en ubiquitine op sommige eiwitten samenwerken. Door de activiteit van 
het proteasoom te remmen, waren we in staat om met behulp van MS drieënzeventig 
eiwitten te identificeren waarop SUMO en ubiquitine samenwerken. Voor deze 
eiwitten werkt de SUMOylering als een signaal om vervolgens geubiquitineerd en 
afgebroken te worden. Andere publicaties betreffende dit onderwerp lieten zien dat 
dit onder andere gereguleerd wordt door het eiwit RNF4, een ligase die specifiek 
bindt aan geSUMOyleerde eiwitten om vervolgens deze eiwitten te ubiquitineren. 
Verder toonden we in dit hoofdstuk aan dat het proteasoom een belangrijke rol 
speelt bij het recyclen van niet-gebonden ‘beschikbare’ SUMO eiwitten die gebruikt 
kunnen worden voor de SUMOylering van een andere set eiwitten. 
 In hoofdstuk 3 zijn we opzoek gegaan naar eiwitten die interacteren met 
RNF4 om zo meer te weten te komen over de samenwerking tussen SUMO en 
ubiquitine. Eén van de eiwitten die we hebben geïdentificeerd als bindingspartner 
van RNF4 is de ubiquitine specifieke protease USP11. Met proeven in reageerbuizen 
toonden we aan dat RNF4 in staat is om ubiquitine eiwitten te koppelen aan SUMO 
eiwitten en dat USP11 deze ubiquitine eiwitten weer kan verwijderen. Waar RNF4 
dus de ubiquitinering en daarbij de afbraak van geSUMOyleerde eiwitten initieert, 
kan USP11 dit tegenwerken door de ubiquitine eiwitten weer te verwijderen. Eén 
van de eiwitten waarop dit proces plaats vindt in cellen is PML. Dit eiwit vormt kleine 
complexen in de kern van een cel, zogenaamde kernlichaampjes. We ontdekten dat 
USP11 deze PML kernlichaampjes beschermt voor RNF4 geïnduceerde afbraak in 
respons op DNA schade. 
SUMOylering vindt vaak plaats op een lysine die zich bevindt in een 
zogenaamde SUMO ‘consensus’ sequentie van vier specifieke aminozuren op een 
rij. Lang niet alle bestaande SUMO consensus sequenties worden echter gebruikt 
voor SUMOylering en SUMO kan ook aan lysines binden die zich niet bevinden 
in deze sequentie. Wetenschappelijk onderzoek naar SUMOylering wordt daardoor 
vaak bemoeilijkt door een gebrek aan kennis over de exacte plekken in een eiwit 
waar SUMO kan binden. Daarom hebben we in hoofdstuk 4 een techniek ontworpen 
waarmee we op grote schaal SUMO-bindingsplekken kunnen identificeren. Door 
een mutatie aan te brengen in het SUMO eiwit werd het makkelijker om met 
behulp van massa spectrometrie SUMO-bindingsplekken te identificeren. In totaal 




bindt. Analyse van de aminozuren rondom de geïdentificeerde lysines liet zien dat 
SUMOylering inderdaad vaak plaats vindt op de SUMO consensus sequentie (76 van 
de 103). Bovendien ontdekten we dat de SUMO consensus sequentie in sommige 
gevallen ook gebruikt wordt voor SUMOylering wanneer deze een omgekeerde 
volgorde heeft in het eiwit. Verder toonden we aan dat een cluster van zogenaamde 
hydrofobe aminozuren rondom de SUMO consensus sequentie kunnen bijdragen 
aan efficiënte SUMOylering. Ook hebben we enkele eiwitten geïdentificeerd waarbij 
de SUMOylering wordt gereguleerd door de fosforylering (een andere PTM) van een 
aminozuur in de buurt van de gemodificeerde lysine.
Voorafgaand onderzoek heeft aangetoond dat SUMOylering een essentiële rol 
speelt bij de levenscyclus van de cel, de celcyclus. Tijdens de celcyclus vinden er 
een opeenvolgende reeks processen plaats in een cel (verdeeld in verschillende 
fases) die leiden tot groei en de deling in twee nieuwe dochtercellen die elk weer 
hetzelfde proces ondergaan. Ondanks dat we weten dat SUMO een belangrijke rol 
speelt tijdens deze processen, hebben we nog maar weinig inzicht in welke eiwitten 
worden gereguleerd door SUMOylering tijdens de celcyclus. Daarom hebben we in 
hoofdstuk 5 met behulp van chemische stoffen cellen gesynchroniseerd in een aantal 
verschillende fases van de celcyclus. Vervolgens hebben we in deze verschillende 
celpopulaties geSUMOyleerde eiwitten geïdentificeerd en gekwantificeerd. In totaal 
hebben we 593 geSUMOyleerde eiwitten kunnen identificeren, van 249 van deze 
eiwitten veranderde de SUMOylering tijdens verschillende fases van de celcyclus. 
Bovendien hebben we met deze methode 203 lysines geïdentificeerd waar SUMO 
aan bindt. In het resterende deel van dit hoofdstuk hebben we ingezoomd op één 
door SUMO gereguleerd eiwit: FoxM1. 
FoxM1 is een zogenaamde transcriptiefactor die de expressie van genen 
reguleert die essentieel zijn voor de deling van een cel. We zagen dat de 
SUMOylering van FoxM1 toenam in die fases van de celcyclus waar een verhoogde 
FoxM1 activiteit nodig is. Door de lysines waaraan SUMO bindt in FoxM1 te muteren 
vonden we dat SUMOylering belangrijk is voor de activatie van FoxM1. Mechanistisch 
gezien voorkomt SUMOylering de interactie tussen twee FoxM1 eiwitten; deze 
zogenaamde dimerisatie van FoxM1 heeft een remmende werking op zijn eigen 
activiteit. Functioneel gezien vonden we dat de activatie van FoxM1 door SUMO 
belangrijk is voor een goede celdeling. Cellen die de FoxM1 mutant tot expressie 
brengen die niet langer geSUMOyleerd kan worden, bevatten vaker meerdere sets 
chromosomen, wat erop duidt dat er in deze cellen iets mis gaat bij de deling. 
Een andere belangrijke rol voor SUMOylering is de regulatie van processen die 
betrokken zijn bij het herstellen van beschadigd DNA. Ook hierbij is er een gebrek 
aan inzicht in welke eiwitten daarbij door SUMO gemodificeerd en gereguleerd 
worden. In hoofdstuk 6 hebben we geSUMOyleerde eiwitten geïdentificeerd in 




of ioniserende straling (IR). We kwamen tot de ontdekking dat voor verschillende 
eiwitten SUMOylering alleen plaatsvindt na UV en/of IR behandeling. Tijdens het 
vervolg onderzoek hebben we ons gericht op de SUMOylering van het Cockayne 
Syndroom-B (CSB) eiwit, die specifiek plaatsvindt na UV geïnduceerde DNA schade. 
Het CSB eiwit speelt een essentiële rol bij een specifiek DNA-herstelmechansime, 
namelijk Transcriptie-gekoppeld DNA herstel (TCR). Dit herstelmechanisme wordt 
geactiveerd wanneer de transcriptie van een gen door een polymerase geblokkeerd 
wordt door de aanwezigheid van DNA schade. CSB bindt hierbij aan de polymerase 
en is verantwoordelijk voor het rekruteren van eiwitten die de schade kunnen 
detecteren en herstellen. Patiënten met Cockayne Syndroom (CS) hebben een 
mutatie in het CSA of CSB gen waardoor het TCR mechanisme niet meer werkt. 
Cellen afkomstig van een CS patiënt vertonen daarom een overgevoeligheid voor 
UV-licht en falen in het herstarten van transcriptie na UV geïnduceerde DNA schade. 
We toonden aan dat de SUMOylering van CSB na UV geïnduceerde DNA schade 
zeer efficiënt is en voornamelijk plaats vindt op twee SUMO consensus sequenties 
in het eiwit. De overgevoeligheid van CS patiëntcellen voor UV kon worden 
teruggebracht door de expressie van zowel het originele CSB eiwit evenals het CSB 
eiwit dat niet langer geSUMOyleerd kan worden. Dit laat zien dat de SUMOylering 
van CSB niet essentieel is voor cellen om te overleven na UV geïnduceerde DNA 
schade. Vervolg experimenten zijn echter nog nodig om te kijken of de SUMOylering 
van CSB belangrijk is voor de kwaliteit en kwantiteit van DNA herstel. 
 Tevens zagen we dat de SUMOylering van CSB zeer snel na UV geïnduceerde 
DNA schade plaatsvindt en daarna weer afneemt. We toonden aan dat het rekruteren 
van CSA door CSB een rol speelt bij deze afname in geSUMOyleerd CSB. CSA is 
onderdeel van een ubiquitine E3 ligase complex; potentieel zou CSA dus kunnen 
werken als een SUMO specifieke ubiquitine E3 ligase op CSB. Dit bleek echter niet 
het geval te zijn en we denken nu dat CSA nodig is om de polymerase waar CSB aan 
bindt na UV behandeling te ubiquitineren. Dit zou kunnen leiden tot de dissociatie 
van CSB van het beschadigde DNA, waarna de SUMO eiwitten van CSB worden 
verwijderd door SUMO specifieke proteases in de nucleus. 
 
Afsluitende opmerking
De resultaten in dit proefschrift tonen aan dat SUMOylering, soms in samenwerking 
met andere PTMs, een belangrijke rol speelt in eiwit stabiliteit, de celcyclus en DNA 
herstelmechanismen. De regulatie van eiwitten door een gebalanceerd SUMOylering 
/ deSUMOylering systeem is dus essentieel om het genoom intact te houden; in 
verschillende humane kanker types is gevonden dat deze balans verstoord is. Het 
herstellen van deze balans is daarom een interessant onderwerp voor toekomstig 





In lijn met wat andere onderzoeksgroepen hebben gepubliceerd, ontdekten 
we dat de rol van SUMOylering in cellulaire processen in sommige gevallen alleen 
verklaard kan worden door de modificatie van groepen eiwitten. Door de ontwikkeling 
van de massa spectrometrie techniek zou het in de toekomst mogelijk moeten zijn 
om het complete ‘SUMO landschap’ tijdens verschillende cellulaire processen in 
kaart te brengen. Daarbij kan de techniek die we ontwikkeld hebben om de plekken 
in een eiwit waar SUMO bindt te identificeren bijdragen aan het onderzoek naar 
individuele geSUMOyleerde eiwitten. Bovendien kunnen we daardoor analyseren 
of de SUMOylering van individuele eiwitten grote gevolgen heeft; in veel gevallen 
is het waarschijnlijker dat dit alleen een kleine bijdrage heeft aan de regulatie van 
een cellulair proces. Een combinatie van massa spectrometrie en vervolgonderzoek 
naar de geïdentificeerde geSUMOyleerde eiwitten zal ons uiteindelijk meer inzicht 
geven in de belangrijke rol die SUMOylering speelt in het leven.
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Ubc9  Ubiquitin carrier protein 9
Ubch5a  Ubiquitin-Conjugating Enzyme E2 D1
UBD  Ubiquitin binding domain 
UBE1  Ubiquitin-Like Modifier-Activating Enzyme 1
UBL  Ubiquitin like
UBL5  Ubiquitin-Like Protein 5
UCH  Ubiquitin Carboxyl-terminal Hydrolase
Ulp  Ubiquitin-like-specific protease
Uls1  Ubiquitin ligase for SUMO conjugates protein 1
URM1  Ubiquitin-related modifier 1
USP11  Ubiquitin-specific-processing protease 11
USP25  Ubiquitin carboxyl-terminal hydrolase 25
USP7  Ubiquitin carboxyl-terminal hydrolase 7




UVSSA  UV-stimulated scaffold protein A
VCP/p97 Valosin-containing protein
WST-1  Water-soluble tetrazolium salt-1
WT  Wild-type
XPC  Xeroderma pigmentosum group C-complementing protein
YFP  Yellow Fluorescent Protein
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